



ELUCIDATING THE FUNCTION AND DYNAMICS 
OF RESIDENT AND RECRUITED MACROPHAGE 



















A dissertation submitted to Johns Hopkins University in conformity with the requirements for the 
























© 2014 H.A. Daniel Lagassé 




Acute lung injury and chronic lung inflammation are major causes of morbidity and mortality in the US and 
worldwide. The cellular and molecular factors that function to limit the extent of acute and chronic 
inflammation in order to preserve the physiological roles of the lungs have not been fully defined. Here we 
use two sources of pulmonary inflammation – severe malaria infection resulting in acute lung injury and 
elastase-induced lung damage leading to chronic emphysema – to investigate the mechanisms that govern 
the nature and extent of lung injury. Employing the P. berghei-C57BL/6 mouse model, we demonstrate that 
sequestration of infected erythrocytes on post-capillary endothelial surfaces results in lung injury and the 
rapid recruitment of inflammatory monocytes from the circulation; which were instrumental in phagocytic 
clearance of adherent parasitized cells. However, in contrast, alveolar macrophages did not contribute to 
clearance of malaria-infected cells. Infection of CCR2-/- animals, which exhibited impaired monocyte 
recruitment and parasite clearance, resulted in elevated parasite burden and exacerbated lung injury. Results 
from CD36-/- and CD36 bone marrow chimeric mice demonstrated that parasite sequestration in the 
absence of CD36-mediated phagocytic clearance by monocytes results in exaggerated lung pathology. 
Hence, the data suggest a model in which the level of malaria-induced lung pathology is proportional to 
steady-state levels of parasite adherence and monocyte-driven phagocytic clearance. Employing the 
elastase mouse model of emphysema, we demonstrated that, unlike the malaria system, lung-resident 
alveolar macrophages, not recruited monocytes, play a dominant role in the inflammatory response. Upon 
elastase-induced lung damage, alveolar macrophages proliferated and dynamically changed their 
morphology, surface phenotype, gene expression profile and adopted a mixed M1/M2 activation 
phenotype. These results suggest upon initial tissue damage, resident alveolar macrophages could 
contribute significantly to the regulation of progressive emphysematous lung injury. These two studies 
have clarified our understanding of the dynamic properties and functional roles that resident alveolar 
macrophages and recruited monocyte-derived macrophages adopt to regulate the degree of acute and 
chronic pulmonary inflammation. Thus, these studies may contribute toward the development of future 
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Inflammation within the pulmonary environment requires highly regulated control processes, as the central 
function of the lungs, gas exchange, must be preserved. Failure to properly control pulmonary 
inflammation can lead to loss of lung function and death. Lung macrophages are innate immune cells that 
are perfectly situated to respond to inflammatory insults originating from either the respiratory or 
circulatory systems. These highly phagocytic cells function to rid the lung environment of possibly harmful 
non-self substances such as bacteria, viruses, parasites, fungi and particulate matter. In addition to their role 
in clearing unwanted material from the parenchyma and airspaces, lung macrophages also play a role in 
maintaining lung homeostasis and in tissue repair processes via the secretion of a variety of effector 
cytokines. 
 
The over-arching goal of my thesis research is to elucidate the underlying mechanisms that control the 
dynamics and function of lung resident macrophage and recruited monocyte/macrophage populations 
following pulmonary insults. The majority of this study will focus on two sources of pulmonary 
inflammation: Plasmodium infection and intra-tracheal liquid elastase challenge. While both insults result 
in lung inflammation, the nature of these insults differs, as the Plasmodium infection results in a crescendo 
of parasite burden and lung injury originating from a pathogenic source (antigen driven process), while the 
liquid elastase challenge model of emphysema results in a non-infectious point insult (protease activity) 
resulting in sterile inflammation and progressive alveolar wall destruction. The goal of this work is to 
elucidate similarities as well as differences in the cellular players and their role in regulating the 
pathogenesis of these inflammatory states of the lung. 
 
1.2 LUNG MACROPHAGES 
 
 3 
1.2.1 Historical Perspective 
Macrophages were first described by the Russian comparative zoologist Ilya Mechnikov (Elie Metchnikoff) 
in the late 19th century during his studies of splinter-pricked Bipinnaria starfish larvae and Daphniae water 
fleas that had ingested needle-like spores [1]. Mechnikov noticed masses of motile cells with moving 
extensions surrounding, devouring, and destroying foreign insults. He termed these cells macrophages due 
to their distinctive role as “big-eaters” stemming from the Greek roots makros or “large” and phagein or 
“eat” [2]. Through his studies of macrophages and phagocytosis, Mechnikov developed his phagocyte 
theory of immunity, in which he posited that phagocytes were the main defense mechanism against all 
infectious agents. In his 1908 Nobel Prize lecture, Ilya Mechnikov stated that to understand immunity, first 
one must understand the nature of phagocytosis [1]. 
 
Whenever the organism enjoys immunity, the introduction of infectious microbes is followed by the 
accumulation of mobile cells, of white corpuscles of the blood in particular which absorb the 
microbes and destroy them. The white corpuscles and the other cells capable of doing this have 
been designated “phagocytes” i.e. devouring cells, and the whole function that ensures immunity 
has been given the name of “phagocytosis”. 
It has been established as a general rule that in all cases of immunity, natural or acquired, either 
by preventative vaccination or following an attack of infectious illness, phagocytosis takes place 
to a marked degree, whereas in fatal or very dangerous diseases, this phenomenon does not exist 
at all or is attenuated.[1] 
 
Mechnikov envisioned the role of phagocytes as the first line of defense and the key to effective immune 
responses. While macrophages and other phagocytes are certainly important players in the innate immune 
response, as well as shaping the adaptive immune response, we now know that Mechnikov’s phagocyte 
theory was important in promoting the role of innate immunity. Unknowingly Mechnikov was one of the 
grandfathers of the innate immunity. Mechnikov, a cellularist, shared the 1908 Nobel Prize in Physiology 
or Medicine with Paul Ehrlich, a humoralist, who, through his Side Chain Theory, laid the foundation for 
understanding humoral immunity; what we know now consider an important facet of adaptive immunity. 
At the time, their views were considered in opposition and mutually exclusive, however, we now know that 
both were describing different aspects of the immune response. In fact, Mechnikov’s and Ehrlich’s 
competing theories of immunity nicely complemented one another. Remarkably, many of the insights that 
Mechnikov and Ehrlich made over a century ago still stand as pillars of modern immunology.  
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1.2.2 Mononuclear phagocyte system (MPS) 
Macrophages are just one subset of cells belonging to a vast family of myeloid cells collectively known as 
the mononuclear phagocyte system (MPS) [3]. The MPS has been considered the central doctrine of the 
myeloid cell compartment since its conception in the late 1960s by Ralph van Furth and Zanvil Cohn [4]. 
The MPS is a conceptual framework that encompasses a direct lineage of cells originating from stem cells 
in the bone marrow to mature circulating erythrocytes, platelets, granulocytes, and peripheral mononuclear 
phagocytes (Figure 1.1A) [5, 6]. Within the bone marrow, hematopoietic stem cells (HSCs) give rise to 
common myeloid progenitors (CMPs) as well as common lymphoid progenitors (CLPs). Multipotent CMPs 
are antecedents to a large number of distinct cell types including platelets, erythrocytes, mast cells, and 
granulocytes (neutrophils, basophils, eosinophils), as well as macrophage/dendritic cell precursor (MDP) 
cells. In the bone marrow, MDPs give rise to peripheral mononuclear phagocytes: monocytes and pre-
dendritic cells [6]. Traditionally, monocytes have been considered to be the origin of tissue dendritic cell 
and macrophage populations; however, recent findings suggest that the origins of some tissue macrophage 
populations may fall outside the purview of the linear MPS conceptual framework [these issues will be 
discussed in more detail later]. While phagocytic capacity is a common trait connecting monocyte, DC, and 
tissue macrophage populations, the overall function of these cell types can vary greatly. Even between 
macrophages of different tissue origin, there is considerable heterogeneity in the function, origin, and 
nature of these related cell populations. 
 
1.2.3 Tissue macrophages 
Generally, macrophages are described as large and granular cells with many pseudopodia, or “false feet” 
used to engulf material. However, macrophages are quite dynamic and can alter their function and 
morphology quite dramatically depending upon their local environment and activation state [7]. As a 
whole, tissue macrophages are long-lived cells that function at the confluence of innate and adaptive 
immune responses and play major roles in phagocytosis, immune surveillance, wound repair, tissue 
homeostasis, and metabolism [8, 9]. Tissue macrophages are distributed in a variety of organ systems 
throughout the mammalian body (Figure 1.1B) and are as functionally distinct as their anatomical location 
[10]. While all related, the functional heterogeneity between tissue macrophage subsets is astounding:  
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Figure 1.1 Mononuclear phagocyte system (MPS) and distribution of tissue macrophage subsets 
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Kupffer cells in the liver, microglia in the central nervous system (CNS), osteoclasts in the bones, 
Langerhans cells in the dermis, and alveolar macrophages in the lungs; all possess unique qualities suited 
for immune surveillance and maintenance of homeostasis within specialized compartments. The 
microenvironment largely dictates the function of a particular tissue macrophage subset. Recently, gene 
expression profiling studies have demonstrated that tissue macrophage subsets maintain a ‘core’ signature, 
but can also be distinguished based on their specialized tissue-specific phenotype [11]. Many tissue 
macrophage subsets have been well characterized; Table 1.1 provides a brief overview of some of the most 
prominent tissue macrophage subsets including some of their key features. 
 
Table 1.1 Location and function of tissue macrophage subsets 
Tissue Macrophage Subset Anatomical Location Major Function 
Alveolar macrophages Lungs Phagocytose inhaled particles 
(dust; allergens) and 
microorganisms; immune 
surveillance; maintain lung 
homeostasis; regulate DC 
activation [12-16] 
Kupffer cells Liver Immune surveillance; iron 
homeostasis; clearance of 
damaged or senescent 
erythrocytes, cellular debris and 
microorganisms from the blood 
[17] 
Langerhans cells Skin Present antigen to T cells in 
draining lymph node [18] 
Microglia Central nervous system CNS immune surveillance; 
promote neuronal survival [19] 
Osteoclasts Bone Resorb bone and support 
erythropoiesis [20, 21] 
Red pulp macrophages Spleen Immune surveillance; clearance 
of damaged or senescent 
erythrocytes and iron homeostasis 
[22] 
Marginal zone macrophages Spleen  Trapping of blood-borne 
particulate antigen; clearance of 
apoptotic cells; minimize 
autoimmune responses [23, 24] 
Subcapsular sinus (CD169+) 
macrophages 
Lymph nodes Immune surveillance; prevent 
systemic dissemination from 
lymphatics to bloodstream; 
present antigen to B cells [25]  
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In order to more fully understand the function and role of tissue macrophages, one must appreciate the 
anatomical context in which they reside. 
 
1.2.4 General lung function 
Maintaining lung homeostasis and function is paramount to an individual’s survival during inflammatory 
insults, whether systemic, localized to distal tissues, but especially when concentrated within the lungs. The 
consequences of impaired lung function are numerous and devastating as the lung serves as the site of gas 
exchange for the bloodstream. Gas exchange is accomplished through the act of respiration where 
deoxygenated venous blood is pumped into the lungs from the heart via the pulmonary artery. Within the 
airways, carbon dioxide is exchanged across the respiratory epithelial surface for atmospheric oxygen 
brought into the lungs upon inspiration. The newly oxygenated erythrocytes return to the heart via the 
pulmonary veins and are pumped out into the systemic circulation. The lung environment is certainly 
unique as it serves as a scaffold for the delicate interface between the largest vascular bed of the closed 
circulatory system and the respiratory tract, a vast mucosal surface that is in constant contact with the 
external environment. 
 
1.2.5 Lung as regulatory mucosal surface 
Mucosal surfaces act as a physical barrier to protect the body from the environment. The lungs of an 
average adult male have a surface area of approximately 100 m2 and come in contact with approximately 
11,000 liters of air a day [26]. In comparison to other mucosal surfaces, the surface area of the lungs is 
much greater than the skin (2 m2) and rivals that of the gastrointestinal tract (300 m2) [27, 28]. Upon each 
inspiration, the airways are assaulted with a myriad of foreign substances, largely innocuous, but generally 
comprised of highly immunogenic antigens, and potentially including pathogenic bacteria, viruses, 
parasites and fungi, as well as harmful particulate matter, noxious chemicals, and allergens. These 
potentially dangerous substances are only a few micrometers away from entering the systemic circulation 
via capillaries that surround the airways, so the body must respond appropriately to harmful insults, while 
limiting damage inflicted upon the lungs. Therefore, in order to maintain lung function, even in the face of 
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an inflammatory insult, many regulatory immune mechanisms must be in place to prevent the elicitation of 
robust inflammatory responses against the numerous foreign and highly immunogenic antigens that are 
continuously introduced to the system. Through highly-regulated immune mechanisms the body avoids 
immune activation in response to all foreign substances entering the airways, as doing so would certainly 
lead to chronic inflammation and impair normal lung function. In order to appreciate how lung homeostasis 
is maintained through immune regulation, it is necessary to understand the anatomy (structure/organization) 
and physiology (function) of the lung tissue.  
 
1.2.6 Lung organization 
The lungs can be divided into two main functional areas, the conducting zone and the respiratory zone. 
Upon inspiration, the diaphragm contracts leading to a reduction in intra-thoracic pressure that results in 
lung expansion. This change in lung pressure causes atmospheric oxygen to be drawn in via the oral and 
nasal cavities. Air then enters conducting zone at the trachea. The conducting zone’s main feature is to 
facilitate the movement of air from the upper airways (nose, pharynx and larynx) into the lower airways 
and to the respiratory zone, the site of gas exchange. The conducting zone is a branched tree of 
progressively smaller and more narrow air-conducting tubes largely comprised of cartilage and smooth 
muscle tissue overlaid with mucosal tissue including ciliated cells and mucous-secreting goblet cells [29]. 
In humans, this highly organized structure may consist of a respiratory tree that branches as many as 23 
generations from the trachea down to the alveolus [30], while murine lungs can branch 13-17 times [31]. 
Distal to the trachea is the first bifurcation point leading to the left and right (primary) bronchi, which 
divide further into lobar (secondary) and segmental (tertiary) bronchi eventually leading to conducting 
bronchioles (Figure 1.2A). Once in the respiratory zone, the respiratory tree continues to branch into 
respiratory bronchioles, leading to alveolar ducts and to alveolar sacs, which finally branch into an 
individual alveolus, where the majority of blood re-oxygenation occurs [29](Figure 1.2B). Intact alveolar 




Figure 1.2 Respiratory tree organization and alveolar structure  
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1.2.7 Alveolar organization 
Alveolar epithelial cells (AECs) are specialized cells that provide the alveolar walls with structure and are 
responsible for gas exchange and lung flexibility. Type I AECs or type I pneumocytes are thin elongated 
cells that facilitate the exchange of oxygen and carbon dioxide across its membrane surface [32]. Type I 
AECs make up approximately ~40% of the total AECs, but cover ~97% of the surface area of the lung 
tissue [32]. Type II AECs or type II pneumocytes are cuboidal epithelial cells that serve two main 
functions, they replenish type I AECs in addition to generating large amounts of pulmonary surfactant. 
Type II pneumocytes comprise ~60% of the total AECs, however they only account for ~3% of the alveolar 
surface area [33]. Pulmonary surfactants are lipoproteins primarily produced by type II AECs that relieve 
surface tension and allow the lungs to expand and contract with ease while also playing a key 
immunomodulatory role [34]. In addition to their main functions, type I and II pneumocytes also maintain 
immune homeostasis directly through physical interactions with lung-resident leukocytes and indirectly 
through the release of immune modulatory effectors. The microanatomical organization of the alveolar 
epithelial surface facilitates the maintenance of normal lung function as well as immune surveillance. 
 
1.2.8 Alveolar leukocytes 
Several highly specialized immune cell types reside within the alveolar space in order to maintain lung 
homeostasis. Alveolar macrophages are the predominant cell-type residing within the airspace, comprising 
approximately 90% of leukocytes in the airways, with dendritic cells and T cells making up the remaining 
airway leukocytes [35] (Figure 1.2). In addition to leukocytes directly situated within the airways, there are 
populations of macrophages, DCs, T cells, and mast cells that reside within the lung parenchyma, the thin 
layer of interstitial tissue that contains the pulmonary capillaries and keeps them in close contact with the 
airspaces. Understanding how these lung-resident leukocytes function is key to understanding the 
maintenance of lung function under normal and inflammatory conditions. 
 
1.2.9 General properties of lung macrophages 
Lung macrophages (LMs) are key cells of the innate immune system well positioned within the 
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parenchyma and alveolar spaces to serve as a first line of defense against a wide variety of foreign 
substances entering the pulmonary space via the airways or the bloodstream [36, 37]. The localization of 
LMs at the interface between respiratory surfaces and the circulatory system necessitates that these cells 
play an active role in a variety of homeostatic functions. These highly specialized phagocytic cells are most 
noted for their ability to take up particulate matter as well as infectious agents and clearing these potentially 
harmful substances without compromising pulmonary function [38]. For example, LMs are key in 
defending against environmental insults such as tobacco smoke [39, 40], asbestos [41], and particulate 
matter [42]. LMs also play key roles in immunity to infectious agents including influenza [43], 
Streptococcus pneumoniae [44], Mycobacterium tuberculosis [12], Aspergillis fumigatus [45], and 
Nippostrongylus brasiliensis [13, 46]. In addition to host defense, LMs maintain homeostasis [29, 47], 
contribute to tissue remodeling [48] and the resolution of inflammatory responses [49]. It is clear that under 
normal conditions LMs are central to limiting pulmonary inflammation and maintaining lung function, 
however, upon dysregulation LMs can contribute to the pathogenesis of pulmonary inflammation as they 
are mediators of inflammatory lung diseases including sarcoidosis [50], idiopathic pulmonary fibrosis (IPF) 
[51], asthma [52, 53], allergy [54], and COPD [55]. Given their pleiotropic functions, LMs play an 
important role in shaping the nature and the extent of pulmonary inflammation. 
 
1.2.10 Phenotypic characteristics of LMs 
Just as all tissue macrophages should not be considered equivalent, LMs can be further sub-classified based 
on their micro-locale: alveolar macrophages (AMs) reside within the airspaces, while interstitial lung 
macrophages (IMs) occupy the lung parenchyma [56]. Although only separated by a thin epithelial cell 
layer, these distinct lung macrophage populations can take on very different roles largely driven by lung 
architecture and influence of the pulmonary environment. Therefore, we must identify some of the 
phenotypic characteristics that are used to define, isolate, and characterize murine LMs under experimental 
conditions. LMs are generally characterized by their large, granular, and auto-fluorescent physical 
properties. Lung macrophages differ greatly from other tissue macrophage subsets as they exhibit low 
levels of surface F4/80, the classic macrophage marker [57, 58]. AMs possess an atypical macrophage 
surface marker phenotype: CD11c+ CD11b-/low F4/80low CD64+ MHCIIlow SiglecF+ [14]. In particular, AMs 
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express high levels of the integrin CD11c, typically associated with dendritic cells, while expressing low 
levels of the integrin CD11b, a common myeloid cell marker [59]. Interestingly, AMs are the only known 
SiglecF-expressing tissue macrophage subset [14, 60, 61]. While a much smaller macrophage population, 
IMs have a more typical tissue macrophage surface marker phenotype (CD11c-/low CD11b+ F4/80low CD64+ 
MHCIImid SiglecF-), however during inflammatory conditions, IMs can be difficult to discriminate from 
recruited inflammatory monocytes. While the possible number of markers used to define LMs are limitless, 
several key phenotypic markers have been identified and are outlined in Table 1.2. Many of the phenotypic 
markers used to define LMs directly contribute to the major functions of these lung-resident myeloid cells. 
 
Table 1.2 Phenotypic characteristics of murine lung macrophages at steady state 








Integrins and Adhesion Molecules CD11b+; CD11c-/low; ICAM-1+  CD11b-; CD11c+; ICAM-1+  
Antigen Presentation MHCIImid; CD80low; CD86-  MHCIIlow; CD80low; CD86-  
Lectins/Scavenger/Fc Receptors SiglecF-; CD36+; Mannose 
receptormid (CD206); CD68low 
(binds low density lipoproteins; 
CD16+; CD32+; CD64+ 
SiglecF+ [14]; CD36+; Mannose 
receptorhigh (CD206); CD68high 
(binds low density lipoproteins); 
Galectin-3+ (binds B-
glycosides); Dectin-1+; 
MARCO+; DEC-205+ [62] ; 
CD16+; CD32+; CD64+ 
Transcription Factors PU.1+; PPAR-γ+; Mafb+ PU.1+; PPAR-γ+; Mafb+ 
Growth Factor Receptor CSF-2Rb+ (GM-CSF receptor, 
unlike other mac pops which are 
CSF1R+ and respond to M-
CSF-2Rb+ (GM-CSF receptor, 
unlike other mac pops which are 
CSF1R+ and respond to M-
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CSF); F4/80low [63] CSF); F4/80low [63] 
Signaling Molecule and Other 
Markers 
CD45+; CD14mid; Ly6C-/low; 
Ly6G-; CD200Rmid; CD103- 
CD45+; CD14low; Ly6C-/low; 
Ly6G-; CD200Rhigh; CD103- 
*these characteristics are highly plastic so may not apply to LMs during inflammatory conditions [56-58]* 
 
1.2.11 LM as sentinels 
Lung macrophages serve as sentinels of the innate immune system and serve as the first line of defense 
against pathogens and other potentially harmful insults. LMs interface with the vast array of foreign 
substances within the lung environment through a myriad of cell surface and intracellular receptors 
specially adapted to detect foreign and potentially harmful substances through the recognition of pathogen 
associated molecular patterns (PAMPs) and damage/danger associated molecular patterns (DAMPs) [64]. 
The idea of the innate immune system’s role in recognizing patterns and danger signals were championed 
by theories devised in the late-1980s and mid-1990s by Charles Janeway [65] and Polly Matzinger [66] 
respectively. These semi-specific receptors allow LMs to set the lung’s danger threshold, as the 
consequences of uncontrolled inflammation within the pulmonary environment are deleterious to the entire 
organism. The most well-characterized of these receptors are the Toll-like receptors (TLRs), a family of 10 
surface and endosomal receptors recognizing the presence of a variety of PAMP structures such as 
lipopolysaccharide (LPS) on the surface of Gram negative bacteria (TLR4), bacterial flagellin (TLR5), 
double-stranded RNA (TLR3), and unmethylated CpG containing DNA (TLR9) [67]. The outcome of TLR 
engagement is the induction of proinflammatory cytokines through MyD88 and/or TRIF signaling. LMs 
deploy these and many other surface and cytosolic pattern recognition receptors (PRRs) such as nucleotide-
binding oligomerization domain (NOD)-like receptors (NLRs) or inflammasomes [68, 69], RIG-like 
helicases (RLHs) [70], lectins [71], and scavenger receptors [72] in order to fulfill their role as cells 
responsible for immune surveillance within the lungs. While the nature of the PAMPs and DAMPs 
recognized by this cadre of innate immune receptors varies wildly, PRR signaling invariably leads to the 
activation of pro-inflammatory cytokine and chemokine production [73, 74]. The downstream signaling 
pathways generally converge on activation of several transcriptional cascades including nuclear factor 
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kappa-light-chain-enhancer of activated B cells (NF-κB), mitogen-activated protein kinase (MAPK), and 
interferon response factor (IRF) pathways. The downstream effector molecules generated by these diverse 
innate immune signaling pathways set the stage and influence the nature and magnitude of adaptive 
immune responses. 
 
1.2.12 LM Phagocytosis 
In alignment with initial Mechnikov’s discovery, the most prominent feature of lung macrophages in their 
role as innate immune cells is their ability to phagocytose foreign material that enters the lungs. Through 
the action of phagocytosis, lung macrophages clear inhaled particulate matter and potential pathogens or 
allergens that have bypassed the mucus-lined bronchial epithelium and entered the respiratory zone, which 
does not contain mucus-secreting goblet cells [75]. The primary objective of alveolar macrophage 
phagocytosis is to sequester antigen emanating from environmental challenge or pathogens from the rest of 
the immune system, thereby shielding the lungs from local specific immune responses [76]. There are 
several mechanisms by which lung macrophages are able to phagocytose foreign material including 
opsonic, non-opsonic and triggered non-specific phagocytosis [77]. The context in which the foreign 
material is initially recognized by LMs dictates the type of phagocytic clearance and immune response (or 
lack thereof) that follows. In order to recognize the variety of self and foreign material requiring clearance 
from the lungs, LMs deploy an array of cell surface receptors to facilitate triggered non-specific, opsonic, 
and non-opsonic phagocytosis. 
 
1.2.13 LM Opsonic phagocytosis 
Lung macrophages deploy a variety of surface complement and immunoglobulin subclass-specific Fc-
receptors in order to perform opsonic phagocytosis. During innate immune responses, the majority of 
opsonic phagocytosis is carried out through complement receptors on the surface of alveolar macrophages. 
LMs express several complement receptors (CR) including CR1 (CD35), CR3 (CD11b/CD18), and CR4 
(CD11c/CD18) [78]. The CRs on the surface of the lung macrophages allow them to recognize a variety of 
serum proteins involved in the classical and alternative complement pathways decorating pathogen 
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surfaces. For example, CR1 binds C3b with high affinity, but iC3b and C4b with low affinity; CR3 binds 
iC3b and β-glucan on bacterial and fungal cell walls with high affinity, however binds to factors C3dg and 
C3d with low affinity; CR4 exclusively binds iC3b [78]. During adaptive immune responses or secondary 
challenge, immunoglobulin receptors on the LM cell surface are also involved in opsonic phagocytosis. 
There are several receptors specific for binding IgG Fc regions (FcγR) found on the LM surface including: 
FcγRI (CD64), the high affinity receptor for monomeric IgG; FcγRII (CD32), the low affinity receptor for 
IgG and aggregated IgG; FcγRIII (CD16), the low affinity receptor for aggregated IgG [79]. Engagement of 
FcγR can result in different outcomes based on downstream signaling events, with FcγRI, FcγRIIA, and 
FcγRIII functioning as activating receptors and signaling through cytoplasmic immunoreceptor tyrosine-
based activation motifs (ITAM) while FcγRIIB functions as an inhibitory receptor signaling through a 
cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) [79]. Despite the fact that LMs reside 
near mucosal surfaces, the majority of LMs bind IgG through FcγR (90%), while fewer have FcεR (17%) 
or FcαR (14%) receptors specific for IgE or IgA respectively [80]. In addition to complement and 
immunoglobulin Fc receptors, LMs can recognize and phagocytose foreign material containing PAMPs by 
deploying non-opsonic cell surface receptors. 
 
1.2.14 LM non-opsonic phagocytosis 
Non-opsonic phagocytosis is accomplished using a variety of lectins and scavenger receptors found on the 
LM cell surface. Notably, AMs express the C-type (calcium-dependent) lectin mannose receptor (CD206), 
macrophage receptor with collagenous structure (MARCO), the class B scavenger receptor CD36, and 
SiglecF on their surface. Mannose receptor (MR) binds to terminal mannose residues common on a variety 
of pathogens such as Mycobacterium tuberculosis, Francisella tularensis, and Streptococcus pneumoniae 
via its c-type carbohydrate recognition domains (CRDs) [81]. Due to its lack of a cytoplasmic signaling 
domain, MR requires association with other PRRs or recognition of opsonized bacteria in order for a 
productive inflammatory response to be elicited [82]. Otherwise, recognition via MR leads to suppression 
of alveolar macrophage inflammatory responses [56]. Macrophage receptor with collagenous structure 
(MARCO) is a class A scavenger receptor (SR-A) that binds to acetylated low density lipoproteins (LDL) 
as well as bacteria, non-opsonized environmental particles, and apoptotic cells [56]. Similar to MR, 
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MARCO acts as an inhibitory receptor on the surface of LMs; in fact MARCO-/- mice show enhanced 
inflammation during influenza infection [83]. CD36 is a lipid-binding class B scavenger receptor (SR-B) 
family member that can bind to an array of ligands including oxidized LDL (oxLDL), collagen, non-
opsonized bacteria, β-amyloid, Plasmodium-infected erythrocytes and apoptotic bodies [84, 85]. CD36 is 
expressed on the surface of a variety of cell-types including endothelial cells, platelets, monocytes, and 
macrophages [85]. Similar to the nature of MR- and MARCO-mediated phagocytosis, CD36-mediated non-
opsonic phagocytosis can lead to pro-inflammatory as well as non-inflammatory signaling cascades, 
depending on concurrent engagement of TLRs [84]. Lastly, SiglecF is a member of the CD33-related 
Siglecs (sialic-acid-binding immunoglobulin-like lectins) family in mice [86]. SiglecF is a 569 amino-acid 
single-pass transmembrane protein with four extracellular Ig-like domains, the first containing a V-set 
domain necessary for sialic acid binding, and two intracellular immunoreceptor tyrosine-based inhibitory 
motif (ITIM)-like domains on the cytoplasmic tail [87]. SiglecF binds specifically to the glycan ligand 6’-
sulfated sialyl Lewis X (6’-sulfo-sLex) [88]. This glycan ligand and the enzymes responsible for its 
synthesis are expressed by airway epithelial cells in the lungs of mice [89]. In mice, SiglecF is 
predominantly expressed on the surface of eosinophils, but is also expressed on AMs and myeloid cell 
precursors in the bone marrow [61, 90]. The cytoplasmic ITIM motifs suggest that SiglecF may act as an 
inhibitory receptor [86], and have been implicated in the induction of apoptosis of eosinophils in order to 
regulate the pathogenesis of allergic responses [90]. Therefore, it has been suggested that SiglecF has 
regulatory properties on the surface of cells. 
 
1.2.15 LM Efferocytosis 
In addition to their role in immune surveillance and phagocytosis of foreign material, lung macrophages 
play an important role in the maintenance of lung homeostasis through the clearance of apoptotic bodies 
and cellular debris. Apoptotic bodies arise as part of normal cellular turnover as well as during and 
following inflammatory reactions. Without proper clearance mechanisms, apoptotic bodies can undergo 
secondary necrosis and inflammatory responses can persist [91]. Efferocytosis, or the clearance of 
apoptotic bodies, is mediated through a wide array of cell surface scavenger receptors including, but not 
limited to CD36, receptor for advanced glycation end products (RAGE), T cell immunoglobulin mucin 4 
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(TIM4), and αvβ3/5 integrins that bind phosphatidylserine (PS) or its oxidized form directly or via bridge 
molecules [92]. PS binding allows for discrimination from healthy-viable cells, as PS is a normally 
localized to the plasma membrane inner-leaflet, however PS becomes cell-surface-associated during 
apoptosis [93]. Following pulmonary insults, lung macrophages are responsible for the clearance of 
apoptotic epithelial cells, stromal cells and leukocytes (neutrophils, lymphocytes) via efferocytosis. The act 
of efferocytosis does not elicit pro-inflammatory cytokine or chemokine production, in fact, anti-
inflammatory responses generally follow efferocytosis, thereby allowing for the resolution of inflammation 
[91]. Another receptor involved in efferocytosis, MER tyrosine kinase (MERTK), a transmembrane 
receptor on the surface of LMs and member of the TAM receptor family with TYRO3 and AXL [94-96] 
indirectly recognizes PS through binding to its ligand growth-arrest-specific-6 (GAS6) [96]. The role of 
MerTK in efferocytosis is central to the function of tissue macrophages. It has been demonstrated that 
MerTK deficient mice displayed normal Fc-mediated opsonic phagocytosis, but exhibited deficits in the 
clearance of apoptotic cells and were associated with elevated anti-nuclear autoantibodies [97]. In fact, 
MerTK, in addition to CD64 (FcγRI), were recently reported to be expressed by all tissue macrophage 
populations [11]. While there are several mechanisms by which LMs can accomplish engulfment of 
particulate matter, pathogens, or apoptotic bodies, in order to limit inflammatory responses in the lungs, the 
act of phagocytosis is not complete until the final steps of degradation take place within the phagosome 
thereby ensuring proper clearance. 
 
1.2.16 LM microbial killing 
Following recognition and phagocytosis of foreign or self matter, ingested material enters the endocytic 
pathway, where the phagolysosome is formed and degradation, the final step of the phagocytic process, is 
carried out. The goal of phagocytosis is to eliminate material through physical clearance and ultimately 
destroy/degrade the foreign material. In LMs, microbicidal activity is largely due to the production of 
reactive oxygen species (ROS) generated by phagocyte nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase (Phox) [98, 99], a six subunit enzyme complex that assembles along the phagosomal 
membrane upon initiation of a respiratory burst [100, 101]. The Phox enzyme complex converts molecular 
oxygen into reactive superoxide anion (O2-), which serves as a precursor to other ROS such as hydrogen 
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peroxide (H2O2, generated by superoxide dismutase (SOD), and hydroxyl radicals (OH) produced in the 
presence of iron [100, 101]. Through its antimicrobial activity NADPH oxidase activity limits 
inflammation [100]. In fact, humans with a defect in an NADPH oxidase enzyme subunit develop chronic 
granulomatous disease (CGD), a heterogeneous immunodeficiency, characterized by severe bacterial and 
filamentous fungal infections due to dysfunctional phagocytic respiratory burst [102]. In addition to its 
importance in the clearance of pathogens and particulate matter, phagocytosis can also promote adaptive 
immune responses.  
 
1.2.17 LM antigen presentation 
In addition to their key role in innate immune responses, LMs can also contribute to the initiation of 
adaptive immune responses as antigen presenting cells (APCs). Exogenous protein antigens can be 
introduced into the endocytic trafficking pathways upon phagocytosis. Within the phagolysosome, protein 
antigens are exposed to a myriad of active lysosomal cysteine proteases, such as cathepsin S [103], that 
cleave protein antigens into smaller peptides. These peptides (15-25 amino acids) are loaded into the 
binding clefts of major histocompatibility complex type II (MHCII) molecules and presented on the cell 
surface to CD4+ T lymphocytes in order to elicit antigen-specific adaptive immune responses. Although 
technically an APC, LMs play a relatively minor role in antigen presentation in comparison to lung 
dendritic cells [104]. LMs are generally considered poor APCs partially due to low B7 costimulatory 
molecule expression (B7-1/CD80 and B7-2/CD86) [105]. Low CD80/CD86 expression may drive anergic 
T cell responses and promote peripheral tolerance to the large number of foreign antigens that enter the 
lungs during respiration [105]. In allergic asthmatics, LMs have been shown to up-regulate CD80 and 
CD86 surface expression, present antigen, and promote pro-inflammatory cytokine production in effector T 
cells within the lungs [106]. While generally restricted to the lung, under certain conditions, LMs have been 
shown to migrate to draining lymph nodes and present antigen [14]. Although their role in antigen 
presentation may be limited, LMs can significantly influence the function of other immune cells and the 
lung environment as a whole upon activation. 
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While these highly-specialized phagocytic cells are most recognized for their ability to take up and clear 
particulate matter as well as infectious agents without compromising pulmonary function [38], LMs play an 
active role in a variety of functions including host defense, maintaining lung homeostasis, tissue 
remodeling and wound repair [29] through the production of effector molecules such as enzymes, cytokines 
and chemokines following activation. 
 
1.2.18 LM Activation 
Lung macrophages, similar to other tissue macrophages exhibit phenotypic plasticity and flexibility; they 
can change from one activation state to another depending on the local environmental cues [10, 107, 108]. 
George Mackaness first described macrophage activation in 1962. Mackaness identified macrophages with 
enhanced non-specific microbicidal activity following infection with Listeria monocytogenes [109]. Later, 
macrophage activation (now termed ‘classical activation’) was found to be antigen-dependent and linked to 
interferon gamma (IFNγ) production and TH1 responses [110]. Thirty years following Mackaness’ initial 
description, Siamon Gordon reported macrophages up-regulating mannose receptor in response to 
interleukin 4 (IL-4) signaling, and termed this phenotype ‘alternative activation’ [111]. These are but two 
examples of how cytokine signaling can elicit particular responses within tissue macrophages, however, it 
is now evident that these activation states are merely conceptual frameworks by which researchers group 
together similar responses to an infinite number of stimuli. To that end, in addition to taking on classically 
activated (CAM; M1) and alternatively activated (AAM; M2) phenotypes [112, 113], there is growing 
evidence that LMs play other important roles in shaping the nature and the extent of pulmonary 
inflammation [112], as other cytokines and signaling molecules that elicit M2-like phenotypes have been 
identified. For example, macrophage activation induced by Fc receptors and immune complexes has been 
termed type II activated or M2b [114], while activation induced by IL-10 and glucocorticoids has been 
termed deactivated or M2c [115]. As the signals and sources for each activation state differ, so do the 
effector molecules produced. Not surprisingly, each functional macrophage phenotype has been associated 
with promoting distinct immune responses. For a more complete overview of the signals, effector 




Table 1.3 Activation states of macrophages 
Activation State Signals (source) Effector Molecules Consequences 
Classical [CAM] 
(M1) 
IFNγ (NK; TH1; some 
macrophages) + LPS 
(bacteria) or TNFα 
(APC);  











IL-4 (TH2; basophil; 
ILC2); IL-13 (TH2; 
ILC2); IL-33 
(epithelial) 








(ICs) + LPS (TLR 
ligands); Fc receptors 







IL-10 (Treg) + 
glucocorticoids (adrenal 
cells) 




While functional macrophage phenotypes are associated with a unique transcriptional networks controlling 
gene expression and production of effector molecules [107], no master transcriptional regulators have been 
identified as in CD4+ helper T cell subsets [116]. Instead, many transcription factors play roles in 
macrophage activation. Generally, M1 and M2 macrophage polarization is controlled through the nuclear 
translocation of interferon response factors (IRFs). The transcription factors IRF5 and signal transducer and 
activator of transcription 1 (STAT1) are among those that drive M1 macrophage polarization [117-119], 
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while NF-kB p50 has been shown to inhibit M1 macrophage polarization [120]. Similarly, the transcription 
factors IRF4, STAT6, peroxisome proliferator-activated receptor-γ (PPAR-γ) and CCAAT/enhancer-
binding protein β (C/EBPβ) control M2 macrophage polarization [13, 121-123]. At rest, tissue 
macrophages are typically polarized towards a type 2-like phenotype as they maintain tissue homeostasis 
[8, 10, 124]. There are several transcription factors including PPAR-γ/retinoid X receptor (RXR) [125, 
126], PU.1 [127, 128], and MafB [129] that have been shown to act as the primary LM global 
transcriptional regulators; responsible for controlling many aspects of LM function. As a consequence of 
macrophage activation, effector molecules are produced in order to direct macrophage metabolism as well 
as eliciting responses in other macrophages or other cell types. 
 
1.2.19 LM metabolism 
The polarization of macrophages can have a profound impact on several metabolic pathways. For example, 
metabolism of L-arginine, an essential amino acid, is central to M1 and M2 polarized macrophage effector 
functions. Upon activation, M1 macrophages elevate production of inducible nitric oxide synthase (iNOS), 
an enzyme that metabolizes L-arginine into L-citrulline and nitric oxide (NO) [130]. By damaging proteins, 
lipids, and DNA, NO is a key mediator of M1 induced microbicidal activity. In fact, iNOS competes with 
arginase 1 (Arg1), an effector of M2 polarized macrophages, for L-arginine substrate [131, 132]. Upon M2 
polarization, Arg1 metabolizes L-arginine into urea and L-ornithine, a precursor of L-proline that promotes 
tissue repair through collagen synthesis [132]. Similarly, metabolism of arachidonic acid, a source of 
effector lipid mediators, differs between M1 and M2 polarized macrophages [133]. Arachidonic acid 
metabolism through the cyclo-oxygenase pathway driven by cyclooxygenase 2 (COX-2) enzymatic activity 
produces of thromboxanes and prostaglandins [134]. COX-2 products (thromboxane B2 (TxA2); 
prostaglandin E2 (PGE2); PGD2; PGF2a), also known as prostanoids, are released by LMs upon LPS 
stimulation and M1 polarization and can mediate inflammatory responses and vasoconstriction [135]. 
Alternatively, arachidonic acid metabolism via the lipoxygenase pathway produces leukotrienes and 
hydroxyeicosatetraenoic acids, such as leukotriene B4 and 5-hydroxyicosatetraeonic acid (5-HETE) upon 
M2 macrophage polarization and activation of 5/12/15-lipoxygenases [133]. These lipid mediators are 
released from LMs upon M2 polarization and can sustain inflammatory responses, however can also 
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contribute to the pathogenesis of allergy and asthma [135]. M1 and M2 polarized macrophages also have 
differing metabolic requirements in relation to glucose, cholesterol and iron metabolism [134]. In fact, 
mechanistic target of rapamycin (mTOR), a serine/threonine kinase, is a key nutrient, growth factor, and 
energy sensor that recently has been implicated in the regulation of macrophage polarization. mTOR is the 
catalytic subunit of two different multi-protein signaling complexes, mTORC1 and mTORC2 that 
phosphorylate and regulate a number of other intracellular signaling pathways involved in cellular growth 
processes [136]. Interestingly, mTORC1 signaling has been associated with M1 macrophage effector 
function, while mTORC2 signaling has been associated with M2 activation [137, 138]. While the initial 
conceptual frameworks described M1 and M2 macrophage activation as dichotomous outcomes, recent 
studies have demonstrated that macrophage polarization should be considered spectral in nature [107, 112]. 
This evolution is similar what has taken place with regards to the differentiation of CD4+ helper T cell 
subsets; as that field moved from the original monolithic view to a more flexible and plastic view [116]. In 
fact, macrophage activation responses depend on the particular milieu of signals that individual cells are 
exposed to within their tissue environment. In addition to location and environmental factors, timing must 
also be taken into account, as macrophage functional states are not static, but highly dynamic in nature. 
Therefore, understanding how these many factors influence the activation state of lung macrophages will 
inform us and continue to elucidate their nature and roles in a variety of biological situations. 
 
1.2.20 Pulmonary environment and immunomodulation 
Many of the immune-modulatory factors that shape the pulmonary environment and LM function are 
produced by AECs. The relationship between AECs and lung macrophages should not be overlooked as 
these cell populations reside within close proximity of one another and together maintain homeostasis at the 
mucosal interface between the environment and the host. Understanding the multitude of soluble factors 
and cell-to-cell contacts responsible for controlling the lung macrophage population under steady state 
conditions is key when studying their function upon inflammatory insult. The alveolar epithelium is a 
major source of cytokines and chemokines that can greatly influence the LM population and the lung 
environment as a whole. 
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1.2.21 Soluble factor-dependent immunomodulation 
Type II pneumocytes produce large amounts of surfactant proteins and lipids [34]. In addition to their 
major role in relieving surface tension within the airspaces, surfactant proteins A and D are members of the 
collectin family of anti-microbial peptides. These collectins can aid in phagocytosis of microorganisms and 
apoptotic bodies through opsonization [34, 139, 140]. For example, surfactant protein A (SP-A) has been 
shown to stimulate the phagocytosis of apoptotic neutrophils (PMNs) by normal alveolar macrophages 
[139], while surfactant protein D can influence integrin CD11b and CD11c expression (subunits of 
complement receptors) on the surface of lung macrophages, thus impacting their phagocytic abilities [140]. 
By directing material for phagocytosis, the AECs can indirectly influence the function and activation state 
of the LM pool.  
 
AECs are major producers of the pleotropic cytokine granulocyte macrophage colony stimulating factor 
(GM-CSF or CSF2) [37]. In addition to its role as a growth factor implicated in macrophage recruitment 
and proliferation, GM-CSF also enhances antigen presentation, opsonic phagocytosis, microbicidal 
capacity, chemotaxis, and adhesion [127](refs). More specifically, GM-CSF stimulates the up-regulation of 
integrin CD11c (integrin α x) expression on the surface of lung macrophages [63, 141, 142]. The constant 
exposure of LMs to GM-CSF in the lung environment imparts a unique feature of lung macrophages 
compared to other tissue macrophages subsets, they express CD11c at high levels on the cell surface [37], 
an uncommon phenotype for tissue macrophages and more common feature of dendritic cell populations 
[143]. GM-CSF signaling regulates the function of lung macrophages through the transcription factor PU.1 
[127] and promotes M1 macrophage polarization via NF-kB and IRF5 nuclear translocation [117]. In GM-
CSF deficient mice, the alveolar macrophage population does not develop properly and has deficits in 
functional capabilities such as phagocytosis and TNFα production [144, 145]. In fact, GM-CSF deficient 
mice develop a condition similar to human pulmonary alveolar proteinosis (PAP) due to deficits in alveolar 
macrophage surfactant catabolism [127, 144, 146]. While exposure to GM-CSF greatly impacts normal LM 
function in a variety of ways, there are other immunomodulatory signals present in the lung environment 
that also influence LM function.  
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IL-10, an inhibitory cytokine, is constitutively secreted by AECs while it’s receptor, IL-10R, is normally 
expressed on the LM surface [147]. IL-10 has many inhibitory effects upon macrophages and DCs 
including the inhibition of pro-inflammatory cytokine production (decreased TNFα, IL-1β, and IL-6) and 
decreased MHCII and costimulatory molecule expression (decreased CD40, CD80 and CD86) preventing 
efficient antigen presentation to antigen-specific T cells resulting in anergic CD4+ T cells [147, 148]. 
Despite constitutive IL-10 production in the lungs, LMs can circumvent this inhibitory mechanism upon 
engagement of toll-like receptors (TLRs) by PAMP ligands [147].  
 
Transforming growth factor β1 (TGFβ), is a multifunctional growth factor secreted by a variety of cell 
types, including macrophages [149, 150]. TGFβ has profound regulatory effects by inhibiting leukocyte 
activation via SMAD-dependent and SMAD-independent pathways [151]. TGFβ-deficient mice develop 
diffuse mononuclear cell infiltrates and succumb to chronic inflammation a few weeks after birth [149]. 
TGFβ is secreted as a latent procytokine (protein complex of TGFβ-homodimer and latency-associated 
peptide (LAP)) requiring proteolytic cleavage or a conformational change to be maintained in its active, 
non-latent form and bind with its receptor [152]. Within the alveolar space active TGFβ is held by the αvβ6 
integrin on the surface airway epithelial cells [152, 153]. When AMs adhere to the airway epithelium, 
active TGFβ contributes to maintaining AMs in a quiescent state through engagement of TGFβR and 
SMAD3-dependent down-regulation of macrophage activity [153, 154]. 
 
As a result of cellular or tissue stress, AECs can release danger/damage signals to alert the immune system. 
These functionally related molecules are collectively referred to as alarmins and include several family 
members such as IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) [64]. There are a variety of non-
pathogenic insults that can lead alarmin release including physical trauma, excessive heat or cold, exposure 
to radiation or chemicals, and insufficient oxygen or nutrients [64]. Similar to PAMPs, these epithelial-
derived cytokines can initiate nonspecific broad-spectrum inflammatory responses; however, alarmins are 
endogenous molecules. For example, IL-33, an IL-1 member cytokine, is released upon cellular stress and 
signals through its receptor ST2/IL1RL1 on the surface of several different cell types including 
macrophages, mast cells and type 2 innate lymphoid cells (ILC2s) [155-158]. A non-membrane bound 
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alternate splicing variant of ST2 is believed to act as a decoy receptor. Similar to TGFβ, IL-33 is released 
as an inactive propeptide requiring protease cleavage in order to release the bioactive form [159]. IL-33 
signaling results in the activation of the NF-κB and MAPK pathways [158]. IL-33 has been shown to 
promote wound-healing TH2 responses through the promotion of downstream factors such as IL-4, IL-5 and 
IL-13 [155]. AECs can also influence LM function through the release of IL-33, thereby inducing 
macrophage alternative activation [155]. The effects of soluble immunomodulatory factors on the LM 
population must not be considered in isolation, as together they shape the pulmonary immune environment 
and dictate the immune homeostatic setpoint of LMs. 
 
1.2.22 Contact-dependent interactions 
In addition to soluble factors, AECs can also modulate lung macrophage function through non-phagocytic 
contact-dependent interactions [160, 161]. CD200 (also known as OX2) is a molecule expressed on the 
surface of a wide array of cell types including, but not limited to AECs, T cells, B cells, and neurons [161-
163]. CD200R is a transmembrane receptor almost exclusively expressed by myeloid cells, but can also be 
expressed by T cells [162, 164]. Of note, CD200R is expressed at high levels on the surface of lung 
macrophages [47, 163]. Ligation of the receptor inhibits macrophage activation through recruitment of 
Dok2 and subsequent RasGAP activation, which mediates inhibition of the Erk, Jnk, and p38 MAPK 
pathways [164-166]. Engagement of CD200R on the surface of lung macrophages negatively regulates the 
level of pro-inflammatory activation and maintains lung homeostasis [47], however, failure to engage the 
inhibitory CD200R can lead to myeloid cell activation.  
 
Recently, another role for AECs has been reported; AECs serve as a conduit for inter-lung macrophage 
communications via calcium ion flux [167]. Recently, multiple studies have illustrated the importance of 
direct interaction between lung macrophages and AECs [47, 154, 167]. In fact, a recent study demonstrated 
that lung epithelial cells act as a conduit and scaffold for inter-macrophage communications [167]. Lung 
macrophages bind to AECs via the gap junction protein connexin 43 and utilize Ca2+ fluxes to 
communicate with distal lung macrophages via AECs [167]. The importance of the relationship of LMs 
with the pulmonary environment and AECs in particular cannot be stressed enough. LM function is tightly 
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controlled by a myriad of local environmental factors. Likewise, LMs can exert control over and regulate 
the function of other leukocytes in the lungs. 
 
1.2.23 LM-mediated suppression 
LMs enact a suppressive role onto dendritic cells, T cells, and neutrophils in the lungs through the secretion 
of soluble immunomodulatory factors as well as through cell-dependent mechanisms. LMs can suppress the 
function of activated T cells through secreted mediators such as NO, prostaglandins, TGF-β and IL-10 
[112, 168-170]. LMs can also induce anergic T cell responses (functionally inactivated) by limiting B7 
costimulatory signals (B7-1/CD80 and B7-2/CD86) [171]. Instead, programmed death ligand 1 (PDL-1; 
B7-H1) and 2 (PDL-2; B7-DC) are expressed on the surface of LMs [46]. These ligands interact with 
programmed cell death 1 (PD1), an immune checkpoint receptor and negative regulator of immune 
function, on the surface of activated T lymphocytes [172]. PD1/PDL-1 engagement inhibits effector T cell 
activation in the lungs [173, 174]. Under M1 polarization, macrophages have been shown to greatly elevate 
PDL-1 surface expression, while under M2 polarization macrophages only slightly up-regulate PDL-1 
levels, but robustly elevate PDL-2 on the surface [175, 176]. Interestingly, hypoxia induced factor 1-α 
(HIF-1α) elevates PDL-1 surface expression under hypoxic conditions [177]. This is of particular 
importance as variety of inflammatory lung insults result in hypoxic conditions and the elicitation of pro-
inflammatory responses [178]. LM-derived soluble factors such as TGF-β, IL-1, PGE2, and NO that 
influence the maturation, function, and migration of lung DCs [62, 179]. LMs also suppress lung DC 
antigen presentation function [15, 62] and migration to draining lymph node (dLN) [62]. Through 
regulation of lung DCs, LMs can control the initiation of adaptive inflammatory responses [63] and set the 
immune threshold. 
 
1.2.24 Dynamics of mononuclear phagocytes  
As is evident from APC migration to lung draining lymph nodes, mononuclear phagocyte populations are 
in flux, moving in and out of the lung environment during inflammatory conditions. These dynamic 
processes are relevant to the maintenance of homeostasis within the lungs and overall health by preserving 
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gas exchange. In addition to LMs and lung DCs trafficking antigen to draining lymph nodes, myeloid cells 
are recruited from the periphery to the lungs. These recruited cells respond to local factors and can 
differentiate upon exposure to the lung environment. In addition, myeloid cell populations can expand and 
contract upon inflammatory insult. Elucidating the underlying mechanisms behind these dynamic processes 
and their contribution to the maintenance of lung homeostasis is key to understanding pulmonary 
immunity. 
 
1.2.25 Migration to draining lymph nodes 
Upon inflammatory insults that exceed the pulmonary immune threshold, antigen loaded APCs migrate to 
the lung draining lymph nodes (dLNs) to present antigen to naïve T cells and elicit adaptive immune 
responses. As immuno-regulatory cells, AMs do not readily migrate to the secondary lymphoid tissue and 
have minimal role in antigen presentation [180]. The role of professional APC is largely carried out by 
migratory lung DCs [143]. However, under certain pulmonary insults such as Streptococcus pneumonia 
infection, CD11c+SiglecF+ AMs migrate to the B cell zone of dLNs [14]. It is proposed that migrating AMs 
may interact with B cells in a similar fashion to CD169+ subcapsular sinus (SCS) macrophages, however 
the exact mechanisms have not been identified [25]. Interestingly, unlike lung DCs, AM migration to the 
dLN is independent of CCR7 signaling [14, 62].  
 
1.2.26 Blood monocyte recruitment 
Typically, pathogen exposure results in the production of chemokines such as CCL2 (MCP-1), CCL3 
(MIP-1α), CCL7 (MCP-3), CXCL10 (IP-10) and CX3CL1 (fractalkine) [181-183], which induce a rapid 
influx of large numbers of mononuclear phagocytes to the lungs [184-186]. These infiltrating cells typically 
display a wide spectrum of activation phenotypes and have been documented during influenza [185], 
Mycobacterium tuberculosis [12, 184] and Nippostrongylus brasiliensis [13, 46] infections. There are two 
major circulating monocyte populations, first, “classical” or inflammatory monocytes and second, the 
“patrolling” or steady state monocytes. In the mouse, the classical inflammatory monocytes are defined as 
CD11b+Ly6ChighCCR2higCX3CR1int [187]. These monocytes are largely driven to emigrate from the bone 
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marrow to sites of inflammation through the CCL2/CCR2 chemokine axis [188, 189]. In fact, alveolar 
CCL2 secretion is sufficient to recruit inflammatory monocytes to the lungs [190]. There are many cellular 
sources of CCL2, also known as monocyte chemotactic protein 1 (MCP-1), including endothelial cells, 
epithelial cells, monocytes, dendritic cells, and macrophages, which produce CCL2 upon activation by pro-
inflammatory cytokines or engagement of PRRs [191]. Inflammatory monocytes have a very short half-life 
in circulation (~19 hours) [192, 193], only neutrophils have a shorter circulating half-life (estimated at 11.4 
hours) [194]. CCR2 is required for Ly6C+ monocyte exit from the bone marrow and the generation of 
Ly6C-CX3CR1+ monocytes [191, 195]; as in the absence of inflammation, inflammatory monocytes traffic 
back to the bone marrow and serve as an obligate intermediate for “patrolling” monocytes as they 
differentiate into Ly6C-CX3CR1hi cells [196]. The murine “inflammatory” monocyte population 
corresponds to the CD14+CD16+ and CD14+CD16- monocyte populations described in humans [187]. The 
“patrolling” monocytes are defined as CD11b+Ly6C-CCR2-CX3CR1high cells that migrate to the lungs and 
other tissues at steady state as they survey endothelial integrity by adhering and crawling along the luminal 
side of endothelial cells [197]. These monocytes have a half-life of 2 days in circulation [196, 198], are 
responsive to the chemokine CX3CL1 (fractalkine), and correspond to the CD14loCD16+ monocyte 
population described in humans [187]. Within the MPS conceptual framework, these Ly6C+ 
“inflammatory” and Ly6C- “patrolling” bone marrow monocyte subsets are directly responsible for seeding 
tissue macrophage populations. 
 
1.2.27 A challenge to the MPS paradigm 
The current conceptual framework, MPS, characterizes monocytes as precursors to tissue macrophage 
populations, as they arise from the same developmental spectrum [5]. However, there were some 
inconsistencies that arose that lead some investigators to challenge the MPS. For example, monocytopenic 
animals have normal tissue macrophage densities [199], an unexpected outcome if monocytes do seed 
tissue macrophage populations. Similarly, in human populations, congenital monocytopenias such as 
reticular dysgenesis [200] and IRF8 null mutations [201] do not lead to global deficits in tissue macrophage 
subsets. Also, macrophages have been detected in tissues prior to the development of monocytes, making it 
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difficult to explain the origin of these early tissue macrophages and their relationship to putative bone 
marrow monocyte precursors [202-205]. 
 
Recent studies have challenged the MPS and the idea that monocytes invariably give rise to tissue 
macrophages. Amidst the development of new technologies and experimental methods allowing for 
advanced cell fate mapping, the macrophage biology field is in the midst of a paradigm shift. The latest 
studies contradict earlier experiments using radiolabeling [4], irradiation chimeras [206], parabiosis [207], 
and replacement after depletion [186] that supported the notion that monocyte populations seeded tissues as 
macrophage precursors and tissue macrophages maintained their population size through continual renewal 
from blood monocyte stocks. In recent parabiosis experiments, there is discordance between monocyte and 
macrophage chimerism: monocytes reach measurable chimerism levels while tissue macrophages do not; 
even at one year post-parabiosis [208]. Due to recent advancements, there are two major areas of 
investigation within the macrophage biology field that are contributing to the evolving paradigm shift: first, 
regarding the origin or seeding of tissue macrophages, and second, local tissue macrophage proliferation. 
 
1.2.28 Tissue macrophage niches are seeded embryonically. 
In the late 1990s, it was postulated that microglia are seeded from yolk sac progenitors and are able to 
proliferate and self-maintain within the brain [209]. However, this notion did not take hold for very long. 
Recently, the field at large has begun to appreciate that many tissue macrophage subsets are not 
continuously being replenished from blood monocyte stocks; in fact, the tissue macrophage niches are 
seeded even before birth and are able to maintain the local population levels through longevity and limited 
self-renewal capabilities [196, 208, 210]. However, just as tissue macrophage function largely depends on 
the local tissue environment and requires individual evaluation, the same considerations must be applied to 
understanding the origins and maintenance of these cell populations. For example, recent studies have 
revealed that microglia are seeded from primitive yolk sac macrophages (embryonic day 8) [203, 211] 
while Langerhans cells, splenic, hepatic, pancreatic, and cardiac macrophages are seeded prior to birth from 
fetal liver monocytes (embryonic day 11.5-12.5) [204, 205, 212, 213]. These studies have revealed that 
adult tissue macrophages arise from two independent hematopoietic waves: first is the “primitive”, arising 
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from yolk sac-derived macrophages (E8.5-9; PU.1 dependent), and second, is the “definitive” arising from 
the fetal liver monocytes (E11.5-12.5; MYB dependent) [214]. While embryonic seeding appears to be a 
common feature of most tissue macrophage populations [196, 210], this is not a universal truth, as intestinal 
macrophages are constantly being reseeded by Ly6C+ monocytes [215] and appear to be an outlier tissue 
macrophage subset. To date there are three proposed models describing the origin of tissue macrophages: 
yolk sac-derived macrophages, fetal liver monocytes, and bone marrow monocytes. 
 
1.2.29 Lung macrophage origins 
The origins of lung macrophages and their replenishment had been previously attributed to a serial 
progression of circulating blood monocyte differentiating into interstitial macrophages and finally to 
alveolar macrophages [186, 216]. However, these experiments utilized diphtheria toxin-mediated 
macrophage depletion in CD11c-DTR mice followed by adoptive transfer of monocytes. A recent study has 
demonstrated that similar to other tissue macrophage subsets, lung macrophage populations are 
embryonically seeded from fetal liver monocyte pools [145]. Mature alveolar macrophage (defined as 
CD11c+SiglecF+ cells) development was GM-CSF dependent and first observed during the first week of 
life (post-natal day 1-3) [145]. The embryonically seeded lung macrophages could then self-renew and 
maintain the cellular niche throughout life, importantly, without recruitment from the bone marrow-derived 
monocytes [145, 208]. Recent studies have also demonstrated that only upon devastating experimental 
manipulations such as macrophage depletion (influenza- or diphtheria toxin- mediated) [208] or lethal 
irradiation [145] were circulating blood monocytes needed to repopulate the decimated LM cellular niche; 
however, any remaining LMs following non-genotoxic ablation also contributed to renewal. In addition, 
another recent study demonstrated that bone marrow monocytes do not contribute to the lung macrophage 
pool; instead they were shown to migrate to the dLN to present antigen [217]. These latest fate-mapping 
studies should facilitate further observations defining the nature and function of lung macrophages. 
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1.2.30 Implications of embryonic tissue macrophage seeding 
Seeding tissue macrophage populations during embryonic development or early in life may be 
advantageous to ensuring the maintenance of homeostasis throughout life. As recent reports demonstrate, 
most tissue macrophage populations can be preserved independently of bone marrow monocyte input, 
thereby allowing for vigor and consistency of tissue macrophage function during immunity, repair, and 
homeostasis. This paradigm shift may remove some of the constraints associated with operating within the 
current conceptual framework (MPS) (Figure 1.3). By presuming that bone marrow monocytes were direct 
precursors for all tissue macrophage subsets, their fates were intimately linked. Revealing alternate tissue 
macrophage origin pathways may allow the field to functionally separate bone marrow monocytes from 
tissue macrophages and decisively resolve differences in their functional roles: as monocytes are generally 
associated with inflammation and pathogen challenge, and tissue macrophages are typically associated with 
development, tissue homeostasis, and the resolution of inflammation. 
 
1.2.31 Tissue macrophages self-maintain  
As cell fate-mapping studies have revealed, most tissue macrophage subsets have the ability to self-
maintain throughout life. Tissue macrophages are able to accomplish this feat through the combination of 
long cellular half-lives and low-level local proliferation. Macrophages promote cell survival by suppressing 
apoptotic pathways such Akt-mediated inhibition of caspase 9 activation [218, 219]. Actually, it has been 
generally accepted that LMs are long-lived cells [220, 221], with half-lives reported on the order of several 
months. However, the idea of local macrophage proliferation has been proposed from time to time over the 
last few decades [222] and has never gained much traction, as it has been the long-held notion that tissue 
macrophages were terminally differentiated cells unable to proliferate. During the 1970s, 80s, and 90s there 
were numerous isolated reports of alveolar macrophage proliferation upon a variety of insults [221, 223-






Figure 1.3 Challenge to the MPS: tissue macrophage origins and maintenance  
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1.2.32 Macrophage proliferation in general 
Recently, there has been another surge in the number of reports that have clearly demonstrated local tissue 
macrophage proliferation. Macrophages have been shown to proliferate locally upon a variety of insults and 
tissue environments including parasitic worm infections in the lungs and pleural cavity [46, 231, 232], 
within atherosclerotic lesions [233], within visceral adipose tissue [234], and following acute self-resolving 
inflammation (zymosan peritonitis) [235, 236]. While the mechanisms that induce macrophage 
proliferation are still being elucidated, recently it has been revealed that macrophage subsets can undergo 
proliferation during TH2 inflammatory responses. For example, lung macrophages show the propensity to 
proliferate locally upon infection with the soil-transmitted helminth, Nippostrongylus brasiliensis [46]. In 
addition, it was recently demonstrated that peritoneal macrophages robustly proliferate in an IL-4 
dependent fashion upon infection of the pleural cavity with the filarial nematode Litomosoides sigmodontis 
[231]. Evidence of macrophage proliferation during TH2 inflammation provides a novel condition for 
macrophage self-renewal outside of tissue development [237] or homeostatic control of tissue macrophage 
numbers [212]. In thinking about these processes from a resources standpoint, the Allen group proposes 
that maintenance of a standing circulating macrophage precursor population (blood monocytes) is 
energetically costly [231]. Therefore in the case of TH2 immunity, it may be advantageous for tissue 
resident macrophages to self-replicate in a limited capacity, thereby preventing the undesirable effects of 
inflammatory cell recruitment and possibility of further tissue injury; this may allow M2-polarized tissue 
macrophages to carry out wound repair and/or parasite sequestration functions [231]. 
 
1.2.33 Lung macrophage proliferation 
Lung macrophage proliferation has sporadically been reported over the last forty years. LMs have been 
shown to proliferate following exposure to inflammatory insults including tobacco smoke [223, 224, 228], 
marijuana smoke [228], carbon particles [226], irradiation [221], and helminth parasite infection [46]. In 
addition, lung macrophage proliferation was described during postnatal development [227], steady-state 
conditions [221, 225], and in patients with idiopathic pulmonary fibrosis, sarcoidosis, or other interstitial 
lung diseases [224, 230]. Prior to the recent paradigm shift, these reports of local macrophage proliferation 
were considered outside of the MPS conceptual framework, as they did not support the concept that bone 
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marrow monocytes maintain tissue macrophage populations. Therefore, these previous reports should be 
reconsidered through a different lens, as recent findings that fetal liver monocytes seed the lungs during 
embryonic development and these precursors give rise to long-lived self-maintaining lung macrophage 
populations have come to light [145, 208]. While the mechanisms directing lung macrophage proliferation 
have not been fully elucidated, in a recent study, following non-genotoxic depletion, LM proliferation was 
dependent on macrophage colony stimulating factor (M-CSF or CSF1) and GM-CSF, but IL-4 independent 
[208]. Certainly further exploration into the signals and mechanisms involved in LM proliferation under a 
variety of situations is warranted. 
 
1.2.34 Summary 
As stated above, the lung is a unique anatomical location from an immunological perspective due to the 
fact that it contains the confluence of the respiratory and circulatory systems. Just a thin epithelial wall 
separates the external environment from the host’s systemic circulation. Therefore, a dedicated population 
of innate immune cells is needed to maintain normal function and homeostasis, as the lung undergoes 
constant bombardment of foreign material introduced via respiration or blood circulation. In order to avoid 
a perpetual inflammatory state, these innate sentinels must be highly regulated and therefore must possess a 
high threshold for activation as uncontrolled inflammation within the lung tissue can lead to impaired 




1.3.1 Public health significance 
Malaria is a worldwide public health problem with greater than 200 million yearly infections resulting in 
over 600,000 deaths per year, mainly in children under the age of five in Sub-Saharan Africa [238]. 
Approximately 3.4 billion people (forty percent of the world’s population) are living in 97 countries where 
malaria infections are currently transmitted, mostly in tropical and sub-tropical climate zones [238]. It is 
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estimated that global malaria infections account for 68 million disability-adjusted life years (DALYs) lost 
and rank as the greatest source of lost DALYs in Southern and Western Sub-Saharan Africa [239].  
In addition to malaria’s direct impact on public health, the effects of Plasmodium infections can also stress 
economic systems in malaria endemic regions due to a deteriorated workforce and significant health care 
expenditures [240]. 
 
1.3.2 Plasmodium life cycle 
The protozoan Plasmodium parasites, P. falciparum, P. vivax, P. malariae, P. ovale, and P. knowlesi can 
infect humans upon transmission of the infective-stage sporozoites from the bite of an infective female 
Anopheles mosquito [241]. Once deposited into the dermis, highly motile sporozoites gain entry to the 
circulatory system by invading dermal blood vessels and migrate to the liver, where they infect hepatocytes 
and begin the subclinical exo-erythrocytic (liver stage) of the Plasmodium life cycle [242]. Over the 
following 24-48 hours within a parasitophorous vacuole, a single sporozoite can asexually replicate and 
differentiate into thousands of erythrocyte-infective merozoite forms [243]. Merozoites erupt from infected 
hepatocytes and are released into the bloodstream. Upon erythrocyte invasion, the symptomatic phase of 
malaria begins. Within the parasitophorous vacuole in red blood cells, Plasmodium parasites transform 
from ring stage to late trophozoites and finally to schizonts. As a schizont, the parasite divides until it 
eventually ruptures the erythrocyte; releasing up to 36 merozoites and continuing the erythrocytic cycle 
[244]. Synchronous erythrocyte lysis results in systemic pro-inflammatory cytokine responses and the 
characteristic cyclical fevers, nausea, and headaches experienced by P. falciparum-infected individuals 
[244]. Additionally, parasite-infected erythrocytes can adhere to tissue microvasculature endothelial 
surfaces leading to other severe clinical manifestations [245]. As the number of Plasmodium parasites 
increases exponentially during the asexual replication stage in red blood cells, a small percentage of 
gametocytes (male and female gamete precursors) differentiate [246]. Gametocytes ingested during a 
subsequent Anopheles blood meal continue the sexual life cycle within the mosquito host. Once within the 
midgut, gametocytes develop into gametes, fuse and transform into a zygote and eventually an ookinete 
[247]. The ookinete traverses the midgut wall to transform into an oocyst, where sporozoites differentiate 
and eventually rupture the oocyst [248]. Finally, sporozoites migrate through the haemocoele to the 
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salivary glands where they can infect another mammalian host upon a subsequent Anopheles blood meal 
[249]. For a visual depiction of the Plasmodium life cycle in the mosquito and human hosts please refer to 
Figure 1.4 
 
1.3.3 Severe malaria and pulmonary pathology 
While Plasmodium infection of erythrocytes commonly results in cyclical fevers and anemia, some of the 
most serious complications of malaria are at the organ level in the brain, placenta and lungs [250-252]. Of 
the five Plasmodium species that infect humans, P. falciparum is responsible for a majority of severe 
malaria infections [244]. Potentially fatal severe malaria infections are diagnosed clinically by vital organ 
dysfunction in addition to laboratory evidence. For a complete listing of the WHO’s official clinical 
features of severe P. falciparum malaria [238], please refer to Table 1.4 
 
Table 1.4 Official WHO clinical manifestations/features of severe P. falciparum malaria infections 
Clinical features of severe P. falciparum malaria [253, 254] 
 
 
 more than two episodes within 24 hours 
 
 





Pulmonary complications such as edema (fluid build up in the lungs) and acute respiratory distress (ARDS) 
occur in ~20% of severe malaria patients [241, 254-256] and are officially recognized by the World Health 
Organization (WHO) as archetypal symptoms of the most severe cases of malaria [238, 257]. It is estimated  
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Figure 1.4 Plasmodium life cycle  
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that between 5% and 25% of adults and up to 30% of pregnant women with severe malaria infections 
develop acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) [241]. Although most 
prominent in severe P. falciparum infections, malaria-induced pulmonary complications have also been 
associated with severe P. vivax, P. ovale, and P. knowlesi infections [241]. Traditionally, malaria-
associated respiratory distress has been attributed to the combined effects of metabolic acidosis, non-
cardiogenic pulmonary edema and severe anemia [241, 258]. The respiratory manifestations of malaria 
infections have also been documented in patients following antimalarial drug treatment, presumably due to 
host pro-inflammatory responses upon the bolus release of parasite material [254]. However, due to the 
gravity of cerebral malaria complications, the magnitude of pulmonary manifestations associated with 
Plasmodium infections are commonly overlooked, even though mortality rates among patients presenting 
with ALI/ARDS exceed 70% [255, 256, 259]. 
 
1.3.4 Parasite sequestration 
Plasmodium sequestration in small caliber vessels is thought to be the central pathophysiological feature of 
severe malaria infections [260]. Cytoadherence and sequestration of infected erythrocytes (iRBCs) to the 
endothelial cell surface within tissue microvasculature impairs circulation and leads to pro-inflammatory 
immune responses [245, 261-268]. Plasmodium sequestration is developmentally advantageous to the 
parasite because it prevents the recognition and clearance of parasite-containing erythrocytes by 
monocytes/macrophages in the spleen and affords the parasite time to complete asexual replication within 
the erythrocyte [263, 267, 269]. The pattern of P. falciparum adherence observed in humans is selective in 
that most sequestration takes place in the lungs, adipose tissue, brain and placenta [270-272]. These 
adhesion events, largely associated with the malarial trophozoite and schizont life stage, result from 
interactions between both host and parasite factors [267]. 
 
Cytoadherence of infected erythrocytes to endothelial cells has been shown to be dependent on interactions 
between an array of host- and parasite-derived factors. P. falciparum erythrocyte membrane protein 1 
(PfEMP1), is the major parasite virulence factor involved in the sequestration of infected erythrocytes and 
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severe malaria pathology [273-275]. PfEMP1 ligands are a family of highly-variable parasite-produced 
molecules and a major determinant of malarial antigenic variation encoded by approximately 60 var genes 
[263]. Each PfEMP1 variant is exported to the surface of the infected erythrocyte and endows trophozoite- 
and schizont-containing red blood cells with the ability to interact with host ligands including chondroitin 
sulfate A (CSA), the scavenger receptor CD36, intercellular adhesion molecule 1 (ICAM-1; CD54), platelet 
endothelial cell adhesion molecule 1 (PECAM-1; CD31), and vascular cell adhesion molecule 1 (VCAM-1; 
CD106) on the luminal surface of vascular endothelium [244, 275-277]. Parasite sequestration in the 
microvascular compartment is not without consequence, as it results in the impairment of blood flow and 
local hypoxia as well as endothelial barrier dysfunction leading to edema at sites of heavy parasite burden 
[278-281]. Cytoadherence of iRBCs to vascular endothelial cells also elicits pro-inflammatory immune 
responses [281]. In fact, endothelial cell activation by pro-inflammatory cytokines such as TNFα or IL-1β 
can lead to elevated levels of host adhesion molecules that facilitate Plasmodium-binding, thereby further 
increasing cytoadherence events and parasite burden [282, 283]. While the pathophysiological 
consequences of parasite sequestration on vascular endothelial cells in the brain and placenta are well 
documented [250, 260, 280, 284-286], little is known about this process in the lungs. 
 
As described in CHAPTER 1.2.14, CD36 is expressed on early erythrocyte precursors, platelets, 
monocytes/macrophages, and vascular endothelial cells. CD36 functions in different capacities in a variety 
of biological systems. In addition to its involvement in the metabolism of low density lipoproteins, CD36 
has also been associated with platelet function, innate immunity, the clearance of apoptotic cells, and 
binding to thrombospondin and a vWF-cleaving protease A Disintegrin And Metalloproteinase with a 
ThromboSpondin type 1 motif, member 13 (ADAMTS13) [85]. CD36 plays a dual role in the pathogenesis 
of severe malaria infections [287, 288]. CD36 on the surface of monocytes/macrophages facilitates 
phagocytosis and clearance of iRBCs through binding to PfEMP1 [289], while CD36 on 
platelets/endothelial cells facilitates parasite cytoadherence and sequestration to the surface of the vascular 
endothelium [264, 290]. Even though CD36-mediated parasite sequestration occurs in the brain and the 
lungs, the underlying mechanisms differ. Interestingly, cerebral vascular endothelial cells do not express 
CD36 on their surface. CD36-expressing platelets mediate cerebral parasite sequestration by bridging the 
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gap between activated vascular endothelial cells decorated with von Willebrand factor (vWF) and iRBCs 
bound via CD36-PfEMP1 interaction [291, 292]. Within the lungs, CD36 is the major host factor 
associated with parasite sequestration to the vascular endothelium and directly facilitates iRBC 
sequestration [264, 278, 288, 293, 294]. From the perspective of the host, adherence of parasitized 
erythrocytes to the pulmonary vasculature is not a benign event, as some injury results from receptor-ligand 
interactions that trigger changes in barrier integrity [278]. In addition, there is a strong positive correlation 
between the level of parasite burden in the lungs and the degree of ALI [295, 296]. However, our 
understanding of the contribution that CD36-mediated sequestration of malaria-infected erythrocytes within 
the lung microvasculature makes to pulmonary distress is limited. 
 
1.3.5 Innate immune responses to malaria 
Malaria induces a robust innate immune response that plays an important role in limiting parasite load 
through mechanisms that direct phagocytic cells to engulf and kill parasites as well as by initiating the 
development of an appropriate T cell-mediated effector response [248, 297]. Severe malaria infections are 
characterized by elevated serum TNFα, IL-1, IL-6, IL-8, IL-4, IL-10, and IFNγ concentrations, which 
correlate with the severity of infection [241, 298]. In addition, chemokines implicated in the recruitment of 
myeloid cells and granulocytes such as macrophage inflammatory protein 1α (MIP-1α; CCL3), MCP-1 
(CCL2), monokine induced by gamma interferon (MIG; CXCL9) and IL-8 are also detected in severe 
malaria patients [299]. This systemic pro-inflammatory cytokine and chemokine milieu is indicative of an 
immune environment supporting mononuclear phagocyte M1 polarization. Not surprisingly, 
monocytes/macrophages have been shown to be critical innate immune cells responsible for the uptake and 
clearance of iRBCs [300]. Macrophage/monocyte innate immune responses are important in the control of 
primary malaria infections as these mechanisms function to limit the maximal level of circulating parasite 
via clearance mechanisms. 
Monocytes and macrophages are able to recognize PAMPs associated with Plasmodium-infected 
erythrocytes or Plasmodium-derived products through their vast array of PRRs (as described in CHAPTER 
1.2.11). TLRs localized to the cell surface and within endosomes recognize Plasmodium–derived PAMPs. 
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For example, TLR1/2 recognizes Plasmodium GPI ligands [301], TLR4 recognizes Plasmodium 
microparticles [302], while TLR9 recognizes Plasmodium CpG DNA [303]. In addition, parasite-associated 
DAMPs including Plasmodium DNA are sensed by the cytosolic NALP3 and AIM2 inflammasomes 
leading to the release of IL-1β and IL-18 [304-307]. Hemozoin, the insoluble black-brown crystalline 
digestion product of Plasmodium hemoglobin metabolism, is generated to protect the parasite from the 
toxic effects of free heme [308, 309]. Also referred to as “malaria pigment”, hemozoin crystals are highly 
stable compounds that are able to modulate cytokine production and the function of monocytes and 
macrophages upon phagocytic ingestion [310, 311]. Monocytes and macrophages are the major cell types 
associated with opsonic and non-opsonic phagocytosis and clearance of Plasmodium-infected erythrocytes, 
free parasites, and parasite-derived material. Opsonic phagocytosis is largely mediated through via 
complement receptors (CR1) [312, 313], and by activating (FcγRI and FcγRIIIa) [314] and inhibitory 
(FcγRIIb) [315] Fc-receptors (although not applicable for innate phase of primary infection). Non-opsonic 
phagocytosis is mediated through CD36 engagement of Plasmodium-derived molecules on the surface of 
iRBCs such as PfEMP1 [84, 289]. While myeloid cells are certainly important players in the clearance of 
infected erythrocytes, lymphoid cells also contribute to innate immune responses. NK cells and γδT cells 
play important roles as they provide early sources of IFNγ needed to polarize mononuclear phagocytes 
towards M1 activation thereby increasing phagocytic and microbial killing activity [316-318]. Still, the 
contributions that innate molecular and cellular responses make to the control of lung injury are not clear. 
 
1.3.6 Outstanding questions 
Although the lungs are known to be sites of severe malaria-associated complications within the clinical 
setting [241, 253, 256, 257, 259, 261, 319-323], there are still serious gaps in the understanding of the 
cellular and molecular mechanisms that mediate malaria-associated lung injury. Therefore, there is a 
significant need to define the role that pulmonary inflammation plays in the morbidity and mortality 
associated with Plasmodium infections. While some malaria-associated pulmonary damage results when 
Plasmodium-infected erythrocytes cytoadhere to the vascular endothelium [278], the contributions that 
innate immune responses make to malaria-associated ALI are still not clear. AMs have been implicated in 
the pathogenesis of non-malarial ALI and ARDS [324], yet their role in malaria associated-ALI/ARDS 
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remains to be investigated. Inflammatory monocytes are key phagocytic cells during innate immune 
responses as CD11bhighLy6C+ cells are central to the clearance of infected-erythrocytes in the spleen, 
resulting in a partial control of peripheral blood parasitemia [325]. However, the role that blood monocytes 
and tissue-resident macrophages play in the regulation of parasite burden in the lungs and malaria-induced 
pulmonary damage has not been defined. 
 
1.3.7 Hypothesis 
The hypothesis to be tested is that lung-resident and recruited monocytes/macrophages control pulmonary 
pathology and inflammation by clearing sequestered parasites from the microvasculature endothelial 
surface, therefore maintaining lung homeostasis and function during Plasmodium infections. 
 
1.3.8 Approach 
Due to the inherent difficulties of studying P. falciparum sequestration in the intact lungs of humans, 
murine models, most of which employ P. berghei infection have been developed [288, 295, 326-330]. 
While, no single animal model can completely reproduce all the hallmarks of severe malaria infections in 
humans, we employed the P. berghei ANKA infection in C57BL/6J inbred mouse strain as a mouse model 
for severe human malaria infections (Figure 1.5) [293, 331-334]. When infected with P. berghei, C57BL/6 
mice succumb due to complications of cerebral malaria (CM) with a median survival of approximately 6.5 
days (Figure 1.5C) [335]. As has been previously reported, P. berghei infected C57BL/6 mice also exhibit 
other pathologies common amongst severe P. falciparum patients including acute lung injury (ALI), acute 
respiratory distress disorder (ARDS) and pulmonary edema [293, 331, 336]. During the asexual 
reproductive erythrocytic stage, changes in morbidity measures such as loss of body mass and temperature 
are evident (Figure 1.5D, 1.5E), in addition to lethargy, piloerection, huddling, and labored breathing while 
peripheral blood parasitemia levels increase to approximately 15-20% prior to death (Figure 1.5B) [333]. 
This mouse model of severe human malaria infection enables us to elucidate the   
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Figure 1.5 Introduction to the Plasmodium berghei mouse model of severe malaria   
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dynamics and function of the cellular players involved in the host’s innate immune response to Plasmodium 
parasite sequestration in the lungs (please see Figure 1.5A for experimental design). 
 
Similar to P. falciparum, P. berghei schizont-containing erythrocytes sequester in the lungs and adipose 
tissue via interactions with CD36 [266, 288, 295]. Using the P. berghei model, it has been demonstrated 
that sequestration in the lungs, in addition to avoiding clearance in the spleen, has the added benefit of 
promoting parasite growth [326, 337]. In P. berghei, there is no PfEMP1 ortholog, however the parasite-
expressed protein SMAC, a conserved rodent malaria protein of unknown function, is transported to the 
erythrocyte cytoplasm and has been implicated in the sequestration of infected erythrocytes along 
endothelial surfaces [326]. Not surprisingly, SMAC expression is highest during schizont development 
[326]. Several studies have demonstrated that CD36 is the major host factor involved in P. berghei 
sequestration to the lungs, spleen and adipose tissue [264, 266, 278, 288, 290]. However, our understanding 
of the contribution that the intense sequestration of malaria-infected erythrocytes within the lung 




1.4.1 Public health significance 
According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is 
currently the world’s fourth leading cause of death effecting 60 million people worldwide and leading to 3 
million deaths per year [338]. The WHO predicts that COPD will increase to the third leading cause of 
death worldwide by 2030, only behind ischemic heart disease and stroke [338, 339]. COPD was the ninth 
highest global cause of DALYs lost in 2010 (out of 291 diseases and injuries) [239]. When parsed based on 
geographic region, COPD ranked as second highest cause of DALYs lost within high income North 
America, third in East Asia, and fifth in South Asia [239]. According to the Centers for Disease Control 
and Prevention, COPD ranked as the third leading cause of death in the US in 2011 [340]. An estimated 15 
million Americans have been diagnosed as having COPD; however, it is appreciated that this figure is 
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certainly an underestimate, as 50% of Americans diagnosed as having low pulmonary function were even 
aware that they have COPD [341, 342]. 
 
1.4.2 COPD definitions 
COPD is a progressive lung disease comprised of two main conditions, chronic bronchitis and emphysema 
both characterized by the impairment of airflow in the lower airways, making expelling air difficult, 
resulting in labored breathing and shortness of breath [343]. Chronic bronchitis is defined as prolonged 
inflammation of the bronchi and bronchioles leading to swelling, irritation, and increased mucus production 
[344]. Emphysema is defined as progressive airspace enlargement due to alveolar tissue destruction [345] 
(Figure 1.6A). Progressive loss of alveolar epithelial cells (AEC) greatly impacts the lung architecture and 
function, resulting in fewer larger airspaces, a loss of surface area, and impaired gas exchange [344]. 
Although associated with chronic bronchitis under the umbrella of obstructive lung disease, the work 
presented in CHAPTER 3 focuses on macrophage dynamics and function in an elastase-driven emphysema 
model, therefore this introductory material will concentrate on emphysema and its underlying mechanisms 
(where appropriate). 
 
1.4.3 Clinical features of COPD 
Cardinal features of COPD include severe immune cell infiltration of the muscosa and submucosa, 
increased mucus production, epithelial cell hyperplasia, and dysregulated tissue repair mechanisms [343]. 
Increased sputum production and long lasting cough are among the most common symptoms of COPD, 
however, acute breathlessness or dyspnea is the most debilitating feature of severe COPD [345]. 
Individuals suffering from emphysema present with an impairment of lung emptying upon expiration, with 
no impact on inspiration [346]. Due to alveolar wall and matrix destruction the lung loses elasticity and 
recoil ability, resulting in elevated lung compliance (a measure of lung elasticity; change in lung volume 
for a given change in pressure) [347]. Upon deficits in lung elasticity, more air becomes trapped within the 
lungs (hyperinflation) and greater effort is required to expel air from the lower airways, leading to shortness 
of breath and tiredness [348].   
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Figure 1.6 Major phases and cellular players in pathogenesis of emphysema  
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The degree of lower airway obstruction can be quantified using FEV1% or the Tiffeneau-Pinelli index, a 
spirometric measurement of lung function defined as the ratio of forced expiratory volume in 1 second 
(FEV1) (volume exhaled in first second after full inhalation) to the forced vital capacity (FVC) (total 
volume exhaled after full inhalation) normalized to a predicted value based on the patient’s age, sex, height, 
and body type [342]. COPD prevalence rates are diagnosed and scored based on the Global Initiative on 
Obstructive Lung Disease (GOLD) airflow obstruction severity index: with stage 1 (mild): FEV1 ≥ 80% 
predicted; stage 2 (moderate): FEV1 50-80% predicted; stage 3 (severe): FEV1 30-50% predicted; and stage 
4 (very severe): FEV1 ≤ 30% predicted [346]. According to a meta-analysis, the global prevalence of 
COPD estimated by spirometric definitions is 9.2% [349]. The most common treatments for COPD are 
administration of daily inhaled β2-agonist bronchodilators, anti-cholinergics and corticosteroids in addition 
to ventilation support through oxygen supplementation and smoking cessation [345, 346]. While these 
pharmacologic and non-pharmacologic interventions are aimed to relieve the symptoms and reduce the risk 
of disease progression, exacerbations, or mortality, to date, there is no emphysema-specific clinical course 
of treatment. 
 
1.4.4 Risk factors 
There are a variety of environmental exposures as well as genetic predispositions that are associated with 
the onset of progressive emphysema. Smoking tobacco is by far the predominant risk factor associated with 
emphysema; with tobacco smokers accounting for ~80% of all emphysema cases [343, 350]. Other 
environmental risk factors such as exposure to air pollution (outdoor, indoor, and occupational), second 
hand smoke, maternal smoking, respiratory infections, other non-respiratory infections (including HIV 
[345]), childhood asthma, hypersensitivity pneumonitis, and exposure to dust and fumes have also been 
associated with emphysematous changes to the lungs [343, 350, 351]. While environmental exposures are 
important, there are also several genetic predispositions associated with the progression of emphysema. For 
example, α1 antitrypsin deficiency (A1AD) is responsible for ~1-2% of COPD cases [352, 353]. A1AD is a 
congenital deficiency in α1 antitrypsin (A1AT), the major inhibitor of neutrophil elastase, leading to an 
imbalance between the activity of proteases and anti-proteases in the lungs and progressive airway 
enlargement. In addition, a macrophage metalloproteinase 12 (MMP12; macrophage elastase) single 
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nucleotide polymorphism (SNP) found in the promoter region of the minor allele (-82A->G) is a protective 
factor for COPD in adult smokers [354]. As more SNP and genome-wide association studies are conducted, 




The development of progressive lung airway destruction should be considered an immunological disorder 
[344]. Broadly, the progression of emphysema pathogenesis can be divided into three major phases: 
epithelial cell damage, innate immune responses, and adaptive immune responses. Forthcoming, a broad 
stroke overview will identify some of the major events associated with the progression of emphysema. In 
addition, several of the major immune cellular players contributing to the pathogenesis of emphysema will 
be highlighted. For an illustrated depiction underscoring these events please refer to Figure 1.6B. 
 
Initially, tobacco smoke or other pulmonary irritants directly injure or stress alveolar epithelial cells [355]. 
The compounds in cigarette smoke can also directly breakdown the lung’s extracellular matrix (ECM) 
[356]. AEC cellular damage leads to the release of DAMPs and other danger signals [64]. These products 
can act as TLR ligands and activate TLR2 and TLR4 signaling [64], while cigarette smoke also directly 
activates endosomal TLR9 [357]. Upon activation by DAMPs and TLR ligands, AECs and lung 
macrophages stimulate NF-κB, the main pro-inflammatory transcriptional regulator associated with the 
progression of emphysema. NF-κB activation results in the release of innate/early inflammatory cytokines 
such as TNFα, IL-1β, and IL-8 [358]. IL-1β release activates alveolar macrophages and induces release of 
the neutrophil recruiting chemokine, IL-8 [359]. These initial cytokine and chemokine bursts lead to 
recruitment of inflammatory cells such as neutrophils, monocytes, and DCs to the lungs.   
 
Upon recruitment to the lungs, inflammatory cells release proteases (elastolytic enzymes) and reactive 
oxygen species (ROS), which can damage the lung tissue further [360, 361]. Typically these inflammatory 
processes are kept in check with a wide array of regulatory mechanisms, however, when they are not 
appropriately controlled by the cadre of anti-proteases [362, 363] and anti-oxidants factors (catalases, 
 49 
superoxide dismutases, peroxidases) [361], the initial pro-inflammatory response ends up leading to further 
tissue damage and an uncontrolled positive feedback loop. It is posited that upon cellular damage and 
irritant-induced necrosis, immature lung DCs take up self-antigens (such as elastin fragments) released 
upon lung damage or AEC cell death [364] and migrate to the draining lymph nodes where they present 
antigen to naïve T cells and direct CD4+ differentiation towards a TH1 program via IL-12 signaling. TH1 
antigen-specific CD4+ and Tc1 CD8+ T cell populations, as well as B cells, subsequently enter the lungs to 
remove the source of antigen, leading to progressive tissue destruction [365]. 
 
1.4.6 Innate immune responses: role of neutrophils 
Emphysema is characterized by neutrophilic airway inflammation as these innate immune cells can be 
detected in the sputum of COPD patients and their numbers correlate with the severity of disease [344, 366, 
367]. Neutrophils can be recruited through the release of CXCR2-signaling chemokines interleukin-8 (IL-8; 
CXCL8) and growth related oncogene alpha (GRO-α; CXCL1), as well as leukotriene B4 (LTB4) by lung 
macrophages and epithelial cells [55] [368, 369]. Upon recruitment and activation, neutrophils become 
highly phagocytic, secrete serine proteases including neutrophil elastase, cathepsin G, proteinase-3, and 
MMPs (MMP8 and MMP9), and release myeloperoxidase (MPO) and human neutrophil lipocalin 
containing granules [370]. In addition, neutrophils can also release their nuclear material in the form of 
neutrophil extracellular traps (NETs) that act as a physical barrier in order to trap pathogens or patch 
damaged areas [371]. Although highly active, neutrophils have a very short lifespan, estimated to be 11.4 
hours [194]. Following secretion of effector molecules, neutrophils undergo apoptosis and are 
phagocytosed by macrophages [372]. Despite their association with disease severity, the exact role of 
neutrophils in the pathogenesis of alveolar tissue destruction remains unanswered. 
 
1.4.7 Innate immune responses: role of macrophages/monocytes 
Recent findings have directed attention to the major role that lung macrophages play in the orchestration of 
immune responses that lead to the progression of tissue destruction [55, 373]. Severe COPD patients are 
characterized by elevated numbers (5 to 10 fold) of LMs in the lung parenchyma, airways, BAL, and 
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sputum [360]. Similar to neutrophils, the severity of COPD correlates with lung macrophage numbers 
[374]. LMs can indirectly impact the progression of emphysema by releasing cytokines and chemokines to 
recruit other immune cells such as neutrophils, monocytes, and CD8+ T cells into the lungs. Macrophages 
recruit monocytes via the release of monocyte chemotactic protein 1 (MCP-1; CCL2) [55], and CD8+ 
lymphocytes by interferon-γ inducible protein 10 (IP-10, CXCL10), monokine-induced by interferon-γ 
(MIG, CXCL9), and interferon-inducible T-cell α-chemoattractant (I-TAC, CXCL11) [55]. As mentioned 
above, lung macrophages/monocytes clear apoptotic neutrophils through phagocytosis; in addition, they 
also clear apoptotic AECs in emphysematous lungs [91, 375]. Most importantly to the pathophysiology of 
emphysema, LMs secrete a wide variety of effector molecules that contribute either directly to tissue 
destruction or by promoting sustained inflammation [55, 373, 376]. For example, lung macrophages secrete 
elastolytic proteases such as matrix metalloproteinase 9 (MMP9) and MMP12 (macrophage elastase) that 
can directly lead to ECM degradation by cleaving collagen or elastin fibers, resulting in a loss of normal 
alveolar structure [363, 377]. In particular, MMP12-deficiency has been shown to be protective from 
cigarette smoke induced emphysema in mice [378]. For a more complete description of macrophage-
derived effector molecules relevant to the pathophysiology of emphysema, please refer to Table 1.5.  
 









8, IL-10, MCP-1, 
GRO-α, I-TAC, 
IP-10, MIG 
Activation of other cell types. Recruit neutrophils, 





cathepsin K, L, S, 
neutrophil elastase 
Cleavage of ECM components: elastin and collagen. 
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Growth Factors TGFβ1 







LTB4: recruits neutrophils and promotes adhesion of 
inflammatory cells to the endothelium. 





Precursor to other ROS (H2O2, OH, HOCl). Anti-microbial 
killing, mediates cellular damage and stimulates pro-




Precursor to other RNS (ONOO-). Antimicrobial killing and 
mediates cellular damage. 
 
1.4.8 Adaptive immune responses: role of DCs and T cells 
While cigarette smokers have elevated lung DC numbers [379], their impact on progressive alveolar tissue 
destruction still remains unclear. As DCs promote antigen-specific T cell responses, it is speculated that 
lung DCs may take up self-antigens following AEC damage [345], however no specific autoimmune 
responses have been reported. A possible emphysema-driving antigen could be introduced in cigarette 
smoke; the tobacco-derived α-glycoprotein has been described as being a highly immunogenic [380]. Still, 
the specific role that dendritic cells play in the pathogenesis of lung tissue destruction and emphysema is 
largely unknown.  
 
CCL5 (RANTES) is greatly upregulated in the sputum of individuals with COPD, attracting CD4+ and 
CD8+ T cells to the lungs via CCR5 [381]. In addition, CD4+ T cells are recruited to the lungs via the 
chemokines (IP-10, MIG, and I-TAC) which all signal through CXCR3 [365, 381, 382]. While the CD4+ T 
cell population is largely TH1 cells [365], there are some regulatory CD4+CD25+Foxp3+ (Tregs) and TH17 
cells that also reside within the lungs. The exact function these Tregs and TH17 cells remains unclear. CD8+ 
T cells greatly outnumber the CD4+ T cell population in the lungs during the progression of emphysema 
[383]. CXCR3+ IFNγ-producing type I cytotoxic CD8+ T cells (Tc1) [365] up-regulate expression of FasL, 
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perforin and granzyme B [384], so have the potential for cytotoxic killing of type I AEC. CD4+ and CD8+ T 
cell populations are actively recruited to the lungs by lung macrophages releasing chemokines in response 
to IFNγ [55]. Activated TH1 cells release more IFNγ inducing further chemokine signaling from activated 
macrophages and establishing a positive feedback loop. The exact role and mechanisms for the 
pathogenesis of emphysema that T cells contribute is still uncertain. 
 
1.4.9 Imbalances contributing to emphysema 
Emphysema can be characterized as a disease of immunological imbalances. In particular, there are three 
arenas that have been identified as contributing to the progression of tissue destruction: imbalance in 
protease/anti-protease activity, imbalance in oxidant/anti-oxidant activity, and imbalance in lung structure 
maintenance program. Typically a delicate balance is maintained in these three arenas, however upon initial 
lung damage induced by cigarette smoke or other pulmonary insult, a dysregulation occurs and the balances 
are tipped. Together these imbalances may contribute to progressive alveolar wall destruction and airway 
enlargement. Therefore, understanding the underlying mechanisms responsible for these imbalanced states 
is key to the pathophysiology of emphysema. For an overview of the molecular factors involved in these 
imbalances, please refer to Table 1.6. 
 
The action of proteases and anti-proteases in the lungs are both necessary to maintain homeostasis, 
therefore, it is critical to preserve a balance between their activities. A multitude of enzymes such as 
elastases, MMPs, cathepsins, caspases, and collagenases can all lead to the degradation of the extracellular 
matrix (ECM) in the lungs [363, 377]. Typically these enzymes are deployed in order to aid in wound 
repair processes, embryonic development, promoting fibrosis, and angiogenic remodeling [362]. Due to the 
dire consequences of their elastolytic and proteolytic activities, proteases are tightly regulated with a cadre 
of anti-proteases that protect the lungs from long term uncontrolled protease activity. However, in the case 
of α1-antitrypsin deficiency, this protease/anti-protease balance is no longer maintained and individuals 
with A1AD develop spontaneous emphysema [352, 353]. Upon exposure to tobacco smoke or other lung 
irritants, the balance between proteolytic activity and the activity of their inhibitors shifts [362]. This 
imbalance can result from either increased proteolytic activity (neutrophil elastase, cathepsins, MMPs) or 
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from deficiencies in anti-proteases (α1-antitrypsin, secretory leukoprotease inhibitor (SLPI), tissue 
inhibitors of metalloproteinases (TIMPs)) [360]. While there are many MMP family members, only MMP2 
(gelatinase A), MMP9 (gelatinase B), and MMP12 (macrophage elastase) are able to cleave elastin [363]. 
In order to maintain tissue homeostasis, these elastolytic proteases are generally controlled by secreted 
TIMPs, which bind to MMPs in a 1:1 ratio and inhibit their activity [385]. However, the activity of anti-
proteases like α1-antitrypsin and SLPI can be negatively impacted by oxidative stress [386-388]. 
 
Reactive oxygen species are a hallmark of innate immune responses. Like protease activity, a balance must 
be reached between oxidants and anti-oxidants in the lungs in order to maintain homeostasis. Activated 
neutrophils, macrophages, and AECs can generate strong oxidants such as super oxide anion (O2-; 
generated by NADPH oxidase) that can be converted to hydrogen peroxide (H2O2; generated by superoxide 
dismutase (SOD)), hydroxyl radical (OH; in the presence of free iron), peroxinitrite (ONOO-; in the 
presence of macrophage-derived nitric oxide), and hypochlorous acid (HOCl; in the presence of neutrophil-
derived myeloperoxidase) [360-362]. These powerful oxidants must be defended against as they can induce 
significant damage to DNA, proteins, and lipids. Enzymatic anti-oxidants such as catalase, SOD, and 
glutathione (GSH) peroxidase can counteract the effects of oxidants in the lungs [361]. In addition, non-
enzymatic scavengers such as reduced glutathione, vitamin C, and mucins can also counteract the activity 
of ROS/RNS [362]. In addition, the transcription factor nuclear factor-like 2 (Nrf2), is responsible for the 
regulation of glutathione peroxidase 2, an antioxidant, by binding to the anti-oxidant response element 
(ARE) [389]. Nrf2-/- mice are more susceptible to the effects of cigarette smoke (CS) exposure and develop 
exacerbated emphysema due to loss of oxidant/anti-oxidant balance [390, 391]. Imbalances in 
oxidants/anti-oxidants can directly lead to AEC damage and increases in pro-inflammatory mediators 
generated by AECs and LMs [362]. 
 
An imbalance in tissue repair mechanisms may contribute to the pathophysiology of emphysema. The lung 
structure maintenance program requires a balance between cell loss and cell regeneration [392, 393]. In 
order for balance to be maintained efficient clearance and replacement mechanisms must be in place. Stem 
cells must substitute for apoptotic cells in order for normal cell turnover to occur and to maintain tissue 
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structural integrity. In the lungs, vascular endothelial growth factor (VEGF), produced by LMs and type II 
AECs [394], is one factor that promotes the survival of capillary endothelial cells and AECs [395]. 
However, pulmonary VEGF and VEGF receptor 2 (VEGFR2; Flk-1/KDR) expression levels are 
diminished in COPD patients [396]. To that end, experimental VEGFR2 blockade [397] and lung-
conditional VEGF-deficiency [398] lead to airspace enlargement and emphysema through elevated 
apoptosis. Growth factors such as VEGF contribute to lung tissue structural and functional homeostasis, 
while disruption of the maintenance program (via interactions with other imbalances such as exacerbated 
protease activity or oxidative stress) can lead to progressive tissue destruction. Cell death, which occurs 
under a variety of scenarios, is the accepted cause for emphysema. It is imperative to gain further 
understanding how interactions between the stress pathways (protease/oxidant/maintenance) can impact the 
pathophysiology of emphysema. 
 
Table 1.6. Imbalances contributing to pathogenesis of emphysema 
Imbalance Major Players 
Protease/anti-protease Proteases: Neutrophil Elastase, 
Cathepsins, MMPs 
Anti-proteases: α1-AT, SLPI, TIMPs 
Oxidant/anti-oxidant Oxidants: O2-, H2O2, OH, HOCl, 
ONOO- 
Anti-oxidants: catalase, SOD, 




apoptosis, matrix proteolysis, 
oxidative stress 
Tissue regeneration: growth factors 
(VEGF, TGFβ1), anti-protease (α1-
AT), anti-oxidant (Nrf2)  
 
1.4.10 Outstanding questions 
There are still many questions surrounding the mechanisms underlying the pathophysiology of 
emphysematous changes to the lungs. For example, while tobacco smoke exposure is highly correlated with 
the progression of emphysema, not all long-term heavy smokers develop emphysema. Therefore, there 
must be other underlying factors that either protect or promote alveolar wall destruction upon 
environmental insult. Furthermore, the distribution of tissue destruction within the lungs of an emphysema 
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patient is not necessarily uniform; there may be micro-environmental differences that account for this 
disease heterogeneity. Also, it is essential to understand how emphysema differs from other pulmonary 
inflammatory conditions that recruit large numbers of inflammatory cells (such as ALI), as these conditions 
self-resolve and do not lead to alveolar wall destruction. It is clear that there are many cellular and 
molecular factors involved in this complex biological process leading to progressive alveolar wall 
destruction, therefore given their longevity and their ability to mediate inflammation long after acute insults 
in the study presented in CHAPTER 3, we will focus on the role of lung macrophages on the progression 
and manifestation of emphysematous changes to the lungs. 
 
It has been reported clinically and experimentally that there is significant expansion in the number of 
macrophages within the emphysematous lung. In human studies, several reports have shown increases in 
the number of LMs ranging from 5-10 fold up to 25 fold compared to non-emphysematous smokers with a 
similar exposure to tobacco smoke [399]. In addition, LMs have been shown to specifically localize near 
areas of alveolar wall destruction [400, 401]. Lastly, studies have shown that the number of LMs correlates 
with the degree of emphysema progression [374]. To date, the explanations provided for increased numbers 
of LMs have been centered on the possibility that additional cells are actively recruited from blood 
monocyte pools [402, 403], or are holdovers from prolonged macrophage survival or impairment of 
clearance mechanisms [404]. Interestingly, while the idea of local resident lung macrophage proliferation in 
the context of emphysema has been proposed in the past [224], the idea of terminally differentiated tissue 
macrophages proliferating is still not commonplace. In light of the recent paradigm shifts in macrophage 
biology discussed in CHAPTER 1.2.27, we set out to characterize the dynamics and function of the LM 
population during emphysematous changes in the lungs. The purpose of the research presented in 
CHAPTER 3 is to more clearly understand the role that lung macrophages play in the progression and 




The hypothesis to be tested is that lung-resident macrophages become activated and proliferate, without 
input from blood-derived monocyte populations, during acute elastase challenge and contribute towards the 
progression of emphysematous changes in the lungs. 
 
1.4.12 Approach 
The porcine pancreatic elastase (PPE) murine model of emphysema has been used since the protease-
antiprotease theory was first proposed in the 1960s [353]. Direct instillation of PPE and other proteases 
such as papain and neutrophil elastase have been used to model human emphysema [405, 406]. The PPE 
mouse model of human emphysema allows researchers to quickly, potently, and reproducibly activate a 
cascade of events that occurs in human populations, by tipping the balance between protease and anti-
protease activity in the lungs. The elastolytic murine models are much more attractive to the investigator as 
they are faster and more reliable than cigarette smoke (CS) model of emphysema. Porcine pancreatic 
elastase (PPE) is a serine protease that cleaves elastin fibers of the extracellular matrix (ECM). The ECM is 
composed of a dense fibrous network of elastin and collagen surrounding the alveoli and lung capillaries 
and allows the alveoli to stretch upon inspiration. In a healthy undamaged lung, the surrounding elastin 
fibers will stretch upon inspiration and cause the alveolus to contract upon expiration forcing out the carbon 
dioxide. However, in the case of emphysema, damage caused by elastolytic enzymes such as PPE, 
neutrophil elastase and MMPs impairs the elasticity of the alveoli, thereby leading to pulmonary 
obstruction. For an overview of the experimental design and histological and cellular dynamics typical of 
the PPE model of emphysema, please refer to Figure 1.7 (data previously incorporated into doctoral 
dissertation [407]). In addition to monitoring the progression of emphysema by lung structure assessments, 
pulmonary function tests (PFTs) can be employed to quantify and characterize the impacts of alveolar wall 
destruction at the tissue level. For an overview of the PFTs employed to assess the progression of 
emphysema in the PPE model, please refer to Table 1.7. Exogenous administration of this highly potent 
enzyme, PPE, acts as a spark plug or mimic for the protease imbalance elicited upon prolonged exposure to 
tobacco smoke in the lungs. The PPE model provides a reliable framework in order to probe the nature and 
dynamics of immune cell populations in the progression of emphysematous changes to the lungs.   
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Figure 1.7 Introduction to the porcine pancreatic elastase (PPE) murine model of emphysema  
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Table 1.7 Measures Used to Assess Emphysema Progression in PPE Model 
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* All measurements using PPE Model and depicted as mean ± SE 
Healthy Value: BALB/c mice administered PBS (i.t.) at day 21 
Emphysema Value: BALB/c mice administered 3U PPE (i.t.) at day 21 
 
1.5 THESIS AIMS 
 
In my thesis research I heed Mechnikov’s advice by paying particular attention to the phagocyte as I aim to 
explore the nature and dynamics of lung macrophage responses to distinct inflammatory insults, with the 
goal of further elucidating their role in immunity and human health. The studies outlined in CHAPTERS 2 
& 3 will focus on the role of resident and recruited macrophage subsets within the lungs in response to 
Plasmodium parasite infection (CHAPTER 2) or following protease-induced lung damage (CHAPTER 3). 
In these two studies, I will explore the nature of pulmonary myeloid cell responses as pertaining to 
inflammatory monocyte recruitment and local tissue macrophage proliferation. In CHAPTER 2, we 
investigate the nature of innate immune responses to an antigenic inflammatory insult (P. berghei: a 
pathogenic parasitic infection), which builds as a crescendo within the lung microvasculature. We 
demonstrate following infection with P. berghei, infected erythrocytes sequestered on the vascular 
endothelial surface result in lung pathology. We reveal that parasitized erythrocytes are cleared via 
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phagocytosis by inflammatory monocytes, but not by lung resident alveolar macrophages. We also 
determine that clearance of sequestered parasitized erythrocytes controls malaria-induced lung damage. In 
CHAPTER 3, we investigate the nature of innate immune responses to an inflammatory point source 
(elastase protease activity) resulting in sterile inflammation within the lower airways. We demonstrate that 
lung macrophages alter their surface phenotype in response to damage to the lung epithelium. In addition, 
we reveal that resident lung macrophages proliferate in response to elastase-mediated lung damage. It is my 
hope that through these studies, I can add some insight into the nature of lung macrophage function and 
dynamics in these inflammatory situations. 
 
1.5.1 SPECIFIC AIMS MALARIA: 
The overall goal of this project is to define the roles of lung-resident and recruited monocyte/macrophages 
in the control of malaria-induced inflammation and lung injury. 
 
Specific Aim 1: Define the role of lung-resident AMs in the control of malaria-induced 
inflammation and lung injury. 
 
Specific Aim 2: Define the role of inflammatory monocytes/macrophages in the control of 
malaria-induced inflammation and lung injury. 
 
1.5.2 SPECIFIC AIMS EMPHYSEMA: 
The overall goal of this project is to define the roles of the lung-resident and recruited 
monocyte/macrophages in the progression of events leading to elastase-induced emphysematous changes in 
the lungs. 
 
Specific Aim 1: Define the role of lung-resident AMs in the progression of elastase-induced 
emphysematous changes in the lungs. 
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Specific Aim 2: Define the role of inflammatory monocytes/macrophages in the progression 
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The contributions made by infected erythrocytes sequestered on lung microvasculature and their 
subsequent clearance by mononuclear cells to pulmonary complications associated with severe malaria 
have not been defined. Employing the P. berghei-C57BL/6 mouse model, we demonstrate that 
sequestration of infected erythrocytes on lung endothelium results in lung injury and a rapid recruitment of 
CCR2+CD11b+Ly6Chi monocytes. Recruited monocytes were activated within the pulmonary environment 
and were instrumental in the phagocytic clearance of adherent cells. In contrast, resident alveolar 
macrophages were not activated and did not participate in the clearance of malaria-infected cells. Infection 
of CCR2-/- animals, which exhibited impaired monocyte recruitment, resulted in enhanced levels of parasite 
sequestration and exacerbated lung injury. Adoptive transfer of CCR2+/+ bone marrow-derived monocytes 
into CCR2-/- animals was sufficient to protect lungs from enhanced injury. Furthermore, results obtained 
from CD36-/- and CD36 bone marrow chimeric mice show that sequestration in the absence of CD36-
mediated phagocytic clearance by monocytes results in exaggerated lung pathology. Hence, the level of 
malaria-induced lung pathology is proportional to the steady-state levels of infected erythrocytes adhering 
to the pulmonary vasculature and a major role of recruited monocytes is to reduce parasite burden in a 





Malaria infects over 200 million people each year resulting in over 600,000 deaths, mainly of children 
living in Sub-Saharan Africa [238]. Of the five species that infect humans, Plasmodium falciparum, P. 
vivax, P. malariae, P. ovale, and P. knowlesi, P. falciparum is responsible for a majority of the 68 million 
disability-adjusted life years (DALYs) lost attributed to malaria infection [239]. While malaria is most 
commonly considered an infection of erythrocytes that results in cyclical fevers and anemia, some of the 
most serious complications of infection are at the organ level in the brain, placenta and lungs [250-252]. 
 
Pulmonary complications occur in up to 25% of adults and 40% of children during the course of severe 
malaria [241, 254-256]. Furthermore, between 5% and 25% of adults and up to 30% of pregnant women 
develop acute lung injury (ALI) and acute respiratory distress syndrome (ARDS); some even after 
administration of antimalarials [241]. Traditionally, this malaria-associated respiratory distress has been 
attributed to the combined effects of metabolic acidosis, non-cardiogenic pulmonary edema and severe 
anemia [258]. While the role of parasite sequestration on vascular endothelial cells in the brain and placenta 
are well documented [409], our understanding of the contribution that the intense sequestration of malaria-
infected erythrocytes to lung microvasculature makes to pulmonary distress is limited and still evolving.  
 
Plasmodium sequestration is thought to be developmentally advantageous to the parasite because it 
prevents the recognition and clearance of the trophozoite- and schizont-containing erythrocytes by 
macrophages in the spleen [269]. The pattern of P. falciparum adherence observed in humans is selective in 
that most sequestration takes place in the lungs, adipose tissue, brain and placenta [270-272]. While the 
pathophysiological consequences of parasite sequestration on vascular endothelial cells in the brain and 
placenta are well documented, little is known about this process in the lungs. The cytoadherence of infected 
erythrocytes to endothelial cells has been shown to be dependent on interactions between an array of host- 
and parasite-derived factors in vitro. For P. falciparum, erythrocyte membrane protein 1 (PfEMP1), a 
parasite-produced molecule that is exported to the surface of the infected erythrocyte, endows trophozoite- 
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and schizont-containing red blood cells with the ability to interact with host ligands including chondroitin 
sulfate A, the scavenger receptor CD36 and the adhesion molecules ICAM-1 and PCAM-1 on the luminal 
surface of vascular endothelium [244, 275-277]. 
 
Because of the inherent difficulties of studying P. falciparum sequestration in the intact lungs of humans, 
murine models, most of which employ P. berghei infection, have been developed [288, 295, 326-329]. 
Similar to P. falciparum, P. berghei schizont-containing erythrocytes sequester in the lungs and adipose 
tissue via interactions with CD36 [266, 288, 295]. In P. berghei, where there is no clear ortholog of 
PfEMP1 in the genome, the parasite-expressed molecule designated SMAC has been implicated in the 
sequestration of schizont-infected erythrocytes on endothelial surfaces [326]. Utilizing the P. berghei 
model, it has been demonstrated that sequestration in the lungs, in addition to avoiding clearance in the 
spleen, has the added advantage of promoting factors that are beneficial for parasite growth [326, 337]. 
From the perspective of the host, adherence of parasitized cells to the pulmonary vasculature is not a 
benign even as there is a strong positive correlation between the level of parasite burden in the lungs and 
the degree of ALI [295]. While some malaria-associated pulmonary damage results from receptor-ligand 
interactions that trigger changes in barrier integrity when Plasmodium-infected erythrocytes cytoadhere to 
the vascular endothelium [278], the contributions that innate immune responses make to the pathogenesis 
of ALI are still not clear. 
 
Malaria induces a robust innate immune response that plays an important role in limiting parasite load 
through mechanisms that direct phagocytic cells to engulf and kill parasites as well as coordinate the 
development of an appropriate T cell-mediated effector response [248]. Specifically, mononuclear 
phagocytes have been shown to critical for the uptake and clearance of malaria-infected erythrocytes [300]. 
While it has been demonstrated that the CD11bhighLy6C+ subset of inflammatory monocytes are central to 
clearance of infected-erythrocytes in the spleen resulting in a partial control of blood parasitemia [325], the 
role that blood monocytes and tissue-resident macrophages play in the regulation of parasite burden in the 
lungs and malaria-induced pulmonary damage have not been defined. 
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In the work presented here, we employed P. berghei infections in mice to define the roles that lung-resident 
macrophages and recruited monocytes play in the regulation of malaria-induced pulmonary damage. We 
demonstrate that coincident with the onset of parasite sequestration in the lungs there is a dramatic and 
rapid recruitment of CCR2+CD11b+Ly6Chi monocytes.  These recruited monocytes were shown to be 
instrumental in controlling the level of damage through clearing infected erythrocytes adherent to lung 
endothelial cells. Lung pathology was significantly exacerbated in CCR2-deficient animals that were 
defective in monocyte recruitment and parasite clearance.  Adoptive transfer of CCR2+ monocytes into the 
lungs of CCR2-/- animals significantly reduced the level of malaria-induced lung damage.  Effective 
clearance by monocytes was shown to be largely dependent on the expression of CD36 on the surface of 
mononuclear cells. Importantly, lung-resident macrophages appeared to play only a minor role in clearing 
parasitized erythrocytes from the lungs, as they showed only minimal activation and did not proliferate in 
response to malaria challenge. 
 
2.3 MATERIALS AND METHODS 
 
2.3.1 Mice 
Age and sex-matched (male 6-12 weeks old) littermates were used for all experiments. C57BL/6J and 
CCR2-/- (B6.129S4-Ccr2tm1Ifc/J)] [410] were obtained from The Jackson Laboratory (Bar Harbor, ME, 
USA). CD36-/- mice on a C57BL/6 background were obtained from Dr. Maria Febbraio (Cleveland Clinic 
Foundation, Cleveland, OH, USA) [411]. All mice were maintained within barrier filter-top cages, 
provided food and water ad libitum, and exposed to a 12-hour light/dark cycle. All animal procedures 
performed in this study were approved by the Johns Hopkins Animal Care and Use Committee (Baltimore, 
MD, USA), and were in accordance with the National Research Council’s Guide for the Care and Use of 
Laboratory Animals federal guidelines. 
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2.3.2 Parasites and infection 
P. berghei ANKA (MRA-671) was obtained from the Malaria Research and Reference Reagent Resource 
Center (MR4) (Manassas, VA, USA). The transgenic parasite P. berghei ANKA-tdTomato (tdTPbA), 
which constitutively expressed the red fluorescent protein (tdTomato) under control of the elongation factor 
1 alpha (eef1a) promoter region, was obtained from Dr. Volker Heussler at the Bernhard Nocht Institute for 
Tropical Medicine in Hamburg, Germany [412]. Cryopreserved parasite stocks were passaged through 
donor mice (C57BL/6J) at least twice prior to infecting experimental mice. Infected donor mice were 
maintained until the eighth passage, when new parasites were started from cryopreserved stocks. Blood 
stage infections were initiated by introducing 106 parasitized erythrocytes via intra-peritoneal injection. 
Progression of the infection was measured by tracking changes in body weight and temperature. In 
addition, peripheral blood parasitemia was monitored via thin blood smear and Giemsa staining. 
 
2.3.3 Antibodies 
The following anti-mouse antibodies were purchased from BD Biosciences (San Jose, CA, USA) CD11b-
PerCP-Cy5.5 (550993), SiglecF-PE (552126), Ly6C-APC (560595), CD64-PE (558455), and CD86-PE 
(553692). F4/80-PE (12-4801-80), MHCII-PE (12-5321-81), CD40-PE (12-0401-81), CD45.2-PE (12-
0454-81), CD45.1-APC (912-0453-81), CD80-PE (12-0801-81), PD-L1-PE (12-5982-81), PD-L2-PE (12-
5986-83), and rat IgG2a κ isotype control-PE (12-4321-80) anti-mouse antibodies were purchased from 
eBioscience (San Diego, CA, USA). Anti-mouse CD11c-APC (130-091-844) was purchased from Miltenyi 
Biotec (Auburn, CA, USA). 
 
2.3.4 Flow cytometry 
Whole lung homogenates were generated as previously described [46]. Briefly, prior to excision from the 
chest cavity, lungs were perfused with 10 mL of room temperature sterile Dulbecco’s PBS via the right 
ventricle of the heart. Lungs were carefully removed and placed in 5 mL RPMI 1640 containing 1 mg/mL 
collagenase type II (1701-015, Life Technologies, Grand Island, NY, USA) and 30 µg/mL DNase I 
(10104159001, Roche Applied Science, Indianapolis, IN, USA), minced thoroughly, and incubated at 37°C 
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for 30 minutes. Minced lung suspensions were then ground through a 100-µm nylon cell strainer (352360, 
BD Biosciences), and the resulting cells were pelleted at 1500g at 4°C. Cells were suspended in ACK 
lysing buffer (118-156-721, Quality Biological Inc., Gaithersburg, MD, USA) to remove any contaminating 
erythrocytes, passed through a second cell strainer, and washed in FACS staining buffer [PBS containing 
2% heat-inactivated FCS (35-011-CV, Mediatech, Inc., Manassas, VA, USA)]. Cells were then treated with 
anti-mouse CD16/CD32 Fc Block (553142, BD Biosciences) 10 minutes prior to the addition of cell 
surface marker specific antibodies. All antibodies were incubated on ice for 20 minutes in the dark. Stained 
cells were then washed in FACS staining buffer prior to flow cytometric analysis. Cell counts were 
performed on a hemocytometer using trypan blue stain (15250-061, Life Technologies) to exclude dead 
cells. All data on whole lung homogenates or peripheral blood cells (collected via tail vein) were collected 
on a BD FACSCalibur flow cytometer (San Jose, CA, USA) and data analyzed using FlowJo (TreeStar 
Inc., Ashland, OR, USA). An Amnis ImageStreamX Mark II (Amnis Corporation, Seattle, WA, USA) was 
used to capture 60X magnification images of phagocytosis of transgenic P. berghei expressing tdTomato 
fluorescent protein by CD11b+ cells in the lungs. Briefly, whole lung homogenates were prepared as 
described above and stained with anti-mouse CD11b-PerCP-Cy5.5 antibodies (BD Biosciences). Cells were 
excited with the 560 nm yellow/green laser Channels containing brightfield (Channel 1: 420-480 nm), 
tdTomato fluorescence (Channel 4: 595-642 nm), or anti-CD11b fluorescence (Channel 5: 642-745 nm) 
and images were captured as single or two-channel (overlay) mode. 
 
2.3.5 Bronchoalveolar lavage (BAL) 
Murine surgeries were performed as previously described [413]. Briefly, mice were anaesthetized with 450 
mg/kg 2,2,2-tribromoethanol (Sigma-Aldrich, St. Louis, MO, USA) via intraperitoneal injection. An 
incision was made through the sternum and BAL fluid was obtained after a tracheostomy and lavaging of 
the lungs with 800 µl of sterile PBS three separate times at room temperature. BAL fluid from the three 
collections were pooled and centrifuged at 1,500 rpm for 3 minutes at 4°C. Cells were suspended in PBS 
and an aliquot was stained with trypan blue (Invitrogen, Grand Island, NY, USA) prior to counting on a 
hemocytometer using the 10X objective of an Olympus BH-2 microscope (Catharpin, VA, USA). Cells 
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(105) from each mouse were adhered to microscope slides with the aid of cytology funnels (Fisher 
Scientific, Houston, TX, USA) and a cytocentrifuge (Shandon Cytospin, Thermo Fisher Scientific, 




A 19-gauge gavage tube was inserted into a small hole in the trachea, and the lungs were inflated slowly 
with zinc-buffered formalin fixative (Z-fix) (174, Anatech Ltd., Battle Creek, MI, USA). The lungs were 
removed and incubated in Z-fix for 48 hours. Inflated and fixed lungs were embedded in paraffin, and 
sagittal, 5 µm sections, were cut from four different levels of lung. Lung sections were placed on slides and 
either left unstained or stained with hematoxylin and eosin. Lung sections (and cytology slides) were 
examined using a Nikon Eclipse E800 light microscope (Nikon Instruments Inc., Melville, NY, USA), and 
images were acquired using SPOT RT charge-coupled device imager and software (Diagnostic Instruments, 
Inc., Sterling Heights, MI, USA). 
 
2.3.7 Evans Blue extravasation 
To measure albumin extravasation in the lungs of mice, 100 µL of a 1% (1 mg total) solution of Evan’s 
Blue dye was administered intravenously via tail vein and allowed to circulate for 1 hour. The lungs were 
then perfused as described above, excised, and weighed. The lungs were homogenized in 1 mL formamide 
using a Polytron PT 10-35 homogenizer (Kinematica, Inc., Bohemia, NY, USA). Lung homogenates were 
incubated at 60°C for 24 hours and then centrifuged at 12,000g at 4°C for 30 minutes. The supernatant was 
removed and the absorbance (OD) was measured at 620 nm and 740 nm using a Molecular Devices 
SpectraMax M2 microplate reader (Sunnyvale, CA, USA) and compared to a standard curve. Corrected 
absorbance values were calculated using the following equation: corrected absorbance (620)= absorbance 
(620)- (1.426 * absorbance (740) + 0.03) [414]. The Evans blue concentration was then converted to µg 
Evans Blue/g of wet lung. 
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2.3.8 Hemozoin quantification 
Hemozoin was purified as previously described [415]. Briefly, frozen lung samples were homogenized in 
distilled deionized water using a Polytron PT 10-35 homogenizer (Kinematica, Inc., Bohemia, NY, USA) 
and centrifuged at 14,000g for 15 minutes. The supernatant fraction was removed and the pellets suspended 
in 1 mL 2% SDS, 100 mM sodium bicarbonate. These fractions were spun down as above and the pellets 
washed in 2% SDS and centrifuged. Washed pellets were suspended in a buffered solution of 1 mg/mL 
proteinase K (Roche, Mannheim, Germany) and incubated overnight at 60°C. Following incubation, 
samples were washed in distilled deionized water. Purified hemozoin pellets were then decrystallized in 1 
ml 2% SDS 20 mM NaOH for 1 hour and spectrophotometrically quantitated by measuring OD 400 nm. 
Initial hemozoin concentrations were determined using a hemin standard curve in a Perkin Elmer HTS 
7000 96 well plate reader (Waltham, MA, USA). 
 
Photographs of representative fields (60X objective lens) from three different levels of the lung were 
counted for hemozoin crystal/pigment containing cells (parasitized erythrocytes or mononuclear cells 
containing dense brown crystals). For each mouse, 30 fields (60X) were counted for hemozoin+ cells and 
cellular area (pixel) was determined by pixel masks (Adobe Photoshop, San Jose, CA). The number of 
hemozoin+ cells was normalized to the peripheral blood parasitemia and cellular area of each field. 
 
2.3.9 Adoptive transfer of monocytes 
Bone marrow derived monocytes (BMMs) were generated as previously described [416]. Briefly, bone 
marrow cells were flushed from the femurs and tibias of donor (C57BL/6J) mice using complete RPMI 
media including 10% FCS. The isolated bone marrow cells were filtered through a 70-µm cell strainer 
(352350, BD Falcon) and pelleted. Erythrocytes were removed by osmotic lysis using ACK buffer. 
Mononuclear bone marrow cells were enumerated and plated at a density of 1x106/mL in complete RPMI 
media containing 10% FCS and 20 ng/mL recombinant mouse M-CSF (130-094-129, Miltenyi Biotec) in 
6-well ultra low adhesion plates (3471, Corning Incorporated, Tewksbury, MA, USA). Bone marrow cells 
were differentiated at 37°C with 5% CO2 for five days. BMMs were collected from the cell culture 
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supernatant (non-adherent cells), washed in Dulbecco’s PBS, and enumerated using a hemocytometer. Prior 
to adoptive transfer, BMMs were characterized morphologically by cytospin and phenotypically by flow 
cytometry. For adoptive transfer, 1x106 BMMs/100 µL Dulbecco’s PBS were administered via intratracheal 
aspiration. 
 
2.3.10 Pulmonary Edema 
Pulmonary edema was assessed by gravimetric analysis. Lungs from naïve or Plasmodium-infected mice 
were extracted following exsanguination via incision of the left inferior vena cava and the abdominal aorta. 
Lobes of the lungs were separated, weighed wet, dried completely in a 65°C oven (>72 hours), and then 
weighed dry to determine the wet:dry ratio. 
 
2.3.11 Nucleic acid isolation and gene expression analysis 
Lungs were harvested and flash frozen in liquid nitrogen prior to homogenization in Trizol Reagent 
(15596018, Life Technologies) using a Polytron PT 10-35 homogenizer (Kinematica, Inc., Bohemia, NY, 
USA). RNA and genomic DNA were isolated from lung homogenates following the manufacturer’s 
instructions. Lung RNA and genomic DNA quantity and purity were assessed by A260/280 absorbance 
using a Nanodrop ND-1000 (Nanodrop Products, Wilmington, DE, USA). Lung RNA (1 µg) was then 
reverse-transcribed using the SuperScript II first-strand synthesis system for RT-PCR (100004925, Life 
Technologies) using oligo (dT) (12-18) primers (58862, Life Technologies). Quantitative real-time RT-
PCR was performed using the Applied Biosystems 7500 realtime PCR system, TaqMan Gene Expression 
Assays-On-Demand, and Taq-Man Universal Master Mix (Life Technologies). The following assays 
(Applied Biosystems) were used: Ccl2 (Mm00441242_m1), Ccl3 (Mm00441259_g1), Ccl4 
(Mm00443111_m1), Ccl7 (Mm00443113_m1), Ccl8 (Mm01297183_m1), Cx3cl1 (Mm00436454_m1), 
Gapdh (Mm99999915_g1), Ifng (Mm00801778_m1), Nos2 (Mm00440502_m1), and Tnf 
(Mm00443260_g1). TaqMan reactions were performed using 1 µL cDNA product or 100 ng genomic DNA 
in a 25 µL reaction volume and the following thermal cycler profile: 10 minutes denaturation at 95°C, 50 
cycles of 15 seconds denaturation at 95°C, followed by 1 minute extension at 60°C. Analysis was 
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performed using the Applied Biosystems 7500 system SDS software package (Life Technologies). Relative 
expression units were generated by comparing individual expression levels to a standard curves generated 
using pooled cDNAs as a template. All genes were normalized to a housekeeping gene control (Gapdh). To 
calculate parasite genome equivalents, known P. berghei genomic DNA standards for comparison with 
samples from whole lung homogenates [417]. 
 
2.3.12 Statistical analysis 
Statistical significance was evaluated by using the 2-tailed t test (Tukey) and the one-way analysis of 




2.4.1 Plasmodium berghei infection results in acute lung injury (ALI) 
As early as day three post-P. berghei infection, when parasitemia (Figure 2.1A) and parasite burden in the 
lungs (Figure 2.1B, 2.1C) was detectible, but limited, mice presented evidence of organ-level pathology 
with lungs that remained engorged with blood following perfusion (Figure 2.2A). As infection progressed 
and the number of parasites associated with the lungs increased, the outward appearance of perfused lungs 
transitioned to a dark, reddish-brown color by day 6 (Figure 2.2A). Employing PCR-based detection of the 
P. berghei 18S rRNA gene, it was estimated that ~1.25 x 108 P. berghei genomes were present in perfused 
lungs at day 5 post-infection (Figure 2.1B). Although parasitemia continued to rise in the peripheral blood 
(Figure 2.1A), the total parasite burden detected in perfused lungs at days 6-7 as measured by 18S (Figure 
2.1B) or by hemozoin accumulation (Figure 2.1C) plateaued or decreased. 
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Figure 2.1 Parasite burden in the lungs of Plasmodium berghei-infected mice.  
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In accordance with the gross appearance of the lungs of infected mice, histological analysis revealed 
hallmarks of acute lung injury including pulmonary edema, alveolar septal wall thickening and 
mononuclear cell infiltration (Figure 2.2B), as well as evidence of parasite material contained within 
mononuclear cells (Figure 2.2C). Parasite accumulation in the lungs was accompanied by a loss of in the 
integrity of vascular endothelial barrier function denoted by a 30-fold increase in the amount of 
extravasated Evan’s Blue in perfused lungs from infected compared to uninfected animals (Figure 2.2D). 
 
2.4.2 Dynamics of lung-resident macrophages and recruited inflammatory monocytes  
The pulmonary damage caused by malaria infection was accompanied by a significant increase in the 
number of immune cells found in the BAL at day 6 post-infection, which were dominated by mononuclear 
phils) and lymphocytes (Figure 2.3A). A 
majority of the cells in the BAL at day 6 of infection had an activated appearance with highly vacuolated 
cytoplasm and a small percentage of the cells showed evidence that they had engulfed parasitized cells 
(Figure 2.3B). The recruitment of inflammatory monocytes into the lungs paralleled changes in 
transcription of the genes encoding CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), CCL7 (MCP-3), 
and CCL8 (MCP-2) – chemokines reported to promote recruitment of mononuclear cells [418] (Figure 2.4). 
Ccl2, Ccl4, Ccl7, and Ccl8 expression levels peaked at day 5 post-infection and waned by day 6. In 
contrast, expression of fractalkine (Cx3cl1), a chemokine involved in recruitment of monocytes and T cells 
to the lung [419] did not increase in response to P. berghei infection (Figure 2.4). 
 
To determine if the observed increase in mononuclear cells in the BAL could be extended to the whole 
lung, flow cytometry of single-cell suspensions from perfused lungs was employed to determine the 
population dynamics of macrophages and monocytes at days 3, 5 and 6 post-P. berghei infection. 
Interestingly, while the number of lung-resident alveolar macrophages (AM; CD11c+ SiglecF+ CD11b- 
Ly6Clo) remained stable over the first six days, there was a substantial increase in the number of cells with 
the surface signature of inflammatory monocytes (CD11c- SiglecF- CD11b+ Ly6C+) as early as day 3 post-
infection (Figures 2.5A, 2.5B). Since these CD11c- SiglecF- CD11b+ Ly6C+ cells were no longer in the  
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Figure 2.2 Plasmodium berghei infection leads to acute lung injury  
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Figure 2.3 Cellular dynamics in the airways during P. berghei infection  
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Figure 2.4 Dynamics of cytokine expression in the lungs of C57BL/6 mice during the course of P. berghei infection  
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Figure 2.5 Dynamics of mononuclear cells in the lungs during P. berghei infection  
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vascular compartment, they were designated monocyte-derived lung macrophages (MDM). This increase in 
MDM numbers in perfused lungs was maintained through day 6 of infection (Figure 2.5B). 
 
2.4.3 Recruited monocytes are responsible for parasite clearance in the lungs 
The significant influx of MDM and the lack of change in the number of AM in the face of increasing 
parasite load suggested that these two mononuclear cell populations may have distinct roles in managing 
parasite load in the lungs. To look at this issue in more detail, we employed a transgenic P. berghei ANKA 
line that constitutively expresses the red fluorescent protein, tdTomato (tdTPbA) [412] to assess the 
dynamics of parasite clearance by phagocytosis. Increases in blood parasitemia, as measured through 
detection of the tdTomato signal (Figure 2.6A) and by counting infected red blood cells in smears (data not 
shown), were comparable to non-transgenic parasites (Figure 2.1A). The fluorescent signal from tdTPbA 
was employed to determine which macrophage subset is responsible for the phagocytic clearance of 
schizont-infected erythrocytes. Lungs were perfused and harvested at days 3, 5 and 6 post-infection and the 
number and surface phenotype of the cells that had taken up the fluorescent parasites were evaluated. There 
was an increase in the number of parasite-positive cells from days 3 to 6 of infection (Figure 2.6B). 
Evaluation of the surface phenotype of the tdTomato+ cells revealed that only a small percentage of the 
fluorescence was associated with AM (8.2%, 3.6%, 3.6% on days 3, 5 and 6, respectively), whereas a vast 
majority of the tdTPbA fluorescent signal was associated with the MDM population (61%, 88%, 88% at 
days 3, 5 and 6, respectively) (Figures 2.6C, 2.6D). Employing flow cytometry-assisted fluorescent 
microscopy it was determined that the nature of the interactions between the MDM and the tdTPbA-
infected erythrocytes included surface attachment, engulfment of intact infected erythrocytes and various 
stages of intracellular degradation of the parasite (Figure 2.7). 
 
2.4.4 Activation status of AM and MDM following P. berghei infection 
To determine if the distinctions in the dynamics and phagocytic function between resident and recruited 
lung myeloid cells observed at day 6 post-infection were reflected in their activation status, the expression 
levels of F4/80, MHCII, SiglecF, CD40, CD80, CD86, PDL1, PDL2, and CD64 on these cells were  
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Figure 2.6 Dynamics of parasite phagocytosis in the lungs during P. berghei infection  
 81 
  
Figure 2.7 Visualization of P. berghei phagocytosis 
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compared. The CD11b- CD11c+ AM from naïve animals were characteristically F4/80low, MHCIIlow, 
SiglecF+, and CD64+ (Figure 2.8A) [11, 57, 58]. The resident cells were also PDL1+ and expressed low 
levels of CD80 at baseline. With the exception of an increase in the expression of MHCII, the AM isolated 
from day 6 had a nearly identical surface phenotype as cells from naïve animals (Figure 2.8A) suggesting 
that AM were only minimally activated by the presence of infected erythrocytes. 
 
Since there was no demonstrable extra-vascular population of monocytes in the lungs of naïve animals, we 
used cells isolated from the peripheral blood of naïve animals to estimate the pre-infection surface 
phenotype of blood monocytes. These CD11b+ CD11c- Ly6C+ peripheral blood monocytes had low levels 
of F4/80, CD80, and CD86 and minimal detectable levels of MHCII, SiglecF, CD40, PDL1, PDL2, and 
CD64 (Figure 2.8B). At day 6 of infection, the peripheral blood monocytes showed evidence of partial 
activation by up-regulated surface expression of F4/80, CD80, PDL1 and CD64. In contrast, the CD11b+ 
CD11c- Ly6C+ MDM isolated from perfused whole lungs displayed notably higher surface levels of F4/80, 
MHCII, CD40, CD80, CD86, PDL1 and CD64 (Figure 2.8C). The recruited MDM remained negative for 
SiglecF and PDL2. Thus, while there is evidence for limited activation of monocytes in the peripheral 
blood during malaria infection, these cells take on a more robust activation phenotype after they are 
recruited to the lungs in the context of malaria infection. 
 
For many of the activation markers on MDM there was a bimodal distribution of staining, suggesting the 
presence of a population of MDM that robustly increased expression and a second population that did not 
(Figure 2.8C). It was hypothesized that the population which up-regulated activation markers such as 
MHCII, CD80 and PDL1 were the MDM in the process of clearing schizont-infected erythrocytes from the 
pulmonary environment. After establishing that CD80, MHC II and PDL1 were all up-regulated and co-
expressed on a common population of MDM (data not shown), the two MDM populations were 
discriminated based on high or low levels of the activation markers to determine the level of parasite uptake 
(tdTPbA+ signal) associated with each population (Figure 2.9). A vast majority of the parasite-positive cells 
were found within the MDM group that had elevated surface levels of MHCII, CD80 and PDL1. These  
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Figure 2.8 Activation of alveolar macrophages (AM) and monocyte-derived macrophage (MDM) populations following malaria infection  
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Figure 2.10 CCR2-deficiency results in altered cell trafficking and parasite uptake  
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results indicate that direct contact with the infected erythrocytes may be required for full activation of the 
monocytes recruited to the lungs during infection. 
 
2.4.5 CCR2-deficiency impairs monocyte recruitment and parasite clearance from the lungs 
Based on the result that the MDM appear to be responsible for the bulk of parasite uptake and clearance, 
we tested the hypothesis that impeding entry of these cells into the lungs results in a higher baseline level of 
parasite sequestration and exacerbated pulmonary injury. This hypothesis was tested employing CCR2-
deficient mice, which do not respond to the major monocyte chemotactic chemokine CCL2 [410], a 
chemokine that is highly expressed in the lungs during malaria infection (Figure 2.4). Infection of CCR2-/- 
mice with tdTPbA resulted in parasite levels in the blood (Figure 2.10B) and numbers and activation status 
of AM (Figure 2.11A) that were not significantly different from WT animals. As expected, the peak in the 
number of recruited inflammatory monocytes and consequently the number of MDM was greatly 
diminished in the lungs from CCR2-/- mice (Figure 2.10A). Consistent with previously published 
observations [195], a majority of the monocytes in CCR2-deficient animals were unable to exit from the 
bone marrow (data not shown). The monocytes found in the lungs of infected CCR2-/- animals at days 5 and 
6 were presumably recruited by chemotactic factors other than CCL2 such as CCL3 and CCL7 (Figure 
2.4). Moreover, the inflammatory monocytes that were present in the blood and the MDM in the lungs of 
CCR2-/- animals at day 6 of infection had a significantly diminished activation status compared to that 
observed in WT animals. In contrast to the response in WT animals, the levels of F4/80+, MHCII+, CD40+, 
CD80+, CD86+, PDL1+ and CD64+ were not up-regulated on the surface of the MDM isolated from the 
perfused lungs of CCR2-/- mice (Figure 2.11C). Consistent with their lower numbers, significantly fewer 
MDM containing tdTPbA-infected RBCs were identified from the lungs of CCR2-/- animals compared to 




Figure 2.11 Activation of CCR2-deficient alveolar macrophages (AM) and monocyte-derived macrophage (MDM) populations following malaria infection  
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2.4.6 CCR2-deficiency results in increased parasite burden, elevated pro-inflammatory cytokine 
expression and exacerbated lung damage. 
The observed deficits in monocyte recruitment and parasite uptake in the lungs of CCR2-/- animals 
suggested that these animals may carry a higher parasite burden and thus suffer elevated levels of parasite-
mediated lung damage [278]. Indeed, despite equivalent peripheral blood parasitemia at day 6 post-
infection (Figure 2.12A), the lungs from CCR2-/- mice had significantly higher parasite burden, as 
measured by lung hemozoin content, than WT mice (Figure 2.12B). In order to assess the impact increased 
parasite burden had on the inflammatory milieu of the lungs, the expression levels of Ccl2, Nos2, Tnf, and 
Ifnγ were measured in the lungs of naïve and P. berghei-infected WT and CCR2-/- mice. We observed 
significantly elevated expression of Ccl2, Tnf, and Ifnγ in both WT and CCR2-deficient mice in response to 
malaria infection (Figure 2.13). Notably, the transcription levels of Ccl2, Tnf, and Ifnγ in CCR2-/- lungs at 
day 6 were significantly elevated compared to WT suggesting a heightened inflammatory state. 
Interestingly, despite the increases in IFNγ transcription in WT and CCR2-/- lungs, malaria infection 
resulted in a similar level of suppression of Nos2 expression both strains (Figure 2.13). Elevated pulmonary 
parasite load and pro-inflammatory cytokine expression were associated with significantly higher lung 
wet:dry ratios in CCR2-/- mice compared to WT controls (Figure  2.14A) indicative of a severe disruption 
to the lung endothelial barrier. The exacerbated loss of endothelial barrier integrity and edema observed in 
CCR2-/- mice was also evident when sections of the lungs were examined by light microscopy (Figure 
2.14B).  
 
2.4.7 Adoptive transfer of monocytes into CCR2-/- lungs is protective. 
The results obtained from CCR2-/- animals suggested that recruited monocytes/MDM play a role in 
restricting the extent of lung pathology and predicted that adoptive transfer of monocytes into CCR2-/- mice 
would lead to protection from the exacerbated lung injury phenotype. WT bone marrow-derived monocytes 
(BMM; 106) were administered IT to CCR2-/- animals at day 4 post-P. berghei infection and lungs were 
harvested at day 6 to assess the levels of edema by wet:dry ratios and lung damage by histology. The BMM 
adoptive transfer resulted in a significant decrease in lung wet:dry ratio (Figure 2.15A) and a notable  
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Figure 2.14 CCR2-deficiency results in exacerbation of lung injury 
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decrease in histological evidence of pulmonary edema compared to the PBS controls (Figure 2.15B). These 
data suggest that a functional MDM population in the lungs is critical for the clearance of parasitized 
erythrocytes and ameliorating pulmonary lung injury. 
 
2.4.8 CD36 is necessary for efficient clearance of sequestered infected erythrocytes by recruited 
monocytes 
Previous studies have demonstrated that the scavenger receptor CD36 plays important roles in the 
dynamics of malaria in the lung [295]. CD36 is expressed on lung vascular endothelial cells where it 
interacts with malaria-derived molecules on the surface of infected erythrocytes and mediates sequestration 
[326, 420, 421]. In addition, CD36 is expressed on the surface of macrophages and monocytes where it 
serves as a key receptor for phagocytosis of infected erythrocytes containing late blood-stage parasites 
[289, 422, 423]. To determine the contribution of CD36 monocyte/macrophage-mediated parasite clearance 
and the development of lung pathology, we infected CD36-deficient mice with tdTPbA and assessed the 
lungs for temporal changes in AM and MDM at days 3, 5 and 6 post-infection. As observed for WT mice, 
infection resulted in a significant increase in CD11c- SiglecF- CD11b+ Ly6C+ MDM and no change in the 
number of CD11c+ SiglecF+ CD11b- Ly6Clo AM in malaria-infected CD36-/- animals (Figure 2.16A). While 
there was a trend for fewer MDM at each day tested, the numbers in CD36-/- animals were not significantly 
different from those observed in WT lungs. As expected, due to absence of CD36-mediated sequestration 
and phagocytosis, CD36-deficient animals had significantly fewer MDM that engulfed parasite material 
(Figures 2.16B, 2.16C) and on a per cell basis the MDM contained a lower mean fluorescence intensity 
compared to cells isolated from WT lungs (Figure 2.16D).  
The AM from CD36-/- animals at day 0 and 6 of infection had nearly identical surface phenotypes to the 
AM from WT mice (Figure 2.17A). It is interesting to note that, although lacking a CD36-mediated 
mechanism to engulf parasitized erythrocytes, the CD36-/- MDM that did take up parasites had an activation 













Figure 2.17 Activation of CD36-deficient alveolar macrophages (AM) and monocyte-derived macrophage (MDM) populations following malaria infection   
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NOTE: Supporting unpublished experiments were carried out in CD36-/- chimeric mice by Dr. Ifeanyi 
Anidi (data previously incorporated into doctoral dissertation [424]). Please refer to APPENDIX I for all 
methods, results, and figures. Dr. Anidi’s experiments described in APPENDIX I will be referenced in the 




Employing the P. berghei-C57BL/6 system to model the dynamics of malaria-induced pathology in the 
lungs, we demonstrated that coincident with the onset of cytoadherence of infected-erythrocytes to the 
pulmonary microvasculature there was a rapid and robust recruitment of CCR2+CD11b+Ly6Chi 
inflammatory monocytes to the lungs. Furthermore, recruited monocyte-derived macrophages (MDM) were 
instrumental in controlling the extent of lung damage, in part through clearing adherent infected 
erythrocytes from the vascular endothelium, thus limiting the steady-state parasite burden in the lung. 
 
The significance of CCR2+CD11b+Ly6Chi monocytes as innate effector cells during malaria has been 
studied previously in the context of the spleen during P. chabaudi infection in mice [325]. This prior study 
demonstrated that a population of CD11bhighLy6C+ cells migrated to the spleen during infection and that 
these monocytes effectively limited acute-stage parasitemia. Similar to the results presented here for the 
monocytes recruited to the lungs, CD11bhighLy6C+ splenic monocytes readily engulfed malaria-infected 
erythrocytes and up-regulated surface markers associated with cell activation and antigen presentation. 
Interestingly, although they expressed molecules that suggested the potential for antigen presentation, the 
recruited CD11bhighLy6C+ splenic monocytes were significantly less efficient than DCs in antigen 
presentation [325]. It is possible that CCR2+CD11b+Ly6Chi monocytes activated in the presence of malarial 
antigens become committed to rapid and extensive degradation of malaria antigens, thus reducing the 
monocyte’s ability to present antigen to T cells despite high levels of MHCII and co-stimulatory molecules. 
In future work, it will be of interest to determine if the recruited CCR2+CD11b+Ly6Chi MDM, which also 
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actively engulfed parasitized cells and showed a robust activation phenotype (Figures 2.6, 2.7, 2.8C), have 
the ability to efficiently present malaria antigens to T cells. 
 
While the surface markers used here allowed us to track changes in the AM and recruited monocytes/MDM 
populations [57, 58, 425], these markers precluded evaluation of the response of lung-resident interstitial 
macrophages to malaria infection. Interstitial macrophages have a distinct surface phenotype [425] which 
presumably reflects different functional properties compared with alveolar macrophages. Additional work 
will be required to define the contribution, if any, that interstitial macrophages provide to the overall 
response to malaria in the lungs. 
 
The activation phenotype of the MDM was distinct from the partial activation status observed for the 
CD11b+ Ly6Chi monocytes sampled from the peripheral blood at the same time (Figures 2.6B, 2.6C). The 
CD11b+ Ly6Chi monocytes in the blood showed little evidence that they were active in taking up parasitized 
cells prior to entering the lung (data not shown). The data suggest that MDM are activated within the 
environment of the infected lung, perhaps upon encounter with the local cytokine milieu or as a 
consequence of engulfing parasitized erythrocytes (Figure 2.7).   
 
Despite increasing numbers of parasitized cells in the blood and, presumably, an increasing number of cells 
sequestering in the lung, the number of MDM peaked at day 5 of infection suggesting a mechanism that 
limits the number inflammatory cells entering the lungs. However, it is also possible that monocytes 
continue to be recruited to the lung, but apoptosis, a substantial change in surface phenotype and/or exit 
from the lungs could combine to result in the appearance of a limit on recruitment. It is interesting to note 
that, although the total number appears to plateau, the proportion of the MDM that had taken up parasite-
containing cells (as measured by fluorescent signal from tdTPbA) increased significantly from day 5 to day 
6 (Figure 2.10D). The use of the fluorescent signal from tdTPbA parasites as a measure of phagocytosis of 
sequestered cells is likely to identify only recent phagocytic events and to be a significant underestimate of 
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the extent of parasite up-take. The presumption is that as the infected erythrocyte is degraded in the acidic 
phagolysosomal compartment of the MDM, the fluorescent signal will be rapidly extinguished. 
 
Lung-resident macrophages (LRM), like the Kupffer cells in the liver, glial cells in the central nervous 
system and osteoclasts in bone, have distinct functional characteristics that are shaped by their local 
environment [9]. Recent studies have revealed that tissue-resident macrophages are seeded into tissues 
prior to birth from progenitors originating from the yolk sac [145, 196, 203, 205] and that these cells have a 
capacity for in situ self-renewal to maintain steady state levels [196, 208], for replacement after depletion 
[426], or in response to infections [231, 427]. In disease settings, this ability of tissue-resident macrophages 
to proliferate has prompted a reevaluation of how we interpret the functional dynamics of the mononuclear 
phagocytes at sites of inflammation and the functional roles assigned to resident macrophages and the 
monocyte-derived cells that are recruited to inflamed tissues. In the absence of disease, LRM, especially 
alveolar macrophages, are vital components of the homeostatic mechanism that prevents pulmonary 
inflammation to common environmental exposures (reviewed in [425]). In the context of the acute malaria 
infection in the lungs, the AM, which showed no evidence of proliferation and little evidence of activation 
(Figures 2.5B, 2.8A), appear to have only a minor role in responding in a pro-inflammatory fashion to 
parasite sequestration in the pulmonary vasculature. The AM retained their apparent non-activated status 
even under conditions of CCR2-deficiency, where blunted monocyte recruitment resulted in an elevated 
parasite burden and exacerbated lung reactivity (Figures 2.12, 2.13, 2.14). It appears that a feature of the 
limited activation status of the AM during malaria is a restricted capacity to engulf and clear schizont-
infected erythrocytes from the lungs. As the chief role of AM is to respond to challenges within the alveolar 
spaces, it is possible that as long as the malaria-infected cells remain in the vascular compartment (or 
within the phagosomes of MDM), AM do not receive the appropriate activation signals. 
 
This lack of responsiveness during malaria infection is in contrast to the AM proliferation observed in 
response to helminth and virus challenge [208, 427]. The lack of AM proliferation could reflect an absence 
of proper signals during the acute phase of infection. Both the larval helminth parasites and influenza virus 
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result in considerable lung epithelial cell damage resulting in the release of DAMPS, alarmins or other 
signaling molecules that could serve as a cue for AM proliferation. IL-4, one of the factors shown to induce 
peritoneal macrophages to proliferate [231, 232], was not detected during the early phase of P. berghei 
infection in C57BL/6 mice (personal communication, J.M. Craig). Although it is clear that AM have the 
capacity to rapidly expand in response to a pathogen challenge [427], it could be that AM proliferation is 
delayed during malaria until the chronic phase of the infection. 
 
Instead of playing an active role in controlling parasite burden, it is possible that the role of AM during 
acute malaria is to regulate the level of activity of the recruited monocytes and set the stage for the 
appropriate anti-malaria adaptive response that will ensue. The surface phenotype (up-regulation of 
MHCII, no expression of CD40, CD86 or CD80 and constitutive expression of PDL1 (Figure 2.8A) and 
their demonstrated capacity to traffic antigen to draining lymph nodes [428] suggests that AM have the 
potential to regulate T cell-mediated immunity. However, the lack of direct uptake of infected erythrocytes 
by the AM speaks against a direct role in modulating the adaptive mucosal immune response against 
malaria. Additional work is required to assign a functional role for the AM during the innate stages of 
malaria infection.  
 
The diminished monocyte influx and increased parasite burden in the lungs of malaria-infected CCR2-/- 
mice was associated with a notable increase in pathology (Figure 2.14). While it is likely that the 
heightened parasite load that resulted from reduced phagocytic clearance played a central role in the 
enhanced level of edema, we cannot exclude a contribution from the altered cytokine environment in 
CCR2-/- lungs. In addition to its role as a powerful chemokine for monocytes, CCL2 signaling influences 
the function of activated mononuclear cells. Defective CCR2 signaling results in cells that produce higher 
levels of TNF and lower IL-10 [429-432]. CCR2-deficient lungs had significantly elevated expression of 
tnf and ifnγ (Figure 2.13) that could contribute indirectly to the severity of the response to malaria. 
 
In an alternate approach to study the relationships between sequestration, macrophage/monocyte function 
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and lung pathology we utilized CD36-deficient mice. In P. berghei infections CD36 plays several 
important roles. It is expressed on lung vascular endothelial cells where it serves as a binding partner with 
SMAC on the surface of parasite-infected erythrocytes allowing adhesion and sequestration [326]. CD36 is 
also expressed on the surface of macrophages and monocytes where it serves as a receptor that mediates 
recognition and phagocytosis of Plasmodium-infected erythrocytes [289, 422, 423]. The results reported 
here are consistent with the observations that CD36-deficient lungs have a significantly reduced parasite 
burden and attenuated pathology [295, 328]. Interestingly, despite a reduced parasite burden in the lungs 
and a notable reduction in phagocytosis, the number of monocytes recruited into the lungs (Figure 2.16A) 
and the level of activation of the MDM (Figure 2.17C) in CD36-/- animals were similar to WT mice. 
 
A majority of the reports that used CD36-/- animals to study malaria in the lungs observed a significant 
reduction in parasite burden and ALI [295, 328], but could not differentiate the contributions of endothelial 
cell-expressed and monocyte/macrophage-expressed CD36 to the phenotype. The single report that 
employed a bone marrow chimera approach similar to the one used here, concluded, based only on survival 
data, that CD36 on non-hematopoietic cells was harmful [288]. We used a CD36 bone marrow chimera 
approach to study the relative contributions of CD36 expression on hematopoietic and non-hematopoietic 
cells at the cellular and tissue levels (APPENDIX I). The work presented here, provides a cellular 
mechanism for this observation. Our results are consistent with a model in which the degree of malaria-
induced lung pathology is proportional to the steady-state levels of infected erythrocytes adhering to the 
pulmonary vasculature (Figure AI.1E, AI.2A, AI.2B). Furthermore, parasite burden in the lungs is 
influenced by the relative level and efficiency of CD36-mediated clearance of sequestered parasites by 
recruited MDM (Figure AI.1C). This model suggests that targeted inhibition of sequestration in the lungs of 
humans at risk for developing malaria-associated ALI or ARDS could be a valuable adjunct therapy to limit 
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There is significant need to reveal the contributions made by lung macrophages to the progression of 
alveolar wall destruction resulting in emphysema. Employing the porcine pancreatic elastase (PPE) mouse 
model of emphysema, we demonstrate that lung-resident alveolar macrophages became activated following 
elastase-induced lung injury. Alveolar macrophages (AM) dynamically changed their cell morphology, 
surface phenotype and activation state. PKH26-PCL, a red fluorescent dye, was used for in vivo labeling of 
lung-resident phagocytic cells prior to PPE administration. Flow cytometric analysis of BAL-derived cells 
and lung homogenates demonstrated that the total number of AM roughly doubled between days 2 and 7 
post-PPE administration before returning to untreated control levels by day 14. Similar AM dynamics were 
observed in CCR2-/- mice, suggesting that the elevated AM numbers were independent of 
CD11b+Ly6C+CCR2+ inflammatory monocyte recruitment. Further analysis revealed that lung-resident 
AM enter cell cycle and proliferate following elastase-induced lung injury. Gene expression analysis 
demonstrated that lung macrophages took on a mixed M1/M2 activation phenotype that changed over a 21 
day period. Given their documented longevity and ability to mediate inflammation long after acute insults, 






Chronic obstructive pulmonary disease (COPD) is currently the world’s fourth leading cause of death 
effecting 60 million people and leading to 3 million deaths per year (~ 5% of all deaths) [338]. The WHO 
predicts that COPD will increase to the third leading cause of death by 2030, only behind ischemic heart 
disease and stroke [338, 339]. Chronic obstructive pulmonary disease (COPD) is defined as progressive 
lung destruction encompassing two conditions, chronic bronchitis (inflammation of the bronchi) and 
emphysema (destruction of the alveolar walls), resulting in reduced gas exchange and impaired airflow in 
the lower airways [343]. Cardinal features of COPD include severe immune cell infiltration of the muscosa 
and submucosa, increased mucus production, epithelial cell hyperplasia, and dysregulated tissue repair 
mechanisms [343]. Increased sputum production and long lasting cough are among the most common 
symptoms of COPD, however, acute breathlessness or dyspnea is the most debilitating feature of severe 
COPD [345]. 
 
There are a variety of environmental exposures as well as genetic predispositions that are associated with 
the onset of progressive emphysema. Smoking tobacco, the predominant risk factor accounting for ~80% of 
cases [343, 350], as well as exposure to air pollution (outdoor, indoor, and occupational), second hand 
smoke, maternal smoking, respiratory infections, other non-respiratory infections, childhood asthma, 
hypersensitivity pneumonitis, dust, and fumes have also been linked to the onset of emphysema [343, 350, 
351]. Additionally, α1 antitrypsin deficiency (A1AD), a congenital deficiency in α1 antitrypsin (A1AT), 
the major inhibitor of neutrophil elastase, leads to an imbalance in protease and anti-protease activity in the 
lungs, progressive airway enlargement and is responsible for ~1-2% of COPD cases [352, 353]. 
 
The development of progressive lung airway destruction should be considered an immunological disorder 
broadly categorized as initial epithelial cell damage followed by innate and adaptive immune responses 
[344]. Initially, tobacco smoke or other pulmonary irritants directly injure or stress alveolar epithelial cells 
(AEC) as well as degrade the lung’s extracellular matrix (ECM) [355, 356] leading to the release of 
DAMPs and other danger signals [64] which activate innate immune signaling pathways [64, 357]. Upon 
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NF-κB stimulation, innate/early inflammatory cytokines and chemokines are released, leading to 
recruitment of inflammatory cells such as neutrophils, monocytes, and DCs to the lungs [359]. Neutrophils 
and mononuclear phagocytes release proteases (elastolytic enzymes) and reactive oxygen species (ROS), 
which can damage the lung tissue further [360, 361]. When these damage-inducing effector molecules are 
not appropriately controlled by a cadre of anti-proteases [362, 363] and anti-oxidants [361], the initial pro-
inflammatory response ends up leading to further tissue damage and an uncontrolled positive feedback 
loop. 
 
A multitude of enzymes including elastases, matrix metalloproteinases (MMP), cathepsins, caspases, and 
collagenases can cleave ECM components in the lungs [363, 377]. Typically these enzymes are deployed in 
order to aid in wound repair processes, embryonic development, promoting fibrosis, and angiogenic 
remodeling [362]. However, upon exposure to tobacco smoke or other lung irritants, a shift occurs in the 
balance between proteolytic activity and inhibitor activity [362], the effects of which are evident in the case 
of A1AD [352, 353]. The porcine pancreatic elastase (PPE) model of emphysema employs an elastolytic 
serine protease to cleave elastin fibers of the ECM, thereby endowing researchers with a quick, potent, and 
reproducible approach to activate a cascade of events similar to that which occurs in human populations, by 
tipping the balance between protease and anti-protease activity in the lungs. 
 
Recent findings have directed attention to the major role that alveolar macrophages (AM) play in the 
orchestration of immune responses leading to the progression of alveolar tissue destruction [55, 373]. Most 
importantly to the pathophysiology of emphysema, alveolar macrophages secrete a wide variety of effector 
molecules that contribute either directly to tissue destruction or by promoting sustained inflammation [55, 
373, 376]. For example, AM secrete elastolytic proteases such as MMP9 and MMP12 (macrophage 
elastase) that degrade collagen or elastin fibers, resulting in a loss of normal alveolar structure [363, 377]. 
The effects of alveolar wall destruction and loss of lung volume are permanent and currently incurable. 
Therefore, there is significant need to reveal the underlying cellular mechanisms that are responsible for the 
initiation and progression of alveolar wall destruction. Given their longevity and their ability to mediate 
inflammation long after acute insults, we hypothesize that during acute elastase challenge lung-resident 
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alveolar macrophages become activated and contribute towards the progression and manifestation of 
emphysematous changes in the lungs. 
 
In the work presented here, we employed the PPE model of emphysema to define the dynamics and roles 
that lung-resident macrophages and recruited monocytes play in the progression of emphysema. We 
demonstrate that following acute elastase challenge, the size of the AM cellular niche transiently increases. 
The approximate doubling in AM numbers was accompanied by dynamic changes to the surface 
phenotype, changes in cellular morphology, and activation status. Using an in vivo phagocytic cell labeling 
approach, our findings suggested that a lung-resident AM subpopulation proliferated following PPE 
challenge. Furthermore, experiments carried out in CCR2-null mice suggested that following PPE 
challenge AM dynamics were CCR2+ monocyte-independent. Importantly, lung-resident AM respond 
acutely to PPE-mediated damage and may contribute to the progression of emphysematous lung injury. 
 
3.3 MATERIAL AND METHODS  
 
3.3.1 Mice 
Age and sex-matched (male 6-12 weeks old) littermates were used for all experiments. C57BL/6J, 
BALB/cJ, and CCR2-/- (B6.129S4-Ccr2tm1Ifc/J)] [410] were obtained from The Jackson Laboratory (Bar 
Harbor, ME, USA). All mice were maintained within barrier filter-top cages, provided food and water ad 
libitum, and exposed to a 12-hour light/dark cycle. All animal procedures performed in this study were 
approved by the Johns Hopkins Animal Care and Use Committee (Baltimore, MD, USA), and were in 




3.3.2 Elastase challenge 
Porcine pancreatic elastase (EC-134; Elastin Products Co., Inc., Owensville, MO, USA) was administered 
directly into the airways via intra-tracheal aspiration. Following brief anesthesia under 35% Isoflurane 
(10019-360-60; Baxter Healthcare Corp., Deerfield, IL, USA), C57BL/6 or BALB/c mice were 
administered 6U (50 µg) or 3U (25 µg) PPE respectively. 
 
3.3.3 Antibodies 
The following anti-mouse antibodies were purchased from BD Biosciences (San Jose, CA, USA) CD11b-
PerCP-Cy5.5 (550993), SiglecF-PE (552126), Ly6C-APC (560595). Mouse anti-rat IgG2b k-biotin 
(553898) was purchased from BD Biosciences. CD11b-APC (17-0112-81), MHCII-PE (12-5321-81), Ki-
67-eFluor660 (50-5698-80), rat IgG2aκ-eFluor660 (50-4321-80), and CD200R-APC (17-5201-80) anti-
mouse antibodies were purchased from eBioscience (San Diego, CA, USA). Streptavidin-PE (12-4317-87) 
was purchased from eBioscience.  Intracellular nuclear staining was performed using eBioscience Foxp3 
Staining Buffer Set (00-5523-00). Anti-mouse CD11c-APC (130-091-844) and CD11c-FITC (120-002-
107) were purchased from Miltenyi Biotec (Auburn, CA, USA). Anti-mouse ST2-APC (FAB10041A) 
antibody was purchased from R&D Systems (Minneapolis, MN, USA). MC-21, rat anti-mouse CCR2 
IgG2b κ was generously provided by Dr. Matthias Mack (Universitätsklinikum Regensburg, Regensburg, 
Germany). 
 
3.3.4 Flow cytometry 
Whole lung homogenates were generated as previously described [46].  Briefly, prior to excision from the 
chest cavity, lungs were perfused with 10 mL of room temperature sterile Dulbecco’s PBS via the right 
ventricle of the heart. Lungs were carefully removed and placed in 5 mL RPMI 1640 containing 1 mg/mL 
collagenase type II (1701-015, Life Technologies, Grand Island, NY, USA) and 30 µg/mL DNase I 
(10104159001, Roche Applied Science, Indianapolis, IN, USA), minced thoroughly, and incubated at 37°C 
for 30 minutes. Minced lung suspensions were then ground through a 100-µm nylon cell strainer (352360, 
BD Biosciences), and the resulting cells were pelleted at 1500g at 4°C. Cells were suspended in ACK 
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lysing buffer (118-156-721, Quality Biological Inc., Gaithersburg, MD, USA) to remove any contaminating 
erythrocytes, passed through a second cell strainer, and washed in FACS staining buffer [PBS containing 
2% heat-inactivated FCS (35-011-CV, Mediatech, Inc., Manassas, VA, USA)]. Cells were then treated with 
anti-mouse CD16/CD32 Fc Block (553142, BD Biosciences) 10 minutes prior to the addition of cell 
surface marker specific antibodies. All antibodies were incubated on ice for 20 minutes in the dark. Stained 
cells were then washed in FACS staining buffer prior to flow cytometric analysis. Cell counts were 
performed on a hemocytometer using trypan blue stain (15250-061, Life Technologies) to exclude dead 
cells. All data on whole lung homogenates or peripheral blood cells (collected via tail vein) were collected 
on a BD FACSCalibur flow cytometer (San Jose, CA, USA) and data analyzed using FlowJo (TreeStar 
Inc., Ashland, OR, USA). 
 
3.3.5 Bronchoalveolar lavage (BAL) 
Murine surgeries were performed as previously described [413]. Briefly, mice were anaesthetized with 450 
mg/kg 2,2,2-tribromoethanol (Sigma-Aldrich, St. Louis, MO, USA) via intraperitoneal injection. An 
incision was made through the sternum and BAL fluid was obtained after a tracheostomy and lavaging of 
the lungs with 800 µl of sterile PBS three separate times at room temperature. BAL fluid from the three 
collections were pooled and centrifuged at 1,500 rpm for 6 minutes at 4°C. Cells were suspended in PBS 
and an aliquot was stained with trypan blue (Invitrogen, Grand Island, NY, USA) prior to counting on a 
hemocytometer using the 10X objective of an Olympus BH-2 microscope (Catharpin, VA, USA). Cells 
(105) from each mouse were adhered to microscope slides with the aid of cytology funnels (Fisher 
Scientific, Houston, TX, USA) and a cytocentrifuge (Shandon Cytospin, Thermo Fisher Scientific, 
Waltham, MA) prior to methanol fixation and subsequent staining with Giemsa for differential cell 
analyses. 
 
3.3.6 In vivo labeling of resident lung macrophages 
Following brief anesthesia under Isoflurane, mice were administered PKH26-PCL, a red fluorescent dye, 
(PKH26PCL-1KT, Sigma-Aldrich, St. Louis, MO, USA) (1.25-10µM) in 50µL phosphate-buffered saline 
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via intra-tracheal aspiration. Typically, PKH26-PCL was used to label lung-resident phagocytic cells one 
day prior to PPE challenge. Under certain experimental conditions, all groups were in vivo labeled on the 
same day and the PPE challenges were staggered so that the time interval between PKH26-PCL labeling 
and lung harvest were equalized. 
 
3.3.7 Lung macrophage depletion 
Clodronate- or PBS- loaded liposomes suspended in sterile PBS (100 µL liposome suspension per animal) 
purchased from Dr. Nico von Rooijen (Amsterdam, The Netherlands), were administered via intra-tracheal 
aspiration following temporary anesthesia under 35% Isoflurane. 
 
3.3.8 Neutrophil depletion 
Rat anti-mouse Ly6G monoclonal antibody clone 1A8 (BE0075-1, Bio X Cell, West Lebanon, NH) was 
used to specifically deplete neutrophils from the circulation [433]. Briefly, mice were administered 500µg 
antibody formulated in 200 µL sterile Dulbecco’s phosphate buffered saline via intra-peritoneal injection 
one day prior to PPE challenge. 
 
3.3.9 Bead selection of lung macrophages 
Single cell suspensions were generated from lung tissue as described above. Following Fc receptor 
blockade, lung cells were stained with anti-mouse CD11c-APC (130-091-844, Miltenyi Biotec) for 20 
minutes on ice in the dark.  Following a wash with FACS buffer, stained cells were centrifuged and 
suspended in 50 µL of anti-APC magnetic bead particle slurry (557932, BD Biosciences) and incubated for 
30 minutes on ice in the dark. Following bead incubation, 1mL MACS buffer (phosphate buffered saline + 
0.5% BSA + 2 mM EDTA) was added to each sample. Samples were then placed in BD IMagnet cell 
separator (552311) for 8 minutes. The non bead-bound cell fraction (CD11c- cells) was removed. The bead-
bound fraction (CD11c+ cells) was again suspended in 1 mL MACS buffer and placed on the BD magnetic 
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cell separator for an additional eight minutes. The cell fraction procedure was repeated as above. Both the 
positive and negative cell fractions were counted using a hemocytometer prior to pelleting and freezing. 
 
3.3.10 Nucleic acid isolation and gene expression analysis 
RNA was isolated from the bead-selected cell samples using the Qiagen RNeasy Plus Mini kit (74134, 
Qiagen, Valencia, CA). RNA quantity and purity were assessed by A260/280 absorbance using a Nanodrop 
ND-1000 (Nanodrop Products, Wilmington, DE, USA). RNA (500 ng) was then reverse-transcribed using 
the SuperScript II first-strand synthesis system for RT-PCR (100004925, Life Technologies) using oligo 
(dT) (12-18) primers (58862, Life Technologies). Quantitative real-time RT-PCR was performed using the 
Applied Biosystems 7500 realtime PCR system, TaqMan Gene Expression Assays-On-Demand, and Taq-
Man Universal Master Mix (Life Technologies). The following assays (Applied Biosystems) were used: 
Arg1 (Mm00475988_m1), Chil3 (Mm00657889_mH), Gapdh (Mm99999915_g1), Il1b 
(Mm00434228_m1), Il6 (Mm00446190_m1), Il10 (Mm00439614_m1), Il12a (Mm00434165_m1), Il18 
(Mm00434225_m1), Il33 (Mm00505403_m1), Ilr1l1 (Mm00516117_m1), Mmp9 (Mm00442991_m1), 
Mmp12 (Mm00500554_m1), Nos2 (Mm00440502_m1), Retnla (Mm00445109_m1), Tnf 
(Mm00443258_m1), Tgfb1 (Mm01178820_m1). TaqMan reactions were performed using 1 µL cDNA in a 
20 µL reaction volume and the following thermal cycler profile: 10 minutes denaturation at 95°C, 50 cycles 
of 15 seconds denaturation at 95°C, followed by 1 minute extension at 60°C. Analysis was performed using 
the Applied Biosystems 7500 system SDS software package (Life Technologies). Relative expression units 
were generated by comparing individual expression levels to a standard curves generated using pooled 
cDNAs as a template. All genes were normalized to a housekeeping gene control (Gapdh). 
 
3.3.11 Histology 
A 19-gauge gavage tube was inserted into a small hole in the trachea, and the lungs were inflated slowly 
with zinc-buffered formalin fixative (Z-fix) (174, Anatech Ltd., Battle Creek, MI, USA). The lungs were 
removed and incubated in Z-fix for 48 hours. Inflated and fixed lungs were embedded in paraffin, and 
sagittal, 5 µm sections, were cut from four different levels of lung. Lung sections were placed on slides and 
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either left unstained or stained with hematoxylin and eosin. Lung sections (and cytology slides) were 
examined using a Nikon Eclipse E800 light microscope (Nikon Instruments Inc., Melville, NY, USA), and 
images were acquired using SPOT RT charge-coupled device imager and software (Diagnostic Instruments, 
Inc., Sterling Heights, MI, USA). 
 
3.3.12 Immunofluorescence microscopy 
Methanol fixed cytospin preparations were stained with biotinylated Griffonia (Bandeiraea) simplicifolia 
lectin 1 isolectin B4 (GSL1)-biotin (1:100) (#B-1205; Vector Laboratories, Inc., Burlingame, CA, USA) for 
20 minutes. Following 2 x 3 minute washes with DPBS, fluorescein-avidin (1:100) (#A-2001; Vector 
Laboratories) was added for 15 minutes. The slides were washed prior to the addition of Vectashield 
Hardset mounting medium with DAPI (#H-1500; Vector Laboratories). Stained slides and coverslips were 
allowed to set in the dark overnight at 4°C prior to imaging. A Nikon Eclipse Ni-E upright microscope 
equipped with an Andor Zyla sCMOS camera (Andor Technology, Ltd., Belfast, UK) and NIS-Elements 
Microscope Imaging Software (Nikon) were used to capture fluorescent images of cytospin preparations 
using a 20X objective lens (Nikon Instruments Inc., Melville, NY, USA). Images were collected for each 
fluorescent channel through each Z-stack. Deconvolution (30 iterations) of Z-stacks was performed using 
NIS-Elements Microscope Imaging Software. 
 
3.3.13 Statistical analysis 
Statistical significance was evaluated by using the 2-tailed t test (Tukey) and the one-way analysis of 
variance (ANOVA) test using GraphPad Prism software version 4 for Mac (La Jolla, CA, USA). 
 
3.4 RESULTS  
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3.4.1 Preliminary data in the PPE model 
Previous studies conducted in the laboratory [407] have demonstrated that significant hemorrhage and 
alveolar tissue destruction was evident in histopathological lung tissue sections from mice that received 
porcine pancreatic elastase (PPE) via intra-tracheal aspiration as early as two days post-challenge. Despite 
administration of a single dose of PPE, with enzymatic activity only lasting approximately 24 hours, the 
lung tissue damage continued and loss of pulmonary epithelial surfaces progressed over the next three 
weeks to fully manifested emphysema at day 21 post-elastase (Figure 1.7B). Not surprisingly, at day 21 
post-elastase challenge, the lung function as measured by diffusing factor of carbon monoxide (DFCO), total 
lung capacity (TLC), residual volume (RV), and static compliance was severely compromised (Table 1.7). 
These studies demonstrated that the composition of cellular populations harvested from the lungs by 
bronchoalveolar lavage (BAL) varied over time. At baseline (no elastase challenge) the cells residing 
within the airways were almost exclusively alveolar macrophages (Figure 1.7C, 1.7D). Upon elastase 
challenge, there was a significant influx of neutrophils, detectable within one hour and peaking at 48 hours 
(data not shown), as well as a mononuclear cell infiltration (including monocytes and lymphocytes) were 
observed at day 7 post-elastase challenge (Figure 1.7C, 1.7D). 
 
3.4.2 Dynamics of myeloid cells in the lungs following PPE challenge 
Given that the composition of cellular populations isolated via BAL following elastase challenge varied 
over time, we wanted to assess the dynamics of myeloid cell populations within the lung tissue with special 
emphasis on monocytes and macrophages. We employed flow cytometric analysis and focused on myeloid 
cell populations by staining lung homogenates with antibodies specific for binding to 
monocyte/macrophage cell surface markers including CD11b and CD11c (both members of the integrin 
family and components of the CR3 and CR4 complement receptors, respectively), SiglecF (a sialic acid 
binding lectin selectively expressed on eosinophils and lung macrophages [58, 61]), MHCII (major 
histocompatibility complex class II), and Ly6C (glycophosphatidylinositol-anchored surface protein 
expressed on monocytes, neutrophils and T cells). To ensure that the cell dynamics profile encompassed 
both the initiation and progression phases of emphysematous changes in the lungs, we assayed the 




Figure 3.1 Identification of myeloid cell populations in the lungs  
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Based on current literature [14, 57, 58] and confirmatory experimental evidence (data not shown), alveolar 
macrophages were designated as CD11c+SiglecF+ cells. AM typically account for 3-5% of the total cells 
isolated from perfused lungs (Figure 3.1A) and can also be identified as the CD11c+CD11b- cell population 
in unchallenged mice (Figure 3.1B). From unchallenged lungs, CD11b+ conventional dendritic cells (cDCs) 
can be identified as the CD11c+CD11b+ cell population [57, 434]; however, unlike AM lung DCs do not 
express SiglecF (Figure 3.1B). We did not include identification of other lung DC populations such as 
CD103+ lung DC or plasmacytoid DC (pDC) in this analysis. Nevertheless, we monitored the dynamics of 
inflammatory or “classical” monocytes [9], defined here as CD11b+hiLy6C+hi cells (Figure 3.1C). While 
circulating inflammatory monocytes are typically characterized as MHCIIlo cells, upon migration to 
inflamed sites these monocytes can increase MHCII surface expression [187]; therefore, we monitored the 
dynamics of CD11b+hiLy6C+hiMHCII- and CD11b+hiLy6C+hiMHCII+ monocyte populations in order to 
distinguish between circulating or recently emigrated monocytes (MHCII-) from differentiating monocytes 
(MHCII+) at the site of inflammation. Similar to previously published studies, we have identified and 
described multiple myeloid cell populations within the lungs based on flow cytometric analysis of cell 
surface phenotype [57, 58, 435]. While we appreciate that there are a variety of other surface markers and 
functional characteristics that can be used to refine these cell populations and further define subpopulations, 
we are confident in the accuracy of the parameters used in this study to discriminate between major 
myeloid cell populations isolated from whole lung tissue. The surface marker phenotypes and defining 
characteristics used in this study are summarized below in Table 3.1. 
 
Table 3.1 Myeloid cells subsets in the murine lung 
Myeloid cell population Defining characteristics 
(used in this analysis)  
Other characteristics 
(not used in this analysis) 
Alveolar macrophages (AM) CD11c+ CD11b- SiglecF+ F4/80low; MHCIIlow; CD64+; PD-L1+; 
high autofluorescence 
CD11b+ lung DCs CD11c+ CD11b+ SiglecF- MHCIIlow; CD205+; low 
autofluorescence 
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Classical/inflammatory monocytes CD11b+high Ly6C+high 
MHCIIlow/high  
F4/80+; CD11c-; SiglecF-; CD64+; 
CD115+; CCR2+ 
 
Since expression of the flow cytometry results as a percentage of a selected cell population has the potential 
to introduce bias into the analysis, the data for each myeloid cell population was expressed in terms of cell 
number calculated based on the total number of lung cells. Combining flow cytometric percentage output 
with total lung cell numbers, we were able to track changes in the myeloid cell populations over a 21 day 
period following elastase challenge (Figure 3.2). The number of CD11c+SiglecF+ AM from unchallenged 
animals was estimated to be near 0.5 x 106 (Figure 3.2A). By day 7 post-elastase the number of AM had 
nearly doubled (Figure 3.2A, 3.3A). This significant increase in lung macrophage numbers was transient, as 
by day 14 and 21 post-PPE, the number of AM was similar to unchallenged mice (Figure 3.2A, 3.3A). 
While the total number of lung DCs is relatively small in comparison to other myeloid cell populations, 
there was a significant increase in this population at day 7 post-elastase compared to unchallenged control 
mice (Figure 3.2B, 3.3B). Surprisingly, the number of inflammatory monocytes (CD11b+Ly6C+) in the 
lungs did not increase compared to controls over the 21 day period (Figure 3.2C, 3.3C, 3.3D), actually there 
was a significant decrease in the number of CD11b+Ly6C+MHCII+ cells at days 14 and 21 (Figure 3.3D). 
Given the robust neutrophil influx in the airways peaking at day 2 following elastase-challenge, it was 
expected that monocytes would be recruited to the lungs to clear neutrophil apoptotic bodies. However, 
under these conditions we did not observe a significant monocyte influx, perhaps, we may have overlooked 
monocyte recruitment to the lungs occurring between days 2 and 7 post-elastase challenge or focused on an 
inappropriate monocyte subset for this type of inflammatory insult. 
 
When we focused specifically on CD11c+SiglecF+ AM in the lungs, it became clear that as early as two 
days following elastase challenge, that a subpopulation had emerged. Typically in unchallenged lungs, cells 
with a CD11c+SiglecF+CD11b+ surface phenotype are not present in abundance (Figure 3.1B). However, at 
days 2 and 7 post-elastase challenge, the number of CD11c+SiglecF+ cells staining positive for CD11b 




Figure 3.2 Dynamics of myeloid cells in the lungs following PPE challenge  
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Figure 3.3 Dynamics of myeloid cell populations in the lungs following PPE challenge  
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Figure 3.4 Dynamics of lung CD11c+SiglecF+ population’s surface phenotype following PPE challenge  
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subpopulation (highlighted in blue) was transient in nature as the size of this cellular niche resembled 
unchallenged controls at days 14 and 21 post-elastase (Figure 3.4). 
 
3.4.3 Examining the role of inflammatory monocytes on the progression of elastase-induced 
emphysema 
In an attempt to understand the origin and significance of this elastase-induced myeloid cell subpopulation, 
we hypothesized that the CD11c+SiglecF+CD11b+ subpopulation trafficked into the lungs from the 
periphery in response to the damage created by the intra-tracheal elastase challenge. Although under these 
conditions we had measured minimal inflammatory monocyte (CD11b+Ly6C+) influx into the lungs 
following elastase challenge (Figure 3.3C, 3.3D), it was still formally possible that the 
CD11c+SiglecF+CD11b+ subpopulation may have been recruited to the lungs via chemokine gradients 
similar to those used to recruit monocytes. CCL2/CCR2 acts as the major chemokine axis for the 
recruitment of inflammatory monocytes to sites of injury from the bone marrow via the blood [9, 187]. To 
this end, we verified that inflammatory monocytes in the lungs deploy CCR2 on their surface (Figure 3.5). 
 
We employed CCR2-deficient mice to aid in testing the hypothesis that the origin of the elastase-induced 
CD11c+SiglecF+CD11b+ subpopulation was due to monocyte trafficking to the lungs. When we compared 
the myeloid cell populations in CCR2-/- and wildtype (C57BL/6) mice, it was evident that there were fewer 
CD11b+Ly6C+ monocytes recruited to the lungs at days 0, 2, and 7 post-elastase challenge in CCR2-/- 
animals compared to WT controls (Figure 3.6A). Not surprisingly, there was no measurable difference in 
number of CD11c+SiglecF+ alveolar macrophages between the wildtype and CCR2-/- animals at days 0, 2, 
and 7 (Figure 3.6B). Importantly, CCR2-deficiency had no impact on the temporal dynamics or increase in 
the elastase-induced CD11c+SiglecF+CD11b+ subpopulation at days 2 and 7 post-challenge (Figure 3.7). To 
further assess the possible impact that recruited myeloid cell populations may have on the progression of 
elastase-induced emphysema, we compared the extent of emphysematous changes in the lungs between 
CCR2-/- mice and wildtype controls. As the total numbers of inflammatory monocytes present in the lungs 
following elastase challenge (Figure 3.3C, 3.3D) may have suggested, recruited inflammatory monocytes 
may not be directly implicated in the pathogenesis of elastase-induced emphysema under these conditions,  
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Figure 3.5 CCR2 surface expression on CD11b+Ly6C+ cells in the lungs following PPE challenge  
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Figure 3.6 Effect of CCR2-deficiency on monocyte and lung macrophage dynamics following PPE challenge  
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Figure 3.7 Effect of CCR2-deficiency on CD11c+SiglecF+ phenotypic changes following PPE challenge  
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as the dynamics of the progression and the extent of the emphysematous changes in the lungs were 
comparable between CCR2-/- and wildtype mice (Figure 3.8). 
 
3.4.4 In vivo lung-resident macrophage staining and cell fate tracking following elastase challenge 
Given that blockade of monocyte recruitment from the bone marrow and peripheral blood (via CCR2-
deficiency) had no impact on the presence of the CD11c+SiglecF+CD11b+ subpopulation in the lungs, we 
then hypothesized that the elastase-induced myeloid cell population originated locally within the lung 
tissue. In order to test this hypothesis, we employed an in vivo cell labeling strategy in order to track the 
fates of lung resident phagocytic cells. By in vivo labeling cells prior to elastase challenge, we could track 
the fate of the AM population over time. PKH26, a stable red fluorescent lipophilic dye, when formulated 
in a specific way forms micro-aggregates that are selectively taken up by phagocytic cells. In addition, the 
dye remains within endocytic vesicles for greater than thirty days [49]. Due to its long in vivo half-life, 
PKH26-PCL is a valuable tool for tracking lung macrophages when administered intravenously or directly 
into the lungs [49, 436-439].  
To this end, following intra-tracheal PKH26-PCL administration into the lungs of naive mice, we were able 
to specifically label CD11c+ cells residing in the alveolar space (isolated via BAL) (Figure 3.9A) as well as 
the lung interstitium (from single cell suspensions of lung tissue) (Figure 3.9B). In addition, we were able 
to titrate an appropriate concentration of dye needed to label lung resident phagocytic cells and monitor 
them over time using flow cytometry (Figure 3.9C). In fact, intra-tracheal administration of PKH26-PCL 
resulted in robustly labeled lung-derived macrophages that were stable over two weeks (data not shown). 
The PKH26-PCL+ cells isolated from perfused lungs were largely CD11c+CD11b- (Figure 3.9D), consistent 
with our previously described definition of AM (Table 3.1). Throughout the descriptions of the in vivo 
labeling experiments, the lung-resident alveolar macrophage population (LRM) is defined using the short-
hand designation of PKH26-PCL+CD11c+ cells. We considered LRM to be lung-resident phagocytic 
CD11c+ cells residing in the airways or lung tissue prior to inflammatory insult. While we appreciate that 
there were potentially other non-macrophage CD11c+ phagocytic cells residing within the lungs prior to 
elastase challenge (such as CD11b+ cDCs), macrophages account for 90-95% of all CD11c+ cells in a naïve 
lung (Figure 3.1, [435]).   
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Figure 3.9 In vivo labeling of lung-resident phagocytic cells with PKH26-PCL  
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We also verified the specificity of PKH26-PCL staining by immunofluorescence microscopy. We 
employed the plant lectin GSL1 that has been described to specifically bind to α-galactose residues on the 
surface of lung macrophages [13, 440] as a surrogate marker to identify AM isolated from the lungs of 
mice via BAL on cytospin preparations. For PKH26-PCL labeled cells isolated in the BAL 4 days 
following administration of the dye, the red fluorescent signal was associated exclusively with GSL1+ cells 
(Figure 3.10). Upon examination of deconvolved Z-stacked images, it was evident that the PKH26-PCL 
dye aggregates were neither associated with the nucleus (DAPI) or cell surface (GSL1), but were cytosolic  
and punctate in nature; consistent with dye micro-aggregates located within endocytic vesicles (data not 
shown). Therefore, we were confident that analysis of PKH26-PCL labeled cells upon elastase challenge 
would allow us to understand the nature and dynamics of LRM over time. 
 
Flow cytometric analyses on LRM (PKH26-PCL+CD11c+ cells) isolated from BAL or whole lung 
homogenates revealed that these cells altered their morphology and surface marker phenotype in response 
to elastase challenge (Figure 3.11). Multiple characteristics of the PKH26-PCL+CD11c+ LRM including 
their size (forward scatter), granularity (side scatter) and CD11b surface levels increased from days 2 to 6 
post-elastase challenge compared to unchallenged controls (Figure 3.11). Since the PKH26-PCL+CD11c+ 
LRM population up-regulated CD11b surface levels early in response to elastase challenge, we recognized 
that we had determined the origin of the CD11c+SiglecF+CD11b+ alveolar macrophage subpopulation. The 
data suggest that under these conditions, the elastase-induced CD11b+ lung macrophage subpopulation 
(Figure 3.4) originated within the alveolar spaces and/or lung tissue and was independent of CCR2/CCL2 
recruitment from the periphery.  
 
We visually verified these findings using immunofluorescence microscopy to analyze the same cell 
samples, again utilizing GSL1 as a surrogate marker to identify lung macrophages. The dynamics of the 
GSL1+PKH26-PCL+ cells cell morphologies were consistent with flow cytometric analyses. At days 2 and 
4 post-elastase challenge, the GSL1+PKH26-PCL+ cells became larger, more granular and ruffled compared 




Figure 3.10 Visualization of in vivo lung-resident phagocytic cell PKH26-PCL staining specificity  
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Figure 3.11 Dynamics of lung-resident PKH26-PCL+CD11c+ cells granularity and surface phenotype following PPE challenge  
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Figure 3.12 Visual evidence for lung-resident macrophage morphological changes following elastase challenge  
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3.4.5 Dynamics of elastase-induced lung-resident macrophage phenotypic changes 
Flow cytometric analysis was used in conjunction with the PKH26-PCL in vivo staining to quantify the 
extent to which the resident AM population was undergoing phenotypic changes in response to elastase 
challenge. We monitored the change in the surface expression of CD11b on PKH26-PCL+CD11c+ cells 
from perfused lung homogenates at days 2, 4, and 6 post-elastase (Figure 3.13A). At baseline only about 
20% of resident AM expressed CD11b on their surface, but following elastase challenge, the LRM 
significantly up-regulated CD11b surface levels (Figure 3.13B, 3.13D). Over the first six days following 
elastase challenge, the LRM transformed from a population that was dominated by CD11c+CD11b- cells to 
a population where more than half the PKH26-PCL+ cells were CD11c+CD11b+ (Figure 3.13B, 3.13D). By 
day 6 a distinct subpopulation emerged that expressed high CD11b levels (CD11b+high subpopulation 
highlighted with gold box) (Figure 3.13B, 3.13C). As noted previously, this AM surface phenotype was not 
sustained (Figure 3.4), as the CD11c+CD11b+ population resembled that of unchallenged mice by day 14 
post-elastase challenge (Figure 3.4). 
 
The elastase-induced changes in CD11b expression on the surface of LRM were accompanied by changes 
in CD200R expression. CD200R (also known as OX-2), upon engagement with its ligand CD200, acts as a 
negative regulator of macrophage function and activation through Dok2-mediated inhibition of the Erk, Jnk 
and p38 MAPK pathways [161, 164, 166]. Following elastase challenge, the PKH26-PCL+CD11c+ LRM 
population, known to be CD200R+ [47, 163], up-regulated CD200R expression to even greater levels 
(Figure 3.14B, 3.14C, 3.14D). By days 4 and 6 post-challenge, approximately 30% of the PKH26-PCL+ 
LRM population exhibited CD200R surface levels that exceeded the already high CD200R levels present 
on LRM from unchallenged mice (Figure 3.14). 
 
In addition, we assessed levels of membrane-associated ST2, a component of the receptor for IL-33, on AM 
following elastase challenge. IL-33 is an epithelial-derived alarmin released upon cellular stress. Our 
laboratory has previously demonstrated that IL-33 protein levels in the lung were elevated within two days 
of elastase-challenge (data not shown). In unchallenged mice, ~8% of the alveolar macrophage population 
had measurable levels of ST2 expression, however, at day 2 post-elastase, the percentage of ST2+   
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Figure 3.14 Dynamics of PKH26-PCL+CD11c+ population’s surface CD200R levels following PPE challenge  
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CD11c+SiglecF+ cells increased significantly to ~33% (Figure 3.15). Similar to the dynamics of surface 
CD11b, this change in ST2 levels appeared to be transient, as the lung macrophage population resembled 
that of unchallenged mice by day 14 and 21 post-elastase challenge (Figure 3.15). Further studies are 
required to more clearly evaluate the dynamics of surface ST2 levels between days 2 and 7 post-elastase 
challenge. 
 
3.4.6 Lung-resident macrophage dynamics following elastase-challenge to the lung 
As noted earlier, we observed a near doubling in the number of CD11c+SiglecF+ cells in the lungs at seven 
days post-elastase challenge (Figure 3.3A). A similar kinetic profile was evident when accessing the 
number of macrophages present in BAL fluid (Figure 1.7D). Under these conditions, our data suggested 
that the increase in macrophage cell number was not attributable to an influx of CCR2+ cells from the 
periphery. Therefore, we hypothesized that the observed increase may be due to proliferation of a lung-
resident macrophage population. Employing the PKH26-PCL in vivo lung macrophage labeling strategy, 
we were able to follow the size of the LRM population following intra-tracheal elastase challenge (Figure 
3.16). Following in vivo labeling, we enumerated the PKH26-PCL+CD11c+ cell population present in the 
lungs of animals at days 0, 2, 4, and 6 post-elastase challenge. Consistent with our hypothesis that lung 
macrophages proliferated following elastase challenge, the number of LRM (PKH26-PCL+CD11c+) 
approximately doubled by day 4 and remained elevated at day 6 compared to unchallenged controls (Figure 
3.17). These results were consistent with our previous findings of macrophage population dynamics in the 
airways (Figure 1.7D) and lung tissue (Figure 3.3A) between days 2 and 7 post-elastase challenge. 
However, we appreciated that an increased number of PKH26-PCL+CD11c+ cells in the lungs following 
elastase challenge (Figure 3.17) could have arisen from a variety of other sources, therefore these data were 
not sufficient evidence to characterize the significant increase as proliferation of the LRM pool. 
 
To validate the proliferation phenotype of these cells, we assayed for the presence of Ki67, a nuclear 
protein only expressed by cells that have entered cell cycle [441]. By flow cytometric intracellular staining, 
PKH26-PCL+CD11c+ cells from unchallenged lungs were ~20% positive for Ki67 (Figure 3.18A). 
Following elastase challenge, the percentage of Ki67+ lung macrophages significantly increased to levels   
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Figure 3.15 Dynamics of CD11c+SiglecF+ population’s surface ST2 levels following PPE challenge  
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Figure 3.16 Experimental design for monitoring PKH26-PCL+CD11c+ LRM population following PPE challenge  
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Figure 3.17 Dynamics of lung-resident PKH26-PCL+CD11c+ population numbers following PPE challenge  
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Figure 3.18 Dynamics of Ki-67 positivity in PKH26-PCL+ and PKH26-PCL- populations following PPE challenge  
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exceeding 50% at days 2, 4, and 6 post-elastase challenge (Figure 3.18A). This effect was specific to the 
PKH26-PCL+ LRM population, as the percentage of Ki67+ cells present in PKH26-PCL- non-phagocytic 
lung cell populations (including lymphocytes and granulocytes) did not change over the six day period 
(Figure 3.18B). Under these conditions, the data suggested that half of the LRM population may have 
entered cell cycle within 2 days of elastase challenge, preceding the increased LRM numbers detected at 
days four and six post-challenge (Figure 3.17). 
 
Importantly, we also assayed for changes in the amount of PKH26-PCL red fluorescence within the LRM 
cell population over time. If indeed this cell population was proliferating locally in response to elastase-
induced damage, then we hypothesized that the PKH26-PCL dye would be diluted between daughter cells. 
However, we did not expect even 1:1 dilution of PKH26-PCL dye between daughter cells as observed with 
amine-reactive dyes such as carboxyfluorescein succinimydl ester (CFSE) [442], due to the nature of 
PKH26-PCL micro-aggregates localized within endocytic vesicles. It has been demonstrated that during 
mitosis endosomes and lysosomes do not partition evenly between daughter cells [443]. Therefore, 
experimental design controlling for decay of the fluorescent signal over time through synchronized labeling 
of LRM in all groups can be used to monitor changes in PKH26-PCL signal following elastase challenge 
(Figure 3.19A). We monitored the mean fluorescence intensity (MFI) of the PKH26-PCL red fluorescent 
signal within the LRM population at days 0, 2, 4, and 6 post-elastase challenge. By monitoring the LRM 
population as a whole, we determined that the mean red fluorescent signal emitted by a given cell decreases 
significantly between days 2, 4 and 6 post-elastase challenge (Figure 3.19A). This decrease in fluorescent 
signal cannot be attributed to progressive quenching or deterioration of the PKH26-PCL signal over time; 
as the dye was administered to all animals on the same day, the only variable between the groups was the 
amount of time that had elapsed post-elastase challenge. More specifically, when we sample the 
PKH26+CD11c+ cell population based on Ki67 positivity, we see the trend for PKH26-PCL dilution was 
pronounced in the Ki67+ cell population while the PKH26-PCL signal remained consistently high in the 
Ki67- subpopulation (Figure 3.19C, 3.19D, 3.19E). This evidence further suggested that two distinct lung 




Figure 3.19 Dynamics of PKH26-PCL fluorescence intensity on a per cell basis following PPE challenge  
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that enters cell cycle, proliferates, and dilutes the PKH26-PCL dye between its daughter cells in response to 
elastase-induced lung damage and another that does not. 
 
Since we focused on understanding the dynamics of lung macrophage population expansion, we did not 
follow the LRM population beyond day 6 post-challenge. However, our previous findings suggest that  
following an early proliferative or expansion phase (between days 2 and 7 post-elastase) the alveolar 
macrophage population may enter a contraction phase (between days 7 and 14 post-elastase), returning the 
size of the AM population to steady-state levels. However, it is also possible that a subset of the AM 
population may alter its surface phenotype resulting in an apparent contraction. Further studies are required 
to understand the nature and dynamics of the possible AM contraction phase. 
 
3.4.7 Gene expression dynamics in CD11c+ cells following elastase-challenge to the lung. 
The dynamic changes in cell morphology, surface phenotype and proliferative status of the AM suggested 
that these cells may become activated following elastase challenge in the lungs. We hypothesized that 
elevated IL-33 levels in the lungs within two days following elastase challenge would polarize the AM 
population towards an M2 or alternatively activated macrophage (AAM) phenotype. In order to test this 
hypothesis, we assessed gene expression of isolated CD11c+ cells from the lungs of control or elastase-
challenged mice at days 2, 7, 14, and 21. We measured the relative gene expression of a number of 
macrophage activation-related genes including: Arg1, Chi3l3, Il1b, Il6, Il10, Il12a, Il18, Il33, Ilr1l1, Mmp9, 
Mmp12, Nos2, Retnla, Tnf, and Tgfb1. All genes were normalized to Gapdh expression levels. Interestingly, 
Nos2 and Arg1 expression were both elevated at day 2 post-challenge. Three genes encoding canonical in 
vitro M2 activation markers were elevated following elastase challenge, however each had a different 
temporal expression profile: Arg1 peaked at day 2, Retnla was elevated at days 2 and 7, and Chi3l3 was 
elevated at days 7, 14, and 21 post-challenge (Figure 3.22). While Nos2 was elevated at days 2 and 7, other 
M1-associated genes such as Tnf and Il12 did not change significantly from baseline levels (Figure 3.20, 
3.21). However, matrix metalloproteinase encoding genes such as Mmp9 and Mmp12 were elevated at day 




Figure 3.20 Dynamics of macrophage activation (innate /M1) gene expression in CD11c+ cells following PPE challenge  
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Figure 3.21 Dynamics of macrophage activation (M1/MMP) gene expression in CD11c+ cells following PPE challenge  
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Figure 3.22 Dynamics of macrophage activation (M2a/M2c) gene expression in CD11c+ cells following PPE challenge  
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1β and IL-18 were both up-regulated at day 21 post-elastase (Figure 3.20). Alarmin encoding gene Il33 was 
elevated at day 2 post-elastase, however the gene encoding the ST2 receptor (Il1rl1) did not change 
significantly (Figure 3.20). Inflammasome-associated Il18 expression was elevated at day 21 post-PPE. The 
gene encoding the regulatory cytokine IL-10 did not significantly change, however the gene encoding 
TGFβ1 was elevated at days 7 and 21 post-elastase challenge (Figure 3.22). The effects of elastase 
challenge had long-lasting effects on AM gene expression as the genes encoding IL-18, MMP9, TGFβ1, 
and Ym1 were all significantly up-regulated at day 21 post-elastase challenge (Figure 3.20, 3.21, 3.22). The 
AM exhibited a mixed polarization phenotype, as M1-, M2a, and M2c-associated genes were up-regulated 
following elastase challenge (Figure 3.20, 3.21, 3.22). 
 
3.4.8 Effect of lung macrophage depletion on the progression of elastase-induced emphysema 
Given the anatomical location and longevity of alveolar macrophages and their well-documented 
production of effector molecules associated with the progression of emphysematous changes in the lungs, 
we hypothesized that lung macrophages contribute to the initiation and progression of emphysematous 
changes following elastase challenge. We tested this hypothesis by administering clodronate-loaded 
liposomes (CLLs) as a strategy to selectively deplete this cellular niche by inducing apoptosis in the lung 
macrophage population [180]. We hypothesized that depletion of the lung macrophage population would be 
protective against the progressive emphysematous changes to the lungs following elastase challenge. In 
preliminary control experiments using naïve mice, we determined that CLL-mediated alveolar macrophage 
depletion was approximately 90% efficacious and effective for 5-8 days (data not shown). Therefore, to test 
this hypothesis, we administered CLLs prior to (day -1) and at differing times post-elastase challenge (days 
2, 7, and 14) to assess if the lung macrophage population was more important during the initiation or 
progression phases of elastase-induced emphysema (Figure 3.23A). When we examined the 
histopathological appearance of lung tissue sections at 21 days post-liposome administration there was no 
evidence of saline- (PLL; no depletion control) or clodronate- (CLL) loaded liposomes contributing to the 
progression of emphysema (Figure 3.23B). In the elastase-challenged groups that received CLLs, there 




Figure 3.23 Effect of lung macrophage depletion on the progression of emphysema following PPE challenge  
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controls (Figure 3.23B). Under these conditions, all groups exhibited similar levels of emphysema, 
regardless of the depletion time point (Figure 3.23B). 
 
The interpretation of the results of this experiment was complicated by issues associated with the efficiency 
of lung macrophage depletion in the context of the elastase model. For these studies, in addition to the day 
21 post-elastase histological endpoint measure, we also monitored the efficacy of alveolar macrophage  
depletion by flow cytometry (Figure 3.24A). We compared the number of AM present in the lungs of 
elastase-challenged animals that were administered saline-loaded liposomes (PLLs) or CLLs at days -1, 2, 
7 or 14 at one day following liposome treatment (days 0, 3, 8, 15 post-elastase challenge) (Figure 3.24B). 
The overall efficacy of AM depletion was highest (83%) when liposomes were administered one day prior 
to elastase challenge. Unexpectedly, the efficacy of AM depletion dropped to 45%, 68%, and 42% at days 
2, 7, and 14 post-elastase, respectively (Figure 3.24B). We also measured differences in the efficacy of 
CD11b- and CD11b+ lung macrophage depletion. CLL depletion was more efficacious in depleting the 
CD11b- (46-87%) compared to CD11b+ (16-62%) AM when administered at days -1, 2, or 14 post-elastase 
(Figure 3.24B). However, when liposomes were administered at day 7 post-elastase, the depletion efficacy 
of CD11b+ AM (80% depletion) exceeded the CD11b- AM subpopulation (63% depletion). Interestingly, 
day 7 post-elastase was when we observed an expansion of the AM population (Figure 3.3A); perhaps these 
cells were more susceptible to clodronate liposome-mediated cell death. Regardless, the variable lung 
macrophage depletion efficacies measured following elastase challenge suggest that this particular 
depletion strategy is not appropriate for testing the hypothesis that lung macrophages contribute to the 
progression of emphysema. 
 
3.4.9 Effect of neutrophil depletion on dynamics of lung-resident macrophage population 
Given the early neutrophil influx into the lungs of mice following elastase challenge (data not shown), the 
well-documented interactions between macrophage and neutrophil populations, and the dynamics of AM 
phenotypic changes following elastase challenge, we hypothesized that AM may respond to inflammatory 
mediators released by neutrophils in the lungs. Therefore, in order to test this hypothesis, we employed a   
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Figure 3.24 Efficacy of lung macrophage depletion following PPE challenge  
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Figure 3.25 Effect of lung neutrophil depletion on lung-resident PKH26-PCL+ population’s surface phenotype following PPE challenge  
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neutrophil depletion strategy to prevent the influx of these cells into the lungs following elastase challenge 
[433]. Our laboratory has demonstrated that neutrophil depletion via intraperitoneal administration of the 
anti-mouse Ly6G monoclonal antibody clone 1A8 is specific and long lived. Neutrophil levels in the blood 
and lungs are well below non-depleted controls at least five days post-depletion (data not shown). Given 
the neutrophil depletion window and the dynamics lung macrophage phenotypic changes, we assessed the 
impact of neutrophil depletion (at day -1) on LRM at four days post-elastase challenge (Figure 3.25A). We 
influx. Flow cytometric analysis on lungs following elastase challenge revealed that surface levels of 
CD11b and CD200R on PKH26-PCL+CD11c+ resident lung macrophages were comparable between 
neutrophil depleted mice and non-depleted controls (Figure 3.25B, 3.25C). While neutrophil depletion had 
no impact on the LRM surface marker phenotype under these conditions, we only monitored surface 
CD11b and CD200R levels and appreciate that this was not an exhaustive LRM phenotyping as many other 
parameters could be assessed to more completely test the hypothesis. Interestingly, the size of the LRM 
population approximately doubled in the neutrophil depleted group (1A8) compared to non-depleted 
controls (PBS) at 4 days post-elastase challenge (Figure 3.26). While under these conditions, this data 
suggests that the presence of neutrophils impacts the degree of local alveolar macrophage expansion 
following elastase-induced lung damage, a more complete time course and monitoring is needed to fully 
understand the nature of neutrophil depletion and its possible impact on macrophage population dynamics. 
 
In this study, the data suggest that the lung-resident alveolar macrophage population responds to a changing 
lung environment following elastase challenge. Upon monitoring the myeloid cell populations in the lungs 
over time, we observed a transient elevation in the size of the alveolar macrophage population. An 
approximate doubling in the size of the lung-resident macrophage population occurred between days 2 and 
4 post-elastase challenge and was coincident with a significant increase in the percentage of LRM that were 
positive for a cell cycle marker, Ki67. Furthermore, the data suggest that the Ki67+ LRM population diluted 
the PKH26-PCL red fluorescent dye while the Ki67- LRM population did not, pointing to the possibility of 
local macrophage proliferation. In addition, the LRM population exhibited increased cell size and 
granularity and concomitant increases in cell surface CD11b and CD200R levels following elastase 
challenge. These morphological and surface phenotypic changes accompanied evidence of macrophage   
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Figure 3.26 Effect of neutrophil depletion on lung-resident PKH26-PCL+ population numbers following PPE challenge  
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activation based on gene expression profiling. Under these conditions, the data suggest that following 
elastase challenge and damage to the lung’s ECM matrix, the lung resident alveolar macrophage population 
responds in a number of capacities to the elastase-induced damage, indicated by a mixed M1/M2 activation 
phenotype. We speculate that these observed changes may be influenced by the loss of several key 
regulatory mechanisms by which alveolar epithelial cells function to keep the alveolar macrophage 




Our studies focused on the dynamics of myeloid cell populations in the lungs of mice following exogenous 
administration of porcine pancreatic elastase (PPE), an enzyme that causes damage to the extracellular 
matrix (ECM) leading to alveolar epithelial cell (AEC) death, the release of danger signals triggering 
inflammatory immune responses, progressive alveolar tissue destruction and the manifestation of 
emphysema. In this murine model of emphysema, under the conditions described above, we observed a 
transient increase in the size of the AM cellular niche. In addition, we observed morphological and 
phenotypic alterations to the cell surface following elastase challenge and a mixed M1/M2 activation 
phenotype. Data collected using an in vivo phagocytic cell labeling approach, as well as experiments 
carried out in CCR2-null mice, suggested that an AM subpopulation, which resided within the lungs prior 
to PPE challenge, entered cell cycle and proliferated. Because of their documented longevity and ability to 
mediate inflammation long after acute insults, we speculate that this AM subpopulation may contribute to 
the progression of emphysematous lung injury. 
 
An elevation in the numbers of AM in emphysema patients compared to non-emphysematous controls has 
been described numerous times [55, 360, 373]. Estimates of the magnitude of AM increase range from 5-
10-fold higher when comparing smokers and patients with COPD to healthy controls [55, 360] to 25-fold 
when comparing smokers with emphysema to normal smokers [399]. While the increased lung macrophage 
population in COPD and emphysema patients has been well documented, the mechanisms and dynamics by 
which this cellular niche expands are still not fully understood. 
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Several possible etiologies could be responsible for the elevated lung macrophage phenotype associated 
with emphysema in humans. First, in response to elevated chemokine expression, a robust monocyte 
infiltration from the periphery could account for the observed increase in lung macrophages. Second, a 
change in apoptotic mechanisms and/or protracted cell survival could lead to an altered cell turnover and an 
accumulation of lung macrophages. Third, the elevated number of lung macrophages associated with 
emphysema could be dependent upon enhanced local cell proliferation. While presented here as 
autonomous mechanisms, it is unlikely that any one of these mechanisms is fully responsible. It is more 
likely that these mechanisms work in concert to generate the observed phenotype. Through model systems, 
researchers can begin to tease apart these mechanisms and elucidate the nature of macrophage dynamics in 
order to understand how it may impact the progression of emphysema in humans. 
 
Historically, the central dogma within the myeloid cell and macrophage field has accepted that monocytes 
are the precursors to tissue macrophages [9, 187, 191, 444-452]. Therefore, it is not surprising that most of 
the COPD and emphysema literature to date supports this idea and operates under the assumption that 
monocytes play a key role in the pathogenesis of emphysematous changes to the lungs, as they are expected 
to give rise to the expanded lung macrophage population [453, 454]. Therefore, it was unexpected when we 
did not detect a clear and robust influx of CD11b+Ly6C+ inflammatory monocytes to the lungs following 
PPE challenge (Figure 3.3C, 3.3D). This phenotype also greatly differs from our findings in a model of 
malaria-associated acute lung injury (see CHAPTER 2), where we observed significant recruitment of 
monocytes into the lungs upon inflammatory insult (Figure 2.5B). Under the experimental conditions used 
here, our data suggest that “classical” inflammatory monocytes (CD11b+highLy6C+highCCR2+) may not play 
a major role in the pathogenesis of PPE-induced emphysema. However, as discussed in CHAPTER 1.2.26, 
not all blood monocyte populations express the chemokine receptor CCR2; as other chemoattractant ligand-
receptor axes such as CX3CL1/CX3CR1 are used for monocyte recruitment. Therefore, it is possible that 
following elastase-induced damage to the lungs, CCL2/CCR2-independent monocyte populations may 
contribute to the progression of PPE-induced emphysema. As such, we appreciate that our investigation 
focused on the CCR2+ inflammatory monocyte population (comparable to human CD14+highCD16- 
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monocytes) and there are other circulating monocyte populations such as “resident” fractalkine receptor-
positive (CX3CR1+) CCR2- monocytes (comparable to human CD14+CD16+ monocytes) that may have 
been recruited to the lungs following elastase-induced damage that fell outside of our analysis [9, 187]. In 
fact, in the murine cigarette smoke (CS) model of emphysema, “classical” CCR2+ inflammatory monocytes 
were not found to be recruited to the lungs, instead, a CX3CR1+ monocyte population was shown to expand 
and associate with the lung interstitium, but not within the alveolar spaces [419, 454]. Our data appears to 
be consistent these findings in the CS emphysema model and suggest that CCR2-dependent monocyte 
populations may have minimal impact on the pathogenesis of PPE-induced emphysema; as we observed a 
similar dynamic pattern for the extent of progressive tissue damage and emphysema in CCR2-deficient 
mice as wildtype controls (Figure 3.8). Under these experimental conditions, our data do not support the 
notion that “inflammatory” CCR2+ monocytes serve as the precursors to the expansion of the lung 
macrophage population we observed in the elastase model of murine emphysema. 
 
Alternatively, the observed increases in the size of the lung macrophage population associated with tissue 
destruction in emphysema and COPD patients may be due to alterations in the turnover rate of these long-
lived tissue-resident cells. Several factors may influence the turnover rate including changes in cell pro-
survival signals, apoptotic cell death mechanisms, or cell proliferation. Lung macrophages have a long 
lifespan, estimated on the order of several months [455] and it is clear that the effects of certain 
environmental exposures are quite long lived in lung macrophages [122]. For example, in an observational 
study, a never-smoker with A1AD emphysema received a lung transplant from a donor with a history of 
heavy cigarette smoking. The transplant recipient was monitored over time for the presence of alveolar 
macrophages containing inclusion bodies containing tobacco smoke particulate [456]. Surprisingly, greater 
than 50% of alveolar macrophages isolated by bronchoalveolar lavage (BAL) still contained smoke-
associated inclusion bodies at 24 months following transplantation [456]. It is remarkable that 
environmental exposures such as tobacco smoke are so long-lasting in this cellular niche, as it has been 
well documented that exposure to tobacco smoke can greatly alter the lung macrophage activation state 
[376, 457]. This observational study did not address whether these tobacco smoke-containing AM were the 
original macrophages that encountered the tobacco smoke or their cellular descendants; it is intriguing to 
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ponder the idea of vertical transmission of an activation state from parent (F0) to daughter (F1) generations 
through epigenetic modifications. Furthermore, there is evidence demonstrating that lung macrophages 
isolated from tobacco smokers have altered cell survival mechanisms, as these cells have higher expression 
of Bcl-XL, an anti-apoptosis factor and therefore increased cell survival [404]. Surely the effects of 
increased cell survival could result in an enlarged lung macrophage population over time, however, 
increases in the rate of local lung macrophage proliferation have the potential to enhance the size of the 
lung macrophage population more quickly. While there is precedent for speculation that there is local lung 
macrophage proliferation in humans in the context of smoking and COPD [224, 228, 457], direct evidence 
of resident lung macrophage proliferation during the progression of emphysematous changes in the lungs 
has not been clearly demonstrated. More broadly, the idea of local lung macrophage proliferation has been 
sporadically discussed in the field [223, 225], but this notion has never fully taken hold. Only recently, as 
was outlined in CHAPTER 1.2.27, the myeloid cell and macrophage community is currently undergoing a 
paradigm shift in regard to the idea that terminally differentiated tissue macrophages have the ability to self 
renew and maintain themselves via local cell proliferation [208]. Tissue-resident macrophage proliferation 
has been demonstrated in a variety of situations including parasitic worm infections localized to the lungs 
[46] and pleural cavity [231], at atherosclerotic lesions [233], and in adipose tissue [234]. Under these 
conditions, our data suggests that between days 2 and 7 post-elastase challenge, a lung-resident 
macrophage subpopulation enters cell cycle and proliferates (Figure 3.16, 3.17, 3.18). 
 
We also observed several morphological and phenotypic changes to the surface of the lung resident 
macrophage population following elastase challenge. These changes were consistent with a lung-resident 
macrophage population quickly responding to alterations to the local microenvironment upon lung damage. 
In fact, all tissue macrophages are influenced by factors in their local environment [458]. The local 
pulmonary environment certainly has a profound impact upon the function of alveolar macrophages, which 
are constantly exposed to high levels of surfactants [459], granulocyte macrophage colony stimulating 
factor (GM-CSF) [127], transforming growth factor beta (TGF-β) [154], and other immune-modulatory 
factors [37, 56, 143, 460]. Generally, changes to the availability of these regulatory factors can lead to 
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alterations in AM function, but in some cases can lead to a severely dysregulated alveolar macrophage 
population and chronic pulmonary inflammation. 
 
GM-CSF is a prime example of a soluble regulatory factor that influences the activation state of the 
alveolar macrophage population. GM-CSF is maintained at high levels in the lung environment and 
functions to maintain homeostasis, however GM-CSF-deficient (Csf2-/-) and GM-CSFR-deficient (Csf2r-/-) 
mice spontaneously develop pulmonary alveolar proteinosis (PAP) [461], a rare condition characterized by 
the accumulation of high levels of pulmonary surfactants [127, 144]. In addition, GM-CSF-/- mice have 
been shown to be devoid of a mature alveolar macrophage population with deficits in phagocytosis, 
surfactant catabolism, cell adhesion, and innate immune function [37, 145, 461]. GM-CSF produced by 
AEC controls the maturation as well as the activation of the lung macrophage population through the 
transcription factor PU.1 [127, 146] and GM-CSF has been shown to directly promote tissue macrophage 
proliferation [142, 462]. We speculate that it is possible that following elastase challenge, the lung-resident 
macrophage population may be stimulated to proliferate through the actions of excess GM-CSF in the lungs 
as elevated GM-CSF levels have measured in the BAL and sputum of COPD patients [463] and in the PPE 
murine model of emphysema [464]. 
 
The expression of integrins on the alveolar macrophage surface can be influenced by several factors present 
in the lung environment, thereby influencing the cellular function [37]. A key feature and defining 
characteristic of murine alveolar macrophages is their low expression of the integrin CD11b (integrin αM) 
[57, 58]. Using surface marker profiling to identify myeloid cell populations, most tissue macrophages are 
defined as being F4/80+CD11b+CD11c- cells [9, 11]. However, alveolar macrophages are distinct from 
other tissue resident macrophage populations, as they are defined as F4/80lowCD11b-CD11c+ cells; a 
surface marker phenotype typically used to identify dendritic cell populations [58]. The integrin CD11b 
(alpha M) performs several functions as it plays a role in phagocytosis, pairs with CD18 (integrin β2) to 
form complement receptor 3 (CR3; also known as Mac-1), and in the adhesion of lung macrophages to the 
ECM and other cell types [234]. An increase in lung macrophage surface CD11b levels has been implicated 
in the increased phagocytosis of bacteria and apoptotic inflammatory cells [465]. Upon intra-tracheal 
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elastase-challenge, we observed a transient upregulation of surface CD11b levels on the lung-resident 
macrophage population (Figures 3.4 and 3.13). Therefore, it would be predicted that a CD11b+ AM 
population would likely exhibit enhanced phagocytic capacities, possibly to clear increased numbers of 
apoptotic AEC and neutrophils present in the lungs following elastase-induced damage [466]. Similar 
alterations to alveolar macrophage CD11b surface levels have been reported upon repeated exposure to 
organic dust extract (DE) [467]. Such changes to the lung macrophage surface phenotype were associated 
with increased IL-6 and CXCL1/GROα release and enhanced phagocytic capacity of the lung macrophage 
pool [467]. Furthermore, a similar phenotype has also been reported in alveolar macrophages following 
Streptococcus pneumoniae infection [63]. At day 3 post-S. pneumoniae infection, approximately 65% of 
the lung macrophage population in the airways and the lung tissue had high levels of CD11b on their 
surface [63]. This phenotypic alteration in surface CD11b level is roughly equivalent to the degree that we 
measured following elastase-induced damage to the lungs between days 2 and 7 post-challenge (Figure 3.4, 
3.13). In addition, the investigators determined using in vitro studies that GM-CSF (and not S. pneumoniae 
lysate, LPS, or IL-10) regulated surface CD11b levels on lung macrophages [63]. The investigators 
speculated that the transient nature of CD11b up-regulation on the surface of the lung macrophages was 
associated with an initial increase in local GM-CSF levels and its resolution to steady-state levels. AEC-
derived GM-CSF has been implicated as a pathogenic mediator of experimental COPD and potential drug 
target due to its profound impacts on lung macrophage survival, proliferation, and activation [468, 469]. 
 
Recently, multiple studies have illustrated the importance of direct interaction between AM and AEC [47, 
154, 167]. In fact, a recent study demonstrated that lung epithelial cells act as a conduit and scaffold for 
inter-macrophage communications [167]. AM bind to AEC via the gap junction protein connexin 43 and 
utilize Ca2+ fluxes to communicate with distal lung macrophages via AEC [167]. Therefore, appreciating 
the physical relationship that exists between these cell types becomes especially important when 
investigating the molecular and cellular mechanisms of emphysema pathogenesis. In the case of PPE-
induced emphysema, damage to the ECM and subsequent AEC death may directly impact the activation 
state of the alveolar macrophage population. When alveolar macrophages adhere to the airway epithelium, 
the immunomodulatory cytokine TGF-β is maintained in its active form by αvβ6 integrin on airway 
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epithelial cells [152, 153] and maintains the AM in a quiescent state [154]. Mice deficient in the integrin β6 
subunit (Itgb6-/-) (functional loss of integrin αvβ6) suffer from elevated MMP12 levels (200-fold increase in 
the lung macrophage population) in the lungs and the spontaneous development of emphysema [153]. The 
investigators determined that this activated alveolar macrophage phenotype in Itgb6-/- mice was due to the 
inability of integrin αvβ6 to bind and activate latent TGFβ, therefore resulting in elevated lung macrophage 
MMP12 production and the progression of emphysema [153]. These findings suggest a direct link between 
AEC and AM, thereby controlling macrophage activation via immunomodulatory factors. 
 
CD200-CD200R interaction serves as another immune-modulatory mechanism by which AEC can 
maintain anti-inflammatory alveolar macrophages [160, 161]. CD200 (also known as OX2) is a surface 
molecule expressed on the surface of a wide array of cell types including but not limited to AEC, T cells, B 
cells, and neurons [161, 162]. CD200R is a transmembrane receptor almost exclusively expressed by 
myeloid cells, but can also be expressed by T cells [162, 164]. Of note, CD200R is expressed at high levels 
on the surface of lung macrophages [47, 163]. Ligation of the receptor inhibits macrophage activation 
through recruitment of Dok2 and subsequent RasGAP activation, which mediates inhibition of the Erk, Jnk, 
and p38 MAPK pathways [164-166]. Engagement of CD200R on the surface of lung macrophages 
negatively regulates the level of pro-inflammatory activation and maintains lung homeostasis [47], 
however, failure to engage the inhibitory CD200R can lead to myeloid cell activation. For example, 
alveolar macrophages from CD200-/- mice have an pronounced activated phenotype, as they do not receive 
the immune-modulatory signal from the AEC [47]. As a result, CD200-/- mice have elevated numbers (more 
CD200R+ cells in the lungs) and elevated MHC class II and CD80 surface levels on lung macrophages [47]. 
Owing to an activated lung macrophage population, CD200-/- mice are able to clear influenza infections 
much more rapidly than wild-type controls, however they also experience higher levels of 
immunopathology and morbidity associated with influenza infection, due to exacerbated anti-viral 
responses [47]. Similar to our observations following elastase-challenge (Figure 3.14), influenza infection 
results in elevated CD200R levels on the surface of the alveolar macrophage population [47]. It would be 
predicted that elastase-induced AEC death would lead to a loss of TGF-β mediated-regulation as well as 
CD200-CD200R engagement. We speculate that upon release of these inhibitory signals, the alveolar 
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macrophage population would elevate surface CD200R levels as a compensatory effect to maintain contact-
dependent regulation. 
 
Alarmins, epithelial-derived cytokines such as IL-25, IL-33 and thymic stromal lymphopoietin (TSLP), can 
be released upon cellular stress and act as another factor involved in the maintenance of the interaction 
between the AEC and lung macrophages [155, 157, 158]. Stress-induced alarmin release and signaling can 
lead to the initiation of type 2 immune responses through the promotion of downstream factors such as IL-
4, IL-5 and IL-13 [155]. A number of cell populations have recently been shown to respond to IL-25 and 
IL-33, including type 2 innate lymphoid cells (ILC2s) and macrophages [157]. IL-33, an IL-1 family 
member, signals through its heterodimeric receptor ST2 (also known as IL1RL1) and IL-1 accessory 
protein via MyD88 [158]. IL-33 signaling has been demonstrated to drive a wound repair response in the 
lung [155]. IL-33 also appears to be important in the progression of emphysema, as anti-IL-33 blockade is 
protective from CS-induced emphysema [470]. Indeed, our laboratory has demonstrated that IL-33 protein 
levels were elevated within 48 hours after elastase-induced damage in the lungs and that ST2-deficient 
mice are protected from the progressive stage of emphysema (data not shown). Therefore, we monitored 
the expression of ST2 surface levels on the alveolar macrophage population following elastase challenge. 
We observed that the number of ST2+ lung macrophages expanded and peaked at 2 days post-elastase and 
subsequently returned to baseline levels by day 14 post-PPE challenge (Figure 3.15). Our data suggests that 
upon AEC damage and cell death the alarmin IL-33 is released and is bound by ST2+ cells in the lungs 
including lung macrophages, and upon IL-33 stimulation, the AM population increases surface levels of the 
ST2 receptor. 
 
Interestingly, our data suggest that the AM exhibit a mixed M1/M2 activation phenotype following elastase 
challenge. Isolated CD11c+ cells concurrently up-regulated Nos2 and Arg1 within two days following PPE 
challenge (Figure 3.20, 3.21). Over the 21 days following elastase-induced lung damage, other M1- and 
M2-associated genes were also concomitantly up-regulated (Figure 3.19, 3.20, 3.21). Alveolar 
macrophages up-regulated the expression of elastolytic enzymes associated with the onset of COPD such as 
MMP12 (days 7 and 14) [153] and MMP9 (day 21) [471]. In addition, AM up-regulated expression of the 
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alarmin, IL-33, at day 2 post-PPE, suggesting that lung macrophages may have been under stress or 
endured damage upon elastase challenge. Interestingly, there was no significant change in ST2 expression 
level; in contrast with our flow cytometric analysis where we observed increased ST2 surface protein levels 
at day 2 post-elastase (Figure 3.15). Furthermore, the data suggest NLRP3 inflammasome activation 
occurred several weeks following elastase-induced damage, as both Il1b and Il18 were significantly up-
regulated at day 21 (Figure 3.20). IL-1β and IL-18 have both been implicated with the onset of COPD and 
in mouse models of emphysema [472, 473]. It is possible that reactive oxygen species [474] or extracellular 
ATP [475] released from dying AEC may trigger NLRP3 inflammasome activation. Overall, the AM 
activation profile was temporally dynamic as the composition of genes up-regulated at day 2 differed from 
those at days 7, 14, and 21 post-elastase (Figure 3.19, 3.20, 3.21). In fact, the effects of an acute 
inflammatory insult such as elastase challenge on macrophage activation can be quite long-lived, as a 
number of the genes assessed were significantly up-regulated 21 days post-challenge. However, given our 
results, it is unknown whether individual macrophages exhibit a mixed activation phenotype or whether the 
population as a whole is composed of a heterogeneous mixture of activated cells.  
 
Macrophages with mixed M1/M2 phenotypes have been previously reported in adipose tissue macrophages 
[476], peritoneal macrophages [477], as well as lung macrophages from GM-CSF-/- mice [478] or isolated 
from smoking patients with COPD [479]. The notion of linear macrophage polarization phenotypes (either 
M1 or M2), as have been characterized in vitro through stimulation with LPS and IFNγ or IL-4 and IL-13 
respectively, does not translate to in vivo systems. Therefore, in vivo macrophage polarization should be 
considered more spectral in nature (reviewed in [112]), as a multitude of macrophage activating factors are 
present and can differ based on the local tissue environment and inflammatory insult. In fact, many of the 
soluble and contact-dependent factors discussed above can profoundly influence macrophage activation 
status. In addition, there is a temporal component to in vivo macrophage polarization that must be taken 
into account as the requirements of macrophage function change from acute inflammatory insult to the 
resolution phase [477] (reviewed in [480]). The underlying molecular mechanisms that control the mixed 
macrophage activation phenotype need to be revealed to gain further insight into the function of these cells 
and their contribution to emphysematous changes to the lungs. 
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In addition to the interactions with AEC, alveolar macrophages also interact with other cells types, 
including neutrophils, following elastase-induced lung damage. It is clear that the neutrophil and lung 
macrophage populations are linked through the release of soluble chemokines, however they are also 
connected through additional indirect and direct physical interactions. Lung macrophages, like endothelial 
and epithelial cells, are responsible for the release of IL-8/CXCL8, a neutrophil chemotactic factor, 
following lung damage [481]. Upon recruitment to the lung, neutrophils phagocytose pathogens or cellular 
debris, release cytokines, degranulate (release granular contents), and apoptose [482]. Upon neutrophil 
apoptosis, tissue macrophages and monocyte populations phagocytose the apoptotic bodies, thereby 
limiting prolonged inflammatory responses [482]. As a consequence of neutrophil activation and 
degranulation, several serine proteases including neutrophil elastase and cathepsin G are released. Previous 
studies have demonstrated that neutrophil elastase and cathepsin G are responsible for the cleavage of IL-
33 into its bioactive form [159]. It is possible that cleavage of IL-33 into its bioactive form is a prerequisite 
for up-regulation of surface ST2 levels on AM. Exogenous IL-33 administration has been demonstrated to 
up-regulate surface ST2 levels on lung macrophages and promotes an alternatively activated macrophage 
(AAM) phenotype [155]. Data collected previously in our group demonstrated that neutrophils rapidly 
influx into the lungs following elastase challenge, peak at 48 hours and resolve by 7 days post-PPE 
challenge (Figure 1.7D). This rapid neutrophil influx paralleled the transient up-regulation of alveolar 
macrophage ST2 levels observed upon elastase challenge (Figure 13.5). Interestingly, our data suggest that 
neutrophil depletion may impact the extent of local lung macrophage proliferation following elastase-
induced tissue damage (Figure 3.25). Certainly further investigation is warranted to elucidate the 
relationship between impaired neutrophil influx and the dynamics of the alveolar macrophage niche upon 
elastase challenge. 
 
In order to test the hypothesis that lung macrophages contribute to the progression of emphysema following 
elastase-induced damage, we utilized clodronate-loaded liposomes (CLLs) administered via intra-tracheal 
aspiration as a depletion strategy. However, CLL administration did not impact the dynamics or extent of 
emphysema progression when administered one day prior to or 2, 7, or 14 days following PPE challenge 
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(Figure 3.22). When we assessed the efficacy of alveolar macrophage depletion over time, it was clear that 
following elastase challenge, the efficacy of depletion was decreased compared to unchallenged lungs 
(Figure 3.23). In an attempt to possibly explain this phenomenon, we devised several hypotheses: first, it is 
possible that the target cells (alveolar macrophages) are inaccessible due to the extensive damage to the 
lung architecture following elastase challenge, or second, the AM are indeed being reached by the CLLs 
however the target cells do not phagocytose the liposomes due to changes in their activation state, possibly 
due to early efferocytosis of dead AEC and neutrophils. These are certainly testable hypotheses and do 
warrant further investigation. Alternatively, there are other strategies that could be employed for the 
depletion of the lung macrophage population that do not require phagocytosis, such as the CD11c-DTR 
transgenic mice [483-485]. This transgenic depletion strategy only requires the diphtheria toxin to 
physically engage the toxin receptor on the cell surface and would work around the requirement for 
phagocytic uptake of the apoptosis-inducing drug. Additionally, we know that CD11c levels on the surface 
of alveolar macrophages remains constant over the 21 day period following elastase challenge (Figure 3.2), 
so their DTR surface levels should remain stable. It is appreciated that there are other CD11c+ cells in the 
lungs over this time period including dendritic cells, but DCs can also be unintended target cells during 
CLL-mediated depletions strategies, so there would be minimal increase in the off-target effects when 
using the CD11c-DTR depletion strategy compared to CLL-mediated depletions. By employing specific 
and effective depletion strategies, we may be able to further elucidate the role of the lung resident 
macrophage population during the initiation and progression of emphysematous changes to the lungs in 
response to PPE challenge. Previous lung macrophage depletion studies, using an in-house generated rabbit 
anti-rat monocyte/macrophage polyclonal sera (antiMoMac), have demonstrated that the specific ablation 
of macrophage-derived elastolytic activity protects from the progression of emphysema following CS 
exposure in rats [486]. 
 
Interestingly, the expansion of the AM population observed following PPE challenge was transient in 
nature. Following a brief proliferative phase, the AM population returned to homeostatic levels by day 14 
post-elastase challenge (Figure 1.7D, Figure 3.3A). While the mechanisms behind this apparent contraction 
phase remain unknown, it may be due to changes in AM surface phenotype, apoptosis, or migration from 
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the lungs. In Figure 1.7D, alveolar macrophages were collected by BAL and identified based on 
morphological assessment, therefore our quantification of AM population size by this method was 
independent of surface marker profile, so it is unlikely that changes to the macrophage surface phenotype 
underlie the apparent contraction. Certainly, further investigations into potential apoptosis or macrophage 
trafficking during this period are warranted. 
 
We have just begun our investigations into the dynamics of the myeloid cell populations in the lungs 
following elastase-induced damage. The data presented here suggest that under these conditions, the AM 
population undergoes early transient phenotypic changes, display a mixed M1/M2 activation phenotype, as 
well as proliferate locally following elastase challenge. We speculate that these morphological, phenotypic, 
and activation changes to the AM population may be influenced, in part, by the release of several immune-
modulatory control mechanisms. Understanding how these interactions with AEC and the lung 
environment at large control lung macrophage activation status and function is paramount to the 
understanding of their role in the progression of emphysematous changes in the lungs. We further speculate 
that an acute insult such as elastase-mediated alveolar ECM destruction and AEC death may lead to 
alteration of the AM population’s activation rheostat. Such a transformation could account for the 
progressive nature of emphysematous changes to the lungs, as alveolar macrophages are long-lived cells 
with the ability to directly secrete effector molecules responsible for progressive emphysema or indirectly 
mediate inflammation long after acute insults. Given the nature of the mediators of emphysema, such a 
response could be considered a poorly-regulated or imbalanced wound healing response. If so, further 
elucidation of the molecular and cellular mechanisms responsible for the maintenance of an altered lung 
macrophage rheostat are necessary, as it may be possible to intervene clinically with the goal of resetting 
the AM activation setpoint. Such interventions would have significant utility to public health as halting the 
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4.1 Macrophage biology: looking ahead 
Recently, there have been substantial advances in our understanding of macrophage and monocyte biology. 
The current paradigm shifts have left the field somewhat in flux, but have afforded investigators a new 
perspective and opportunities to assess and reassess the mechanistic roles of tissue-resident and infiltrating 
mononuclear cells. There are several key areas of investigation in relation to the advancement of our 
understanding of lung macrophage function that warrant mention. Currently, one of the most intensely 
studied aspects of macrophage biology is the classification of particular activation states such as M1 
(CAM), M2a (AAM), M2b (type II), and M2c (deactivated) under a spectrum of inflammatory conditions 
[112, 480]. Macrophage activation is not linear in nature as the M1-M2 paradigm initially suggested, as this 
framework ignores the source and context of activation stimuli. Unlike the single-activator in vitro systems, 
in vivo macrophage-activating stimuli are multifactorial, temporally complex and non-mutually exclusive. 
Recent studies have demonstrated that instead of distinct phenotypes macrophage polarization should be 
considered spectral in nature [107, 112]. Macrophage polarization is plastic and flexible, as tissue 
macrophages do not form stable subsets, but instead conform and respond to the local tissue environment 
[487]. Plasticity of gene expression is particularly important given most tissue macrophages are 
embryonically seeded cells with the ability to maintain homeostatic levels throughout life. Owing to this 
dynamic nature, macrophages can be categorized as having mixed phenotypes at the population level or 
even at the single-cell level [476, 477, 488, 489]. The exact macrophage activation phenotype depends on 
the milieu of environmental signals that each cell is exposed to within the tissue. Therefore, in response to 
these dynamic processes, investigators must account for space and time when evaluating the contextual 
functionality of lung monocytes and macrophages. As such, more comprehensive analyses of lung 
macrophage activation phenotypes under a variety of conditions are needed. 
 
Researchers continue to strive towards a clearer understanding of the interconnections and functional 
differences between monocytes, tissue-resident macrophages and DCs. In light of the current paradigm 
shift, the origins of these cell populations may be more disparate than previously appreciated. Still, 
questions remain as to why some tissue macrophage populations are constantly replenished by monocytes, 
whereas other tissue macrophage populations are able to self-maintain independent of monocyte 
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contributions [196, 208, 210, 215]. The survival signals and underlying mechanisms that control these 
different situations remain unclear and certainly warrant further investigation. In order to more carefully 
delineate the function of these cell types, their core homeostatic features must be elucidated through 
transcriptional, epigenetic, proteomic, and metabolic profiling studies. The field is first working towards 
defining baseline expression profiles for different mononuclear phagocyte populations within a variety of 
tissue environments in order to identify key transcriptional networks [11, 490]. In fact, several large 
collaborative multi-site projects such as the Immunological Genome Project (ImmGen) [491], Human 
Immunology Project Consortium (HIPC) [492] and InnateDB [493] take advantage of expertise garnered 
within individual member laboratories and are working towards more clearly defining baseline 
transcriptional networks controlling immune cell populations both in humans and mice. 
 
4.2 Macrophages in malaria 
Human malaria infections result in a complex disease state that differs based on geography, age, prior 
exposure to Plasmodium, prior exposure to other pathogens, immune status, environment, and genetics. 
While no animal model of malaria is fully able to recapitulate the human disease, certain aspects of malaria 
pathogenesis in mouse models apply to human malaria infections. With that in mind, we have compiled the 
findings presented in CHAPTER 2 to create a working model of an understudied aspect of malaria 
infection – malaria in the lungs. This proposed model is presented in Figure 4.1. Briefly, as peripheral 
blood parasitemia rises, circulating Plasmodium-infected erythrocytes cytoadhere to the luminal surface of 
pulmonary post-capillary vascular endothelial cells. In our model, these host-pathogen interactions are 
largely mediated through direct contact between CD36 on the endothelial cell surface and a parasite-
derived protein schizont membrane-associated cytoadherence protein (SMAC), a surrogate for the 
seemingly more complex interactions between parasite-derived PfEMP1 and an array of host proteins in P. 
falciparum malaria in humans (Figure 4.1A). The intimate, receptor-mediated contacts between 
Plasmodium-infected erythrocytes and endothelial cells result in endothelial barrier disruption and pro-
inflammatory cytokine and chemokine release, possibly an endothelial cell response to parasite-derived  
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Figure 4.1 Current working model: malaria  
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reactive oxygen species produced as a consequence of hemoglobin metabolism (Figure 4.1B). In an effort 
to clear sequestered parasites from the vasculature, a robust chemokine gradient is established; with several 
mononuclear phagocyte-recruiting chemokines expressed at high levels in the lungs. These chemokines 
gradients (largely the CCL2-CCR2 axis) recruit CCR2+ inflammatory monocytes from the peripheral blood 
and bone marrow. The recruited inflammatory monocytes may tightly adhere to the luminal endothelial 
surface or localize in extra-vascular space, as they are retained in the lung tissue following perfusion 
(because the cells are no longer in the circulation and are lung-associated, we have termed these cells, 
monocyte-derived macrophages (MDM)). Upon recruitment to the lungs, the MDM population is the major 
driver of parasite clearance during primary acute infection. CD36-mediated non-opsonic phagocytosis is a 
key mechanism by which Plasmodium-infected erythrocytes are cleared (Figure 4.1C). Associated with 
parasite uptake, the MDM population up-regulates expression of co-stimulatory and other activation-
associated molecules on their surface. Coincident with increasing parasite burden and monocyte 
recruitment to the endothelial surface, the endothelial barrier is compromised leading to non-cardiogenic 
pulmonary edema, which impacts gas exchange and lung function, as proteinaceous fluid enters the airways 
(Figure 4.1D). 
 
Despite lung injury, the data indicates that the resident alveolar macrophage population (AM) does not play 
a major role in the clearance of sequestered parasites. In fact, with the exception of elevated surface MHCII 
levels, alveolar macrophages remain in an inactivated state even in the face of the elevated lung injury in 
CCR2-deficient mice that result from a block in the ability of monocytes to traffic to the lungs (Figure 2.11, 
4.2). We hypothesize that alveolar macrophages play an anti-inflammatory/pro-homeostatic role in the 
resolution of malaria-induced lung injury. Our data suggest a basic model in which the dynamic interplay 
between the damage generated by CD36-mediated parasite sequestration and the protective action of 
CD36-mediated monocyte-driven parasite clearance largely determines the extent of malaria-induced lung 
injury during the acute phase of malaria infection (Figure 4.1, 4.2, 4.3). In future studies, we will use this 
current working model (Figure 4.1) as a springboard to form new testable hypotheses to mature our 
understanding of the complex pathophysiological mechanisms involved in malaria-induced lung injury. 
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Figure 4.2 Current working model: malaria  
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Figure 4.3 Current working model: malaria  
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The use of the available CCR2- and CD36-deficient strains necessitated that experiments be carried out 
using mice on the C57BL/6 genetic background. Since our C57BL/6 mouse model of severe malaria results 
in the onset of experimental cerebral malaria (ECM) and death at seven days post-infection, we were only 
able to study acute, innate immune responses to the presence of parasites in the lungs. It is intriguing to 
speculate on the fate of the inflammatory monocyte population in mouse strain-Plasmodium species 
combinations that result in more protracted infections. A longer infection window would provide 
opportunities to investigate the role of adaptive immunity on the parasite-induced lung inflammation and to 
determine the fate of the MDM that engulf parasite material. It is possible that the inflammatory monocytes 
are cleared from the lungs via Fas-mediated clearance mechanisms as has been shown in other lung injury 
models including influenza virus infection and LPS instillation [49]. Furthermore, we would be able to 
study the dynamics and function of the resident alveolar macrophage population in the context of the 
adaptive immune response. As the alveolar macrophages are known to play an active role in the 
maintenance of lung homeostasis, we hypothesize that their role is more pronounced during the adaptive 
phase. In future studies, it would be beneficial to explore the ability of MDM and alveolar macrophages to 
traffic to draining lymph nodes and present malaria antigens to T cells. Additionally, it would be 
advantageous to employ other parasite strains such as P. chabaudi or P. yoelii to determine if differences 
exist in the degree of pulmonary parasite sequestration, monocyte clearance and overall malaria-associated 
lung injury. 
 
The findings presented in CHAPTER 2 contribute towards a clearer understanding of the implications of 
some of the current proposed approaches to employ pharmacological agents that alter CD36 levels as 
adjunct therapy for severe malaria patients. Some of these investigations aim to reduce malaria-induced 
pathology by increasing parasite clearance by employing PPARγ [494, 495] and Nrf2 agonists [496] to 
pharmacologically up-regulate CD36 levels on the surface of monocytes/macrophages. In addition, other 
anti-adhesion blocking therapies focus on limiting the level of parasite sequestration through CD36 
blockade (reviewed in [497]). For example, the anti-helminthic drug Levamisole limits CD36-mediated 
sequestration of Plasmodium-infected erythrocytes by blocking CD36 dephosphorylation and preventing 
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the high affinity binding form of CD36 [498, 499]. As our data presented in CHAPTER 2 demonstrates, the 
relative contributions of both parasite sequestration and monocyte clearance need to be taken into account 
as both contribute to malaria-induced lung injury (and possibly to injury at other tissue sites). Therefore, 
careful consideration must be taken when proposing pharmacologic alteration of CD36 levels as a means to 
increase parasite clearance, as such a strategy may have deleterious consequences on the extent of CD36-
mediated parasite sequestration. Conversely, therapeutic blockade of CD36-mediated parasite sequestration 
may alter the ability of mononuclear phagocytes to effectively clear parasites via non-opsonic 
phagocytosis. While a complex biological problem, development of adjunct therapies for severe malaria 
patients may someday prove to be an effective drug regimen. 
 
4.3 Macrophages in emphysema 
While exposure to cigarette smoke is the predominant risk factor associated with emphysema, not all 
smokers develop emphysema and for those that do years of exposure are required to cultivate the disease. It 
is becoming clear that there are multiple environmental, physiological and genetic factors that contribute to 
the initial damage that leads to the progressive destruction of alveolar tissue and development of 
emphysema. While specific initiation events are yet to be identified, lines of evidence suggest that 
physiological imbalances such as alterations in the relative concentrations of proteases and anti-proteases 
develop in certain individuals and serve as drivers of emphysema. Given that the exact initiation events are 
likely to be variable in humans, we employed a mouse model to simulate the protease/anti-protease 
imbalance associated with the development of emphysema. We have compiled our findings presented in 
CHAPTER 3 to create a working model. This proposed model is presented in Figure 4.4. In this model, 
porcine pancreatic elastase (PPE) is used as a surrogate for the complex mixture of proteases released from 
neutrophils (neutrophil elastase, cathepsin G, proteinase-3) and macrophages (MMP9, MMP12) in response 
to the toxic substances and epithelial damage caused by cigarette smoke. Upon administration into the 
lungs, PPE degrades elastin, a component of the lung’s extracellular matrix. Matrix degradation leads to 
epithelial cell stress and death, and release of DAMPS (such as nuclear proteins, DNA, RNA, ATP) and 
alarmins (such as IL-33, IL-25, TSLP) (Figure 4.4B). Furthermore, due to mechanical stress alveolar 
epithelial cells die via necrosis as well as apoptosis. Neutrophils are recruited early to the lungs and peak   
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Figure 4.4 Current working model: emphysema  
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within two days. Unexpectedly, the data suggests that inflammatory monocytes are not recruited to the 
lungs in large numbers following elastase challenge. Therefore, we presume that alveolar macrophages play 
a major role in the clearance of apoptotic neutrophils and alveolar epithelial cells (Figure 4.4C). Our data 
suggest that upon alveolar epithelial cells loss, contact-dependent macrophage regulatory  
mechanisms (such as CD200-CD200R interactions and active TGFβ engagement by TGFβR) are lost. 
Relieving macrophage regulatory mechanisms may contribute to alveolar macrophage activation, pro-
inflammatory cytokine production and proliferation following elastase-induced lung damage (Figure 4.4C). 
It is possible that a dysregulation of resident macrophage activation contributes to the progressive 
destruction of alveolar epithelial cell layer and emphysematous changes in the lungs (Figure 4.4D). Going 
forward, we will use this working model (Figure 4.4) as a starting point to form new testable hypotheses in 
order to further our understanding of the role of lung macrophages in the progression of elastase-induced 
emphysema. 
 
Interestingly, in stark contrast to the vigorous infiltration of inflammatory monocytes observed during the 
innate phase response to malaria in the lung, PPE challenge did not result in a robust inflammatory 
monocyte recruitment; instead we observed local macrophage proliferation. In future experiments, it would 
be valuable to reveal the factors involved in promoting local macrophage proliferation following elastase-
induced lung injury. Moreover, it would be advantageous to isolate and assess the activation status of the 
proliferative and non-proliferative AM subpopulations, as they may acquire distinct activation phenotypes 
and differ in their contributions to progressive alveolar tissue destruction. While the inflammatory insults 
studied in CHAPTER 2 and CHAPTER 3 certainly differ, they highlight an issue that has become more 
pertinent in light of the ongoing paradigm shifts in the macrophage biology. It is still unclear which 
environmental signals promote local tissue macrophage proliferation. Furthermore, investigators are 
working to understand the costs and benefits associated with tissue macrophage proliferation versus 
recruitment of inflammatory monocyte pools from the periphery during inflammatory insults. While 
inflammatory monocytes exhibit a number of beneficial functions, including facilitating clearance of 
pathogens, they also require a resolution phase in order to prevent chronic monocyte-driven pathology. 
Therefore, it has been proposed that under certain settings, it may be beneficial (from an resources 
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perspective) to contend with inflammatory insults through local proliferation of the tissue macrophage 
population, as these cells are already in tune with the local tissue environment and function to maintain 
tissue homeostasis. It is possible that our observation of transient local macrophage proliferation following 
elastase-induced lung damage may provide insights that contribute to a greater understanding of the 
underlying factors involved in tissue macrophage proliferation.  
 
The observations presented in CHAPTER 3 have implications for the development of strategies for 
therapeutic treatment of patients with progressive emphysema. It may be possible and beneficial to 
reprogram or shift the polarization of lung macrophages in order to treat emphysema. Due to their inherent 
plasticity, it may be easier to manipulate tissue macrophages than other immune cells (such as T cells) 
implicated in disease states. Alveolar macrophages in particular are a desirable target for tissue macrophage 
modification, as they are easily reached through the use of inhalers. There are many potential mechanisms 
to focus on for reprogramming the alveolar macrophage population. If long-lived activated lung 
macrophages indeed contribute to the progression of emphysema, it would be beneficial to restore 
macrophage regulatory mechanisms such as PDL-1 or CD200R that keep the lung macrophage population 
in check since corticosteroids are ineffective against macrophages of COPD patients [481]. As we observed 
elevated alveolar macrophage CD200R surface levels following elastase-induced damage, it may be 
beneficial to use CD200R agonists as a therapeutic. This therapeutic approach would recapitulate the 
immune-modulatory role that alveolar epithelial cells exert upon the alveolar macrophage [47] and could 
possibly restore lung homeostasis. Such a therapeutic strategy could potentially benefit other lung diseases 
in which macrophages have been implicated in the pathogenesis. At present, there is a serious need for any 
therapy that could halt the progression or even reverse the effects of alveolar tissue destruction leading to 
emphysema. 
 
4.4 Final thoughts 
Upon first glance, the study of the pathogenesis of severe malaria and emphysema may have little in 
common. However, these seemingly disparate studies have touched upon several key issues currently being 
tackled within the macrophage biology field. In CHAPTER 2, we studied the differing roles of tissue-
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resident macrophages and recruited inflammatory monocytes in an infectious disease setting. We found that 
monocyte-derived macrophages played a key role in parasite clearance, while alveolar macrophages did 
not. Conversely, in CHAPTER 3, we studied the dynamics and function of tissue-resident macrophages in a 
model of sterile inflammation leading to emphysematous changes in the lungs. Unlike our studies using the 
malaria model, we found that inflammatory monocytes may not contribute in a significant way to the 
elastase emphysema model, instead, the alveolar macrophage population underwent morphological 
changes, became activated and proliferated following elastase-mediated lung damage. While both studies 
involved models of pulmonary inflammation, the dynamics and functions of macrophage and monocyte 
populations differed quite dramatically. Given that monocytes are no longer thought to be precursors to 
lung macrophages, our findings presented in CHAPTERS 2 and 3 are but two examples of pulmonary 
insults in which the roles of tissue macrophages and monocytes differ. Therefore, understanding how the 
myriad of molecular mechanisms combine to result in a tailored immune response specific to the 
inflammatory insult at hand and how the local milieu of environmental factors influences the function of 
these mononuclear phagocytes is of key importance. 
 
Since the initial observations made by Ilya Mechnikov, countless biologists have been captivated by the 
nature of macrophage biology. While these innate immune cells have been intensely studied for over one 
hundred years, the field is still dynamic and constantly evolving. Although tissue macrophages reside 
within varied locales throughout the body, their core functions of phagocytosis, immune surveillance and 
maintenance of homeostasis connect them. Recent studies have shed new light on the origins of tissue 
macrophages and the contribution of monocytes to their maintenance. 
 
Basic research investigating the roles of monocytes and tissue macrophages in inflammatory settings has 
translational potential as these cells have been implicated in many protective as well as pathogenic disease 
outcomes. In order to develop intervention measures aimed at mitigating their role in damage or harnessing 
their protective power, a more detailed understanding of phenotypic commitment and activation 
requirements of tissue-resident macrophages are required. Additionally, understanding the plasticity of 
these mononuclear phagocytes is key to developing interventions aimed at altering monocyte/macrophage 
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function during pathogenic situations. Given the recent paradigm shift, this issue has become more 
important as altering the functional state of tissue macrophages may have profound long-term impacts as 
most macrophage populations have been identified as embryonically seeded, long lived, self-maintaining 
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AI.1 MATERIALS AND METHODS 
 
AI.1.1 Mice 
Age and sex-matched (male 6-8 weeks old) littermates were used for all experiments. C57BL/6J were 
obtained from The Jackson Laboratory (Bar Harbor, ME, USA). CD36-/- mice on a C57BL/6 background 
were obtained from Dr. Maria Febbraio (Cleveland Clinic Foundation, Cleveland, OH, USA) [411]. B6-
Ly5.2 congenic mice expressing the Ly5.1 antigen were purchased from the National Cancer Institute 
(Frederick, MD, USA).  All mice were maintained within barrier filter-top cages, provided food and water 
ad libitum, and exposed to a 12-hour light/dark cycle.  All animal procedures performed in this study were 
approved by the Johns Hopkins Animal Care and Use Committee (Baltimore, MD, USA), and were in 
accordance with the National Research Council’s Guide for the Care and Use of Laboratory Animals 
federal guidelines. 
 
AI.1.2 Parasites and infection 
P. berghei ANKA (MRA-671) was obtained from the Malaria Research and Reference Reagent Resource 
Center (MR4) (Manassas, VA, USA). Cryopreserved parasite stocks were passaged through donor mice 
(C57BL/6J) at least twice prior to infecting experimental mice. Infected donor mice were maintained until 
the eighth passage, when new parasites were started from cryopreserved stocks. Blood stage infections 
were initiated by introducing 106 parasitized erythrocytes via intra-peritoneal injection. Progression of the 
infection was measured by tracking changes in body weight and temperature. In addition, peripheral blood 
parasitemia was monitored via thin blood smear and Giemsa staining. 
 
AI.1.3 Bone marrow chimeras 
Bone marrow cells were extracted from the femurs and tibias of CD45.1+ C57BL/6 (WT) and CD45.2+ 
CD36 deficient (CD36-/-) mice.  After removal of erythrocytes using ACK lysis buffer (Quality Biological, 
Gaithersburg, MD, USA), bone marrow cells were suspended in PBS.  Cohorts of WT and CD36-/- mice 
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were irradiated with 900 rads using a 137Cs γ-source (MSD Nordion Gammacell 40 Exactor; Laval, Quebec, 
Canada) and reconstituted 2-4 hours later with 1 x 107 heterologous or autologous bone marrow cells 
introduced via the tail vein in 150 µl of PBS.  Mice were subsequently maintained on Sulfatrim (Actavis, 
Morristown, NJ, USA)-supplemented water for 4 weeks and allowed to recover for nine weeks before 
infection.  At four and eight weeks post-irradiation, the effectiveness of chimerism was evaluated by 
assessing the levels of CD45.1, CD45.2 and CD36 on CD11b-postive cells.  After applying Fc Block™ 
(BD Pharmingen), cells were incubated with the appropriate fluorochrome-conjugated antibodies in FACS-
staining buffer (PBS containing 2% heat-inactivated FCS (35-011-CV, Mediatech, Inc., Manassas, VA, 
USA)) for 20 minutes on ice in the dark.  Data were acquired on a FACSCalibur flow cytometer using 
CellQuest software (BD Biosciences, Mountain View, CA, USA) and results were analyzed using FlowJo 
software (Tree Star, Inc., Ashland, OR, USA).  
 
AI.1.4 Antibodies 
The following anti-mouse antibodies were purchased from BD Biosciences (San Jose, CA, USA) CD11b-
PerCP-Cy5.5 (550993) and anti-CD16/CD32 Fc block (553142). CD45.2-PE (12-0454-81) and CD45.1-
APC (912-0453-81) anti-mouse antibodies were purchased from eBioscience (San Diego, CA, USA). Anti-
mouse CD11c-APC (130-091-844) was purchased from Miltenyi Biotec (Auburn, CA, USA). Mouse anti-
mouse CD36 (ABM-5525) was purchased from Cascade Biosciences (Winchester, MA, USA). Mouse IgG 
Fc fragments (015-000-007) were purchased from Jackson ImmunoResearch (West Grove, PA, USA).   
 
AI.1.5 Bronchoalveolar lavage (BAL) 
Murine surgeries were performed as previously described [413]. Briefly, mice were anaesthetized with 450 
mg/kg 2,2,2-tribromoethanol (Sigma-Aldrich, St. Louis, MO, USA) via intraperitoneal injection. An 
incision was made through the sternum and BAL fluid was obtained after a tracheostomy and lavaging of 
the lungs with 800 µl of sterile PBS three separate times at room temperature. BAL fluid from the three 
collections were pooled and centrifuged at 1,500 rpm for 3 minutes at 4°C. Cells were suspended in PBS 
and an aliquot was stained with trypan blue (Invitrogen, Grand Island, NY, USA) prior to counting on a 
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hemocytometer using the 10X objective of an Olympus BH-2 microscope (Catharpin, VA, USA). Cells 
(105) from each mouse were adhered to microscope slides with the aid of cytology funnels (Fisher 
Scientific, Houston, TX, USA) and a cytocentrifuge (Shandon Cytospin, Thermo Fisher Scientific, 




A 19-gauge gavage tube was inserted into a small hole in the trachea, and the lungs were inflated slowly 
with zinc-buffered formalin fixative (Z-fix) (174, Anatech Ltd., Battle Creek, MI, USA). The lungs were 
removed and incubated in Z-fix for 48 hours. Inflated and fixed lungs were embedded in paraffin, and 
sagittal, 5 µm sections, were cut from four different levels of lung. Lung sections were placed on slides and 
either left unstained or stained with hematoxylin and eosin. Lung sections (and cytology slides) were 
examined using a Nikon Eclipse E800 light microscope (Nikon Instruments Inc., Melville, NY, USA), and 
images were acquired using SPOT RT charge-coupled device imager and software (Diagnostic Instruments, 
Inc., Sterling Heights, MI, USA). 
 
AI.1.7 Lung injury scores 
Hematoxylin and eosin-stained histological sections from test and control groups were evaluated in a 
blinded fashion by three investigators.  A lung injury score was devised using three categories of 
histological change: intra-alveolar hemorrhaging and infiltrates, alveolar septal thickening and intra-
alveolar edema.  Each of these categories was scored using a four point 
tissue section involved; 2 = 10 – 30% of tissue section involved; 3 = 30 – 50% of tissue section involved; 4 
= > 50% of tissue section involved.  
 
AI.1.8 Statistical analysis 
Statistical significance was evaluated by using the 2-tailed t test (Tukey) and the one-way analysis of 
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AI.2.1 CD36 and malaria-induced ALI 
To determine the relative contributions of endothelial cell- and mononuclear cell-associated CD36 to 
malaria-induced lung pathology, we generated CD36 chimera mice where CD36 expression in the lungs 
was restricted to either vascular endothelial cells or cells of hematopoietic origin (Figure AI.1A). CD36 
chimeric and control mice were infected with P. berghei ANKA at 9 weeks post-bone marrow transfer. 
Groups that were deficient for CD36 expression on cells of hematopoietic origin (CD36-/->WT and CD36-/-
>CD36-/-) had a significantly greater drop in body weight at day 6 post-infection (Figure AI.1B). Compared 
to WT>WT animals, all of the other transfer groups had a significantly lower percentage drop in body 
temperature (Figure AI.1B). It was notable that the animals in the CD36-/->CD36-/- group were best able to 
maintain their body temperature during malaria. Parasitemia was significantly higher at days 5 and 6 post-
infection in the group that selectively expressed CD36 on the vascular endothelium (CD36-/->WT) (Figure 
AI.1B). 
 
The gross appearance of the lungs from mice where CD36 was expressed exclusively on endothelial cells 
(CD36-/->WT) was markedly red and inflamed compared to the lungs from mice that expressed CD36 on 
cells of hematopoietic origin but not on vascular endothelial cells (WT>CD36-/-) (Figure AI.2A). This 
observation was in contrast to the lungs derived from the CD36-/->CD36-/- controls, which consistently 
appeared the least congested and inflamed of the four groups. The outward appearance of the lungs was 
reflected in the intensity of the cellular responses. CD36-/->WT animals had the most robust cellular 
infiltrate and the CD36-/->CD36-/- animals had the lowest intensity cellular infiltrate (Figure AI.1D). The 









Histological analysis showed that the lungs from the CD36-/->WT animals exhibited markedly more 
malaria-induced pulmonary pathology than the other three bone marrow transplant groups (Figure AI.2B, 
center panels). The lungs of CD36-/->WT mice displayed areas of widespread edema, focal regions of 
erythrocyte and inflammatory cell leakage into the air spaces, and extensive thickening of alveolar walls. 
The WT>WT and WT>CD36-/- groups showed similar forms of lung injury, but to a lesser extent. In 
contrast, the lungs from the CD36-/->CD36-/- group exhibited the lowest levels of malaria-induced lung 
pathology. Additionally, staining for intra-alveolar fibrin, a pathological hallmark of ALI [500], revealed 
that the highest levels of fibrin production were in lungs from CD36-/->WT mice that expressed CD36 only 
on the vascular endothelial cells (Figure AI.2B, bottom panels). Focal areas of fibrin deposition were also 
found in the lungs from the WT>WT and WT>CD36-/- groups, but these areas were absent in the CD36-/-
>CD36-/- lungs. Employing a blinded scoring system to quantify the histopathological outcomes, the CD36-
/->WT lungs scored significantly higher and the CD36-/->CD36-/- lungs scored significantly lower compared 
to WT>WT for all of the measures of lung damage (Figure AI.1E). Given the importance of CD36 in the 
ability of macrophages/monocytes to clear malaria-infected RBCs [84, 289, 328], it was hypothesized that 
the lungs from mice that selectively expressed CD36 only on the vascular endothelial cells (CD36-/->WT) 
would have the highest levels of lung-associated malaria-infected RBCs. The heightened pathology in the 
lungs from CD36-/->WT animals was associated with significantly more parasites sequestered in the lungs 
(Figure AI.1C). Conversely, the lungs from CD36-/->CD36-/- had the lowest number of parasite-positive 
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